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Introduction: For almost 25 years, BRCA testing has been used to successfully personalize 
cancer risk for primary prevention, and can serve as model for integration of genetics and 
genomics into routine clinical care.  Historically, most studies of BRCA testing and downstream 
healthcare utilization have focused on clinical populations.  Recent efforts have looked at 
population-wide uptake of BRCA testing using claims analysis, but have not correctly and fully 
identified historical BRCA tests, since billing practices have been complex.  Angelina Jolie’s 
editorial in 2013 discussing her risk-reducing surgery due to her positive BRCA status provides a 
natural experiment to assess whether BRCA uptake and downstream utilization is affected by 
public endorsements. Methods: The current study utilized the Healthcare Cost Institute (HCCI) 
multi-payer claims database to assess a novel method for identifying BRCA tests with increased 
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accuracy.  Analysis focused on characterizing enrollees eligible for BRCA testing and drivers for 
BRCA testing, and assessing adherence to clinical management guidelines for BRCA carriers. 
Results: This method identified more BRCA tests than the other published methods.  The testing 
rate among eligible enrollees was 5.1%.  Most BRCA tests were ordered on young enrollees, with 
a family history that justifies the medical necessity of the test.  From 2008-2017, there was an 
increase in BRCA testing across all ages, cancer diagnoses and types of family history. A clear 
“Jolie Effect” was observed especially in young, unaffected enrollees.  These effects persisted 
after adjusting for covariates. The BRCA mutation pick up rate was 7.3%. About one quarter of 
BRCA carriers chose risk-reducing procedures in the first year post BRCA testing.  The majority 
of BRCA carriers who chose screening, underwent at least one recommended surveillance 
procedure in the first year, but adherence decreased throughout the five-year follow-up period, 
dropping to under 10% for annually recommended screenings.  Conclusion: Complicated billing 
methodology, and changing procedure codes make it challenging to capture all BRCA tests via 
claims analysis.  The current method leveraged knowledge of BRCA testing methodology and 
billing practices of laboratories, to maximize BRCA test identification from claims analysis. 
BRCA testing rates, and BRCA mutation pick-up rates were less than 10%.  Risk reducing 
surgery had incomplete uptake, and there was a lack of adherence to recommended increased 
screening among BRCA carriers.  These testing and healthcare utilization patterns may diminish 
the primary prevention effect of BRCA testing across large populations. 
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CHAPTER 1.  BRCA TESTING AS A MODEL FOR PERSONALIZED MEDICINE 
 
INTRODUCTION 
Personalized medicine has the potential to tailor treatment, prevent disease and thereby 
improve health outcomes. However, there are concerns about its cost and accessibility despite 
recent improvements in both areas. 
  Since 1994, BRCA1 and BRCA2 (BRCA) testing, has been the hallmark procedure 
through which personalized medicine has entered mainstream healthcare.  For the last 25 years, 
researchers, clinicians and patients have crafted referral, management and prevention guidelines 
that now serve as a model for the use of genetic information to improve health outcomes. 
 This study was funded by the Robert Wood Johnson Foundation, via their Health Data 
for Action mechanism, to investigate BRCA testing in commercial claims, to address the bias 
often seen in genetic testing studies that rely on clinical patient samples as a research cohort. 
 
BACKGROUND 
History of BRCA testing and billing 
  Until recently, the economic aspects of BRCA testing were challenging. The patent on the 
BRCA1 and BRCA2 genes enabled the patent holder (Myriad) to set extremely high prices, 
effectively placing this test and the services associated with it beyond the reach of many patients 
until June 13, 2013 when the Supreme Court overturned the patent (Supreme Court, 2013).  The 
high cost of BRCA testing until then, led to limited demand and low adoption of the test, which 
in turn resulted in lack of interest in studying the downstream effect of BRCA testing on practice 
patterns and patient outcomes.  In addition, the identification of patients who had BRCA testing 
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was challenging, because of limitations of Current Procedure Terminology (CPT) coding in 
administrative data, which did not distinguish between types of DNA tests.   
 Beginning in 1997 when commercial BRCA testing first came on the market, billing for 
this lab test utilized non-gene specific, molecular pathology procedure codes billed in a stacked 
manner.  In April of 2003, gene-specific temporary S-codes were introduced, and in Jan 2013 
they were finalized into CPT codes and enforced as the way to bill for BRCA testing.  However, 
around the same time, after the BRCA patent dissolution in June of 2013, genetic testing for 
breast and ovarian cancer predisposition expanded to include genes beyond BRCA1 and BRCA2, 
and laboratories began to offer multi cancer gene panel tests that included BRCA1 and BRCA2, 
as well as other cancer predisposition genes.  Between 2013 and 2016, to account for cancer gene 
panel testing and the attendant increased laboratory costs, many providers utilized an unlisted 
molecular pathology code, or DNA-exon non-specific codes, stacked using varied numbers of 
units of service, billed in addition to the gene-specific BRCA codes established in 2013.  This 
code-stacking allowed laboratories to bill higher charges than using BRCA-specific gene codes 
alone.  To address this issue, in 2016, a CPT code for a cancer gene panel that included BRCA 
testing was created. 
On the clinical end, there was also insufficient provider and patient education about the 
value and uses of BRCA for patients with newly diagnosed breast, ovarian and colon cancers, as 
well as those with family histories of cancer.  A 2012 study found that of the approximately 
220,000 BRCA mutation carriers in the US, only 5-6% had been identified at the time (Drohan B, 
2012).  A more recent study estimated that only 20% of women with a breast or ovarian cancer 
who meet current genetic testing guidelines have undergone genetic testing (Childers CP, 2017). 
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There have been improvements in both cost and access to BRCA testing in the years since 
the patent was overturned.  Recent competition for BRCA testing among new laboratory 
providers has resulted in decreased cost and charges, and improvements of genetic testing 
guidelines have made more patients eligible for BRCA testing.  Adding to this new genetic 
testing landscape, the publicity around actress Angelina Jolie’s testing and subsequent personal 
journey to prophylactic surgery, based on her Opinion Editorial (OpEd) piece in the New York 
Times (the “Jolie Effect”) (Jolie, 2013) has been reported to increase uptake of genetic testing in 
clinical samples of patients. Improvements on previously cumbersome and non-specific CPT 
codes have facilitated improved tracking of these tests as each gene has been assigned a specific 
code.  
In theory, these advancements should lead to increased uptake and better mutation carrier 
identification, enabling clinicians and patients to make more informed decisions, thereby 
harnessing the potential of risk-reducing and preventive measures, as well as tailored treatment 
options at the time of diagnosis.  
However, the consequences of the recent advancement in BRCA testing on healthcare 
utilization are not clear. Although several recently published studies have addressed this issue, 
they were all flawed in the ascertainment of BRCA testing. 
 
Literature Review 
 Several papers have attempted to determine if the utilization of BRCA testing over time 
has increased, particularly before and after May 2013, when Angelina Jolie’s editorial on the 
management of her BRCA mutation was published. 
 In June 2016, the first BRCA testing claims analysis was published by Wright et al. 
looking at a period of five years ending immediately after Jolie’s editorial of May 2013.  The 
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authors used the Truven MarketScan TM claim database from July 2009 to June 2013 and 
specifically focused on newly diagnosed breast and ovarian cancer patients.  Wright et al. found 
that BRCA testing for both breast and ovarian cancer increased over time.  BRCA testing 
increased from 42.3% in 2009 to 57.3% in 2013 in women newly diagnosed with breast cancer 
under the age of fifty.  BRCA testing increased from 15.8% to 23.3% for women newly 
diagnosed with ovarian cancer over the same period.  Overall (non-age specific) increases were 
not as large; BRCA testing increased from 20.9% to 41.6% for women with breast cancer and 
from 12.1% to 21.0% for women with ovarian cancer (C. L. Wright JD, Tergas AI, Acordino M, 
Ananth CV, Neugut AI, Hershman DL, 2016). 
 Zhuo Chen, Muin Khoury and several other collaborators published a paper in September 
of 2017 that utilized the Truven MarketScanTM database to assess trends in BRCA testing 
utilization over time.  Chen et al.’s findings showed a dramatic increase in BRCA testing from 
2012 to 2014 with 68% more women undergoing testing.  Relative to 2012, BRCA testing rates 
in 2013 increased by 57%, compared to an average annual increase of 10% in the three preceding 
years (Chen et al., 2017).  
 Roberts and Dusetzina also looked at the Truven MarketScanTM claims database from 
2012 to 2014 and found that BRCA testing increased between April and May 2013 (month of 
Jolie’s editorial) from 12.6 to 16.4 tests per 100,000 women, but there was no difference in 
testing over time by covariates (age, region, relationship to plan holder, and health insurance 
type) in bivariate analyses.  Interestingly, Roberts found that use of post-BRCA test health 
services (breast MRI, surgeon visits, mastectomy) declined, but there was a slight increase in 
mammography, whereas utilization of genetic counseling remained constant (Roberts MC, 
2017).  
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 Finally, Guo and colleagues from University of Texas used the Optum claims database to 
identify use of the BRCA test from 2004-2014, originally agnostic to the natural experiment 
represented by the Jolie editorial (H. J. Guo F, Lin Y, Richardson G, Levine L, Berenson A, Kuo 
Y, 2017).  Guo found that BRCA testing increased from 24.3% to 61.4% in 2014 at a p<0.001. 
Although their analysis identified significant interactions between year of BRCA testing and age, 
geographic region and family history of breast and/or ovarian cancer, they did not parse the data 
more finely to identify the degree to which the Jolie effect played a role in the increase in genetic 
testing.  Prompted by a comment (Nabi H, 2017) on their original paper, they re-analyzed the 
data and identified that the month following the Jolie editorial showed an increase in BRCA of 
42% in unaffected women and 14 to 20% in women with breast and ovarian cancer respectively 
(H. J. Guo F, Lin Y, Richardson G, Levine L, Berenson A, Kuo Y., 2017). 
 All these publications identified an increase in BRCA testing after the Jolie editorial.  
However, all these publications also relied upon inaccurate units of service and an incomplete set 
of CPT codes.  In particular, all these studies identified BRCA tests via non-specific, molecular 
pathology CPT codes with incorrect units of service, new CPT codes that are gene-specific 
and/or their precursor temporary S-codes which although available for use during the period, 
were not used exclusively.  
 Until 2013, despite the availability of temporary gene-specific CPT codes (S-codes), the 
most common way to bill for DNA-based tests was by using non-specific molecular pathology 
codes, which represented the methodology, not the gene tested. These non-specific molecular 
pathology codes were billed in a “stacked” way with a specific number of stacked units that 
accounted for the specific number of DNA segments analyzed for each gene.  This was the case 
irrespective of the gene analyzed.  For BRCA1 and BRCA2 a total of 81 segments of DNA 
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needed to be analyzed for sequencing (the most commonly ordered test).  These non-gene 
specific molecular pathology codes were: 83891 DNA Isolation; 83898 x81 DNA Amplification; 
83904 DNA Sequencing x81; 83909 Capillary & Electrophoresis x81; and Interpretation & 
Reporting 83912. These non-specific codes were also used for genes other than BRCA1 and 
BRCA2, such as Cystic Fibrosis (CF) and her2neu; the only difference would have been the units 
of service, which are gene-specific. 
 It is likely the findings of these studies do not correctly estimate the effect of the Jolie 
editorial on BRCA testing rates.  Those studies that used the non-specific molecular pathology 
codes without assigning the correct number of units (n=81) counted BRCA tests as well as other 
genetic tests, such as CF of her2neu. Those studies that did not use the non-specific molecular 
CPT codes at all likely missed a significant number of the BRCA tests because until 2013 only 
one lab performed and billed for BRCA, and this lab was using a combination of both non-
specific molecular pathology codes and temporary S-codes. 
 As a result, the changes in BRCA testing after the Jolie editorial are incorrectly estimated. 
Please refer to Appendix Ch. 2 Table 1 for a summary of the old CPT molecular pathology 
codes, the preliminary S codes and the final HCPS/CPT codes that have been used to represent 
BRCA tests. 
 Three of the previous four studies used the Truven MarketScanTM database which is 
comparable to the database used in this study although the latter has 25% more claims.  The Guo 
publication utilized the Optum database, which is limited to claims obtained from United 
HealthcareTM only, and as such may not be an accurate representation of healthcare trends 
nationwide.   
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 The database used for this study is the HealthCare Cost Institute’s (HCCI) Outpatient, 
Inpatient, Physician and Pharmacy claims dataset with claims from January 1, 2008 through 
December 31, 2017, enabling longitudinal analysis of BRCA testing and downstream services.  
HCCI’s claims database includes enrollment files and medical and pharmacy claims for more 
than fifty million individuals per year from Aetna, Humana, and United Health from all fifty 
states and Washington, DC. The medical and pharmacy claims include allowed amounts (actual 
amounts paid) to providers, as well as unique provider identifiers and member IDs that can be 
tracked over time. Table 1 shows a comparison of the three claims databases in question. 
Table 1. Comparison of the three claims databases used in claims analysis for BRCA testing trends. 
 Truven MarketScan Optum Database HCCI database 
Covered 
lives 
~77.7 million ~180 million ~100 million (~60 million commercially 
insured; ~ 40 million managed Medicare-
insured) 
Number of 
Payers  
~100 (insured employees, 
COBRA enrollees, early 
(non-Medicare) retirees with 
dependents 
1 (UnitedHealth) 4 (Aetna, Humana, UnitedHealthcare, 
Kaiser Permanente) and all Medicare FFS 
on 40 million lives 
 
BRCA status drastically alters clinical management  
Clinical management for individuals with BRCA mutations is drastically different than 
for patients matched on all criteria except for a BRCA mutation.   
In female carriers of a pathogenic BRCA mutation, but without a diagnosis of breast 
cancer (also referred to as unaffected BRCA carriers) a bilateral risk-reducing mastectomy 
(RRM) reduces the risk of breast cancer by approximately 95% in women with prior or 
concurrent bilateral risk-reducing salpingo-oophorectomy (RRSO) and by approximately 90% in 
women with ovaries in situ (Rebbeck TR, 2004).  
The management of breast cancer risk in a patient with unilateral breast cancer and a 
BRCA mutation also differs significantly from that used in matched patients but without a 
mutation. First, the risk for contralateral breast cancer developing over the five years following 
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initial diagnosis in a patient with a BRCA1 or BRCA2 mutation can be as high as 63%, especially 
if the breast cancer occurs before age forty (Graeser MK, 2009) and up to 83% for BRCA1 and 
62% for BRCA2 to age seventy (Mavaddat et al., 2013). The risk of ovarian cancer within ten 
years after a diagnosis of breast cancer in BRCA positive women is 12.7% (Metcalfe KA, 2005).  
Unaffected female carriers of a pathogenic BRCA mutation also benefit from RRSO.  In a 
multi-center prospective cohort study by Domchek and colleagues (Domchek SM, 2010) of 
2,482 women with BRCA mutations, RRSO was associated with a statistically significant 
reduction (HR 0.31, 95% CI 0.12–0.82) in the risk of ovarian cancer among BRCA1 mutation 
carriers between 69%- 85% depending on personal history of breast cancer.  Among BRCA2 
mutation carriers with and without a history of breast cancer, no cases of ovarian cancer were 
observed after RRSO. In the same study, RRSO was also associated with a 37% reduction in the 
risk of future breast cancer among BRCA1 mutation carriers without prior breast cancer, and a 
64% reduction in the risk of future breast cancer in BRCA2 mutation carriers without a prior 
history of breast cancer. Women with BRCA mutations treated with RRSO alone had decreased 
all-cause mortality (3% vs. 10%), decreased ovarian cancer mortality (0.4% vs. 3%), and 
decreased breast cancer mortality (2% vs. 6%) compared to carriers who did not have RRSO 
(Domchek SM, 2010).  
Given the high risks of developing breast and ovarian cancer and the high effectiveness 
of RRM and RRSO procedures, it is important to identify who among the general population 
carries a BRCA mutation to enable risk-tailored management. The timing of the increase in risk 
compared to the general population will affect not only the timing of increased surveillance and 
decisions about risk-reducing surgeries, but also the timing of BRCA testing.  For example, the 
cumulative risk for breast cancer in a BRCA1 female carrier is 43% by age 50, and as such the 
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option of RRM may be relevant in the 30s and 40s for such patients (Kuchenbaecker et al., 
2017).  Conversely, the cumulative risk for ovarian cancer in a BRCA2 carrier starts to increase 
after age 50, and therefore RRSO may be delayed to later in life for such patients.  Specific 
family history must always be considered as well. If cancers are seen in the family earlier than 
what is expected based on published estimates that should be considered when providing options 
for risk management. Table 2 represents a summary of risks in BRCA carriers from a recent 
publication, stratified by decade of life from Kuchenbaecker et al. (2017). 
Table 2. Breast and Ovarian Cancer cumulative risk, by 10 year age groups. Adapted from from (Gamble C, 2017; 
Kuchenbaecker et al., 2017) 
 Age (years) Cumulative Risk in % (95% C.I.) 
Breast Cancer   
BRCA1 Mutation Carriers   
 </=20 - 
 21-30 4 (2-7) 
 31-40 24 (21-29) 
 41-50 43 (39-48) 
 51-60 56 (51-61) 
 61-70 66 (61-72) 
 71-80 72 (65-79) 
   
BRCA2 Mutation Carriers </=20 - 
 21-30 4 (2-9) 
 31-40 13 (9-19) 
 41-50 35 (29-41) 
 51-60 53 (46-59) 
 61-70 61 (55-68) 
 71-80 69 (61-77) 
   
Ovarian Cancer   
BRCA1 Mutation Carriers   
 </=20 - 
 21-30 - 
 31-40 2 (1-3) 
 41-50 8 (6-12) 
 51-60 20 (16-26) 
 61-70 41 (33-50) 
 71-80 44 (36-53) 
   
BRCA2 Mutation Carriers </=20 - 
 21-30 - 
 31-40 0 (0-2) 
 41-50 0 (0-2) 
 51-60 7 (4-11) 
   10 
 61-70 15 (10-23) 
 71-80 17 (11-25) 
   
 
Modeling analyses have shown that RRSO alone results in incremental savings of 2.6 life 
years; preventive RRM alone results in incremental savings of 3.5 life years; and both 
procedures together result in incremental savings of almost 5.0 life years.  These findings support 
efficacy of RRM in preventing breast cancer, and of RRSO in preventing both breast and ovarian 
cancer in BRCA mutation carriers. 
According to the National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian, BRCA carriers 
without breast cancer may receive either heightened surveillance (annual breast MRI and/or 
mammography depending on age) or discuss RRM as an important risk-reducing intervention. 
RRSO, rather than surveillance, is recommended to reduce ovarian cancer risk because screening 
for these cancers is not as effective.  As recently as 2016, a large study out of the U.K. showed 
that concomitant use of trans-vaginal ultrasound and CA125 serology is better than either alone, 
but did not demonstrate a reduction in mortality of screening for this malignancy (Menon U, 
2009) (Jacobs IJ, 2016)  
NCCN guidelines for a carrier of a BRCA mutation are as follows, and differ substantially 
from recommendations for the general population (Table 3, below) (Daly MB, 2019). 
Table 3: BRCA Mutation Positive Management. Adapted from: NCCN BRCA-Related Breast and/or Ovarian Cancer 
Syndrome, Version 3.2018, 10/03/17 © National Comprehensive Cancer Network, Inc. 2017. Downloaded 
03/31/2019 from https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Daly MB, 2019); 
SERM=Serum Estrogen Receptor Modulator; RRM=risk-reducing mastectomy; RRSO= risk-reducing salpingo-
oophorectomy 
Starting 
Age 
(years) 
Recommendation Frequency Comment 
18 +  Breast awareness -  
25+ Clinical Breast Exam Every  
6-12 mos 
 
25-29 Breast MRI with contrast  Every  Mammogram with consideration for tomosynthesis if 
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12 mos MRI not available; may be individualized based on 
family history  
30-75 Mammogram  Every  
12 mos 
Consider tomosynthesis 
 Breast MRI with contrast Every12 mos Consider mammography with tomosynthesis if not 
available 
75+ Individualized  
 
 - Based on personal and family history  
All ages Discuss RRM 
 
- Discuss reconstruction  
35-40 Discuss RRSO - Upon completion of childbearing; BRCA2 can delay 
RRSO to age 40-45 due to later onset of ovarian 
cancer in that group 
30-35 Trans-vaginal ultrasound 
with serum CA125 
- Clinician discretion; efficacy unclear 
All ages Oral Contraceptive Use 
 
- Consider on individual basis 
 SERM Use 
 
- Consider on individual basis 
 
 
Expected Patient Flow for BRCA testing 
 The diagram below (Fig. 1) shows the expected patient flow through the healthcare 
system and includes probabilities of various outcomes based on available data.  It does not 
represent a bona fide decision analysis tree, but is intended to provide an overview of the flow of 
patients across the various points of interaction with the healthcare system. 
For patients with a newly diagnosed breast or ovarian cancer, identification of carrier 
status at the time of diagnosis facilitates prevention of additional cancers.  An RRSO will prevent 
ovarian cancer and a bilateral mastectomy will treat the first cancer and prevent a second new 
breast cancer.  Ovarian cancer patients may opt for a bilateral risk-reducing mastectomy that 
would prevent both a first and second breast cancer primary.  For those who do not wish to 
undergo surgery to address the increased risk, chemoprevention in the form of oral 
contraceptives for ovarian cancer and tamoxifen for breast cancer exist, as well as increased 
screening with breast MRI, mammography, trans-vaginal ultrasound and CA125 serology.  
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Importantly, there are now tailored treatment options designed specifically for BRCA carriers, 
such as PARP1 inhibitors, which prolong survival (Helleday, 2011). 
 
 
Fig. 1. Expected patient flow through healthcare system for BRCA testing and follow up care. OCP=oral 
contraceptive pill; SERM=serum estrogen receptor modulator; ID-ed= identified; Dx-ic = diagnostic; FHx 
  
For BRCA carriers without cancer (unaffected), the same options exist with the added 
advantage of primary prevention.  A New England of Medicine study from 2004 found that 
breast MRIs identified 43.2% more invasive breast tumors measuring 10mm or less compared to 
mammography alone (Kriege et al., 2004). As such, many BRCA carriers, regardless of their 
screening regimen prior to BRCA testing, should undergo a breast MRI soon after being 
identified as mutation positive.  
Enrollee	
Coded	with	FHx		Dx-ic	Code	
Has	BRCA	testing	(CPT	codes)	
Tests	+ve		(BRCA	carrier)	
Ovarian	and	Breast	Cancer	Screening	
Breast	Cancer	ID-ed	
Ovarian	Cancer	ID-ed		
Chemoprevention	(OCPs,	SERM)	
Breast	Cancer	ID-ed	
Ovarian	Cancer	ID-ed		
Prophylactic	Surgery	
Breast	Cancer	ID-ed		
Ovarian	Cancer	ID-ed	
Tests	-ve	(non	BRCA	carrier)	
May	continue	breast	&	ovarian	cancer	screening	if	+ve	Fhx	
Breast	Cancer	ID-ed	
Ovarian	Cancer	ID-ed	
May	opt	for	chemoprevention	
Breast	Cancer	ID-ed	
Ovarian	Cancer	ID-ed	
May	opt	for	Prophylactic	Surgery	
Breast	Cancer	ID-ed		
Ovarian	Cancer	ID-ed		
Does	not	have	BRCA	testing	(No	CPT	codes)	
Not	coded	with	Fhx	Dx-ic	Code	 Unknown	BRCA	status	
Population	Breast	Screening	 Breast	Cancer	ID-ed	
Population	Ovarian	Screening	 Ovarian	Cancer	ID-ed		
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However, since not all patients with breast and/or ovarian cancer and/or family history of 
breast and/or ovarian cancer have an identifiable mutation in BRCA, many BRCA negative 
patients with a family history also may have received recommendations for heightened breast 
screening, such as annual MRI.  However, typically clinicians did not recommend risk-reducing 
surgeries to mutation negative women with strong family histories; such surgeries were (and 
continue to be) typically recommended to known BRCA mutation carriers.  These finer points of 
hereditary breast and/or ovarian cancer are important to keep in mind when evaluating claims for 
the presence of increased screening in the absence of documented BRCA mutation (documented 
via diagnostic codes; see Ch. 3 Appendix, Table 2 for BRCA carrier diagnostic codes) 
 Although diagnostic codes for labeling patients (and by extension enrollees in a claims 
database) as BRCA carrier have existed for a while, they are rarely used in practice.  The concern 
for miscoding of other genetic test results as BRCA positive exists, especially in cases where a 
Variant of Uncertain Significance is found.  VUSes are indeterminate results that cannot and 
should not be used to change management.  However, lack of understanding of the true meaning 
of such results can lead to VUS carriers being labeled incorrectly as BRCA carriers.  However, it 
would appear that this concern is not supported by a study performed at Kaiser Permanente in 
northern California, which compared women with Variants of Uncertain Significance (VUS) and 
BRCA mutation carriers and demonstrated that BRCA positive women were more likely to 
undergo surveillance only in the first year post-testing.  Importantly however, only 11% of VUS-
carrying women had an RRM and 30% had an RRSO versus 44% and 74%, respectively, among 
BRCA mutation carriers (L. L. Garcia C, Littell RD, Powell CB, 2014).  
Given that in clinical practice VUS carriers are viewed on a spectrum of risk that falls 
between BRCA mutation carriers and BRCA negative patients, the finding of reduced uptake of 
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preventive surgery in VUS carriers is consistent with my clinical experience that BRCA negative 
patients (with and without a strong family history) rarely choose preventive surgery as a risk-
reducing procedure, but rather opt for surveillance.   
 
AIMS 
Aim 1. Analyze uptake of BRCA testing among all enrollees, changes in patient characteristics, 
and assess variations in uptake by geographic region (state).  Specifically the following analyses 
will be undertaken, on all enrollees (both males and females). 
• Overall number of BRCA tests and proportion of BRCA tests among affected versus 
unaffected enrollees, with or without family history of cancer, ordered before, during, and 
after 2013.  
• Patient characteristics among BRCA tested enrollees, such as affected versus unaffected, 
age, family history versus no family history, age of testing, average OOP payment, type 
of insurance, etc.  
Aim 2. Assess the uptake of surgical procedures (risk-reducing mastectomy and risk-reducing 
salpingo-oophorectomy) and screening procedures (breast MRI, mammography, trans-vaginal 
ultrasound+CA125) among female, unaffected BRCA carriers over study period (2008-2017). 
a. For unaffected female enrollees who had BRCA testing due to family history (and 
not a cancer diagnosis) have the rates of RRM, annual breast MRI screening, 
annual mammography, RRSO, six-monthly ovarian screening (TVU+CA125) 
changed over time? (For example, are more BRCA carriers opting for RRM versus 
breast MRI and RRSO versus TVU after 2013?) 
i. Do the rate changes (if any) vary by age-band? 
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ii. Do the rate changes (if any) vary by family history status? 
 
HYPOTHESES 
1. An increase in BRCA testing will be observed from 2008 through 2017 with an accelerated 
increase from 2013 to 2014 due to a confluence of key factors, notably patent dissolution and 
public figure endorsement of BRCA testing, both of which occurred in 2013. 
2. The proportion of risk-reducing surgeries among female enrollees who are BRCA mutation 
carriers will increase after 2013 compared to breast MRI and ovarian screening (trans-vaginal 
ultrasound and CA125 serology) procedures.  
 
Expected Findings 
An increase in the uptake of BRCA testing should be observable starting in 2013 due to 
key events facilitating increased public awareness of BRCA testing and better test tracking.  
Longitudinally, as the cost of BRCA testing decreases and awareness of the testing 
increases, utilization should increase, and identification of individuals at hereditary risk for 
cancer should improve.  We should therefore see an increase in the number of BRCA tests. We 
expect that after the Jolie disclosure of May 13, 2013 and the Supreme Court decision of June 
14, 2013, an immediate surge in BRCA testing will be observed with a continuing uptrend, albeit 
at a more moderate pace, through 2014 and 2015.  
Decisions on post-BRCA testing clinical management are influenced by test results. 
Unaffected women with BRCA mutations can choose to have increased screening (including 
annual breast MRI and/or six monthly TVU+CA125 serology) or preventive surgeries (RRM 
and/or RRSO) to address the increased cancer risk that accompanies BRCA mutations. We expect 
to observe an increase in preventive procedures post 2013 (due to the “Jolie Effect”) relative to 
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screening procedures for breast and ovarian cancer among female BRCA carriers (breast MRI, 
mammography and TVU+CA125 serology). 
CONCEPTUAL MODEL 
A model for diffusion of BRCA testing and downstream healthcare utilization should 
address both adoption of innovation (in this case, BRCA testing) by providers, and the use of 
healthcare services by patients as ordered by providers.  Claims analysis does not offer an 
opportunity to investigate patient preferences since it is difficult to ascertain from an insurance 
claim whether a procedure was performed due to patient preference alone, or rather, more likely 
as a result of a decision-making process and discussion between the patient and the provider.  
 The analysis will focus on enrollees’ uptake of BRCA testing, geographic region variation 
(state-level), and healthcare utilization thereafter, focusing specifically on breast and ovarian 
screening and risk-reducing procedures (RRM, RRSO) in unaffected females.   
To look for evidence of utilization of recommended procedures in insurance claims, an 
adaptation of the Anderson model of health services utilization addresses the issue of hereditary 
predisposition in the context of not only the patient’s characteristics, but also contextual 
characteristics(Anderson RM, 2014).  For BRCA testing, contextual characteristics would include 
healthcare policy coverage and financial specifications: price of BRCA test (charges), cost of 
recommended procedures (RRM, RRSO, breast MRI, TVU+CA125), out-of-pocket (OOP) costs, 
etc.  Enrollee’s choice or risk-reducing surgery and/or increased surveillance in BRCA carriers, 
would therefore be affected by both contextual and enrollee (aka patient) characteristics.  Fig. 3 
demonstrates a general overview of how the Anderson model could be applied to BRCA testing 
in eligible enrollees and risk-reducing procedures and/or increased cancer surveillance in BRCA 
carriers. 
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Fig. 3. Proposed Conceptual Model for BRCA testing effects on the healthcare system, including BRCA testing and 
uptake of risk-reducing procedures and screening. SES= Socio-economic Status. 
 
MEASUREMENT MODEL 
A Measurement Model based on the Conceptual Model may be found below (Fig. 4).  
Due to limitations in claims analysis, not all conceptual variables can be translated into 
measurement variables; such variables have been crossed out in the model below.  Variables in 
the Conceptual Model that can be identified from the HCCI claims database will be highlighted 
in italics. Variables that may not be measurable are struck out.   
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Provider Characteristics that can be measured include: Predisposing, exemplified by 
demographics of ordering provider by geocode and demographics of laboratory provider by 
geocode, and Enabling, exemplified by financing of laboratory provider by total charges and net 
paid.   
Patient Characteristics (enrollee characteristics for the purposes of this claims analysis) 
that can be measured include Predisposing and Enabling, featuring demographics using gender, 
age, geocode, insurance type, genetics using diagnostic codes ICD 9 and ICD 10 and financing 
using Out of Pocket (OOP) amounts.   
Enrollee Health Behaviors that can be measured include Personal Health Practices, 
exemplified by type of information processer (seeker versus information averse) and access to 
providers that can order BRCA tests by searching for presence of BRCA test code, and Use of 
Personal Health Services, exemplified by adherence to recommended management guidelines by 
searching for utilization of follow up care using CPT codes for BRCA-recommended risk 
reducing procedures (RRM and RRSO) and increased screening (breast MRI, mammography and 
TVU+CA125). 
Only one of the four Anderson model Outcomes can be measured using the HCCI claims 
database.  This is Evaluated Health, exemplified by known BRCA status and identified by using 
diagnostic codes (ICD 9 and ICD 10) that label enrollees as carriers or non-carriers of BRCA 
mutations.  
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Fig. 4. Proposed Measurement Model for BRCA testing effects on the healthcare system, including enrollee uptake 
of BRCA testing and risk-reducing procedure and screening. Variables that can be identified from the HCCI claims 
database are highlighted in green.  Measures that have no corresponding variable in the HCCI database are crossed 
out. 
 
 
SUMMARY METHODS  
Please see Table 4 for a synopsis of the methods.  Each Aim will be analyzed and 
presented separately in subsequent chapters, and specific methods, results and discussion will be 
presented therein. 
Table 4. Planned analyses, covariates and models for each SubAim, with corresponding Tables numbers. CA= 
cancer diagnosis; FHx= family history of cancer 
Aim Analytic 
Dataset  
Outcome 
measure 
Covariates of 
Interest, or 
Strata of 
Interest 
Type of Model 
Aim 1. Assess the uptake of BRCA testing among healthcare plan enrollees, and analyze variations in uptake by 
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geographic region, provider and patient characteristic, to identify diffusion patterns for these innovations and the 
drivers for BRCA testing. 
1A. Assess 
uptake of BRCA 
testing 
(6million) 
 
Eligible 
Enrollees 
Dataset  
(Cohort 1), 
includes 
M/F 
Descriptiv
e analyses 
Cancer 
diagnosis 
(none, breast, 
ovary, breast 
and ovary, 
other); Family 
history of 
cancer (none, 
breast, ovary, 
breast and 
ovary, and 
other), year of 
test, age, 
gender, 
insurance type 
Univariate analysis for all 4 covariates; Bivariate 
analysis (3 covariates by year) 
 
Ch. 3, Tables 1 through 6  
 
  BRCA test Year of test, 
age, gender, 
insurance type  
Five Multivariate Logistic Regressions (see below for 
step by step): 
REGRESSION 1: 
1. Drop 0-17 age group, drop unknown Age, drop no 
indication for testing. 
2. Regression #1 w/ CA type & Fhx type interacted, no 
Age. 
3. Margins  
Please see: 
Ch. 4 Fig. 1 
Ch. 4 Appendix, Tables 1, 2 
 
REGRESSION 2:  
4. Drop cells if N tested <1 or N eligible <5. 
5. Regression #2 w/ 3-way interaction: CA type/Fhx 
type/Age 
6. Margins 
Please see:   
Ch. 4 Figs. 2-4 
Ch. 4 Appendix, Tables 3, 4 
Ch. 4 Appendix, Figs. 1, 2 
 
REGRESSION 3: 
7. Regression #2, but w/ 3-way interaction: 
CAtype/Fhx type/Year 
8. Margins 
Please see: 
Ch. 4 Figs. 5, 6 
Ch. 4 Appendix, Tables 5, 6 
Ch. 4 Appendix, Figs. 3-5 
 
REGRESSION 4: 
9. Regression 3, but w/ collapsed categories (CA+No 
Fhx; CA +Fhx; No CA + Fhx) interacted with Year and 
Age  
10. Margins 
Please see:  
Ch. 4 Figs. 7-9 
Ch. 4 Appendix, Tables 7, 8 
 
REGRESSION 5:  
10. Drop the following entire categories: No CA + 
Other Fhx; Other CA + No Fhx; Other CA + Other 
Fhx. 
11. Regression #5 w/ only BR/OV/No CA + Fhx 
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No/BR/OV/.  2-way interaction: CA type/Fhx type and 
3-way interaction: CA type/Fhx type/Age. This 
regression does not include Other CA, only enrollees 
w/ BR and/or OV and/or NO cancer and only Fhx 
BR/OV/No CA 
12. Margins 
Please see 
Ch. 4 Appendix, Tables 9, 10 
Ch. 4 Appendix, Figs. 6-18 
1B. 
Characteristics 
of patients 
undergoing 
BRCA testing. 
(300K) 
BRCA Test 
Dataset 
(Cohort 2), 
includes 
M/F 
No 
dependent 
variable 
b/c 
everyone 
had BRCA 
Year, age, 
insurance type, 
charges, OOP, 
net paid  
Univariate Analysis for all 6 covariates; Bivariate 
analysis for age/year, charges/year, OOP/year, net 
paid/year) 
 
Ch. 3 Appendix Tables 13-16 
Aim 2. Assess downstream uptake of BRCA-risk specific procedures and tests: (2A) risk-reducing mastectomy, 
risk-reducing salpingo-oophorectomy; and (2B) breast MRI, mammography and trans-vaginal ultrasound and 
CA125 serology (among unaffected female enrollees who are BRCA positive).   
2Ai. Changes in 
uptake of RRM 
in BRCA 
positive, 
unaffected 
female enrollees 
BRCA 
Positive 
Dataset, F 
only 
(Cohort 3) 
 
Descriptiv
e Analysis 
Year of test, 
age 
Bivariate analysis (Surgery/Year, Screen/Year) 
Multiple Logistic Regression Surgery/Year, stratified 
by Age) 
 
Ch. 5 Table 9 
 RRM Age, family 
history, 
insurance type  
Logistic Regression 
 
Ch. 5 Table 11 
2Aii. Changes in 
uptake of RRSO 
in BRCA 
positive, 
unaffected 
female enrollees 
BRCA 
Positive 
Dataset, F 
only 
(Cohort 3) 
 
Descrip-
tive 
analysis 
Year of test, 
age 
Bivariate analysis (Surgery/Year, Screen/Year) 
Multiple Logistic Regression Surgery/Year, stratified 
by Age) 
 
Ch. 5 Table 10 
 RRSO Age band, 
family history, 
insurance type 
Logistic Regression 
 
Ch. 4 Table 11 
2Bi. Changes in 
uptake of breast 
MRI in BRCA 
positive, 
unaffected 
female enrollees 
BRCA 
Positive 
Dataset, F 
only 
(Cohort 3) 
 
Descrip-
tive 
analysis 
Year of test, 
age 
Bivariate analysis (Surgery/Year, Screen/Year) 
Multiple Logistic Regression Surgery/Year, stratified 
by Age) 
 
Ch. 4 Table 14 
2Bii. Changes in 
uptake of 
mammography 
in BRCA 
positive, 
unaffected 
female enrollees 
BRCA 
Positive 
Dataset, F 
only 
(Cohort 3) 
 
Descrip-
tive 
analysis 
Year of test, 
age 
Bivariate analysis (Surgery/Year, Screen/Year) 
Multiple Logistic Regression Surgery/Year, stratified 
by Age) 
 
Ch. 4 Table 13 
2Biii. Changes 
in uptake of 
TVU+CA125 in 
BRCA positive, 
unaffected 
female enrollees 
BRCA 
Positive 
Dataset, F 
only 
(Cohort 3) 
 
Descrip-
tive 
analysis 
Year of test, 
age 
Bivariate analysis (Surgery/Year, Screen/Year) 
Multiple Logistic Regression Surgery/Year, stratified 
by Age) 
 
Ch. 4 Table 15 
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Datasets 
The HealthCare Cost Institute (HCCI) dataset is comprised of claims from commercial 
insurers for the years 2008 to 2017 and will be used for data analysis. HCCI’s claims database 
includes enrollment files and medical and pharmacy claims for over fifty million individuals per 
year from Aetna, Humana, and United Health, from all fifty states and Washington, DC. The 
medical and pharmacy claims include allowed amounts (actual amounts paid) to providers, as 
well as unique provider identifiers and member IDs that can be tracked over time.  
Please refer to the HCCI Data Dictionary for a list of available fields.  We will be using 
Data Set #2, which includes Member and Provider Zip Code, but does not include DOB.  Rather 
each Member will be assigned to one of nine age bands: 0-17, 18-24, 25-34, 35-44, 45-54, 55-64, 
65-74, 75-84, 85+.  
The “Eligible Enrollees Dataset” or Cohort 1 is comprised of enrollees of all ages with a 
diagnosis of the following cancer(s): breast, ovarian, pancreas, colon, unspecified female organs 
(to account for possible coding of fallopian tube cancer), eye (to account for possible coding of 
uveal melanoma), and cutaneous melanoma, as well as a personal history of breast and/or 
ovarian cancer. Enrollees with a family history of the following cancer(s) are also included: 
breast, ovary, gastrointestinal, and other (other cancer is included to allow for coding of family 
history of melanoma).  This dataset also contains all enrollees identified to have had BRCA 
testing (“BRCA Test Dataset”), who are almost completely subsumed under the “Eligible 
Enrollees Dataset”, with the exception of those enrollees who had BRCA testing for no 
indication. 
The “BRCA Test Dataset”, or Cohort 2 is comprised of all the enrollees for whom a 
BRCA claim was identified, regardless of gender, cancer diagnosis, family history of cancer, or 
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eligibility for testing.  This dataset includes enrollees without any indication for testing (i.e./no 
cancer or family history of cancer diagnostic code was associated with the BRCA claim). This 
dataset includes the “BRCA Positive” dataset below. 
The “BRCA Positive Dataset”, or Cohort 3 is comprised of all enrollees who had BRCA 
testing and tested positive, are female, and have not had a cancer diagnosis at the time of being 
coded as BRCA positive. 
 
Measures  
The following measures will be created and used in data analysis:  
• Affected = enrollees with a diagnosis of the following cancer(s):  breast (male and female), 
ovary, unspecified female organs (fallopian tube), colon, pancreas, cutaneous melanoma, 
uveal melanoma); enrollees with a diagnosis of a personal history of the following cancer (s).  
All three diagnostic fields will be interrogated using ICD-9 and ICD-10 codes that are used 
to code for these malignancies, and a measure “affected” will be created. Please see Ch. 3 
Appendix, Table 2 for description of these codes. 
• Affected measure will be subdivided into specific cancer diagnoses as follows: breast cancer, 
ovarian cancer (includes ovarian cancer and fallopian tube cancer), breast and ovarian cancer, 
colon cancer, pancreatic cancer, and melanoma (includes cutaneous and uveal melanoma). 
Please see Ch. 3 Appendix, Table 2 for description of the ICD-9 and ICD-10 codes used to 
create the cancer diagnoses.  
• Unaffected = enrollees without cancer, but with a family history of: breast cancer, ovarian 
cancer, breast and ovarian cancer or other cancer.  All three diagnostic fields will be 
interrogated using ICD-9 and ICD-10 codes that are used to code for these types of family 
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histories, and a measure “unaffected” will be created. Please see Ch. 3 Appendix, Table 2 for 
description of these codes. 
• BRCA test = this is a composite measure containing claims coded with all the known single 
CPT codes that identify BRCA testing (BRCA sequencing, BRCA single site, BRCA 
rearrangement test, aka BART) as well as claims that triangulate BRCA before the 
introduction of gene-specific CPT codes.  Specifically until Jan. 1, 2013, non-gene-specific 
codes were used to bill for BRCA testing, and from 2008-2013 only one lab was able to bill 
under these codes: 83891 DNA isolation x1; 83898 DNA amplification x 81 units; 83904 
DNA sequencing x 81 units; 83909 capillary electrophoresis x81; 83912 interpretation and 
reporting x1.  The combination of these 5 codes with exact units (1 unit for the first and last, 
and 81 units for the middle 3) was used to identify claims for BRCA testing before 2013, in 
addition to the temporary S-codes that stand for gene-specific DNA analysis and the final 
gene-specific DNA codes that came into effect Jan. 1 2013. Please see Ch. 3 Appendix, 
Table 1 for description of these codes 
• Age = age band at diagnosis (exact age not an option in the HCCI dataset with geographic 
variables) 
• Insurance type = Type of insurance: PPO, HMO, POS, EPO, Individual, PFF, STP or Other 
• Risk-Reducing Mastectomy (RRM) also described as Bilateral Prophylactic Mastectomy 
(BPM) = CPT codes used to identify enrollees who had risk-reducing bilateral mastectomy. 
Please see Ch. 4 Appendix, Table 2 for description of these codes.  
• Risk-Reducing Salpingo-Oophorectomy (RRSO), also described as Bilateral Salpingo-
Oophorectomy (BSO) = CPT codes used to identify enrollees who had risk-reducing bilateral 
oophorectomy.  Please see Ch. 4 Appendix, Table 2 for description of these codes. 
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• Breast MRI = CPT codes used to identify bilateral breast MRI with and without contrast, as a 
screening procedure for identifying breast cancer. Please see Ch. 4 Appendix, Table 2 for 
description of these codes. 
• Mammography = CPT codes used to identify bilateral mammography (screening or 
diagnostic), as a screening procedure for identifying breast cancer. Please see Ch. 4 
Appendix, Table 2 for description of these codes. 
• TVU+CA25 = CPT codes used to identify trans-vaginal ultrasound and CA125 serology, 
which are then grouped together on the same date of service to be used as a screening 
procedure for identifying ovarian cancer.  Please see Ch. 4 Appendix, Table 2 for description 
of these codes. 
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CHAPTER 2.  IDENTIFICATION OF BRCA TESTS IN A CLAIMS DATABASE 
 
KEY FINDINGS 
• The method for identifying BRCA claims outlined in the current paper is more accurate 
and specific than two other previously published methods. 
• The current method found 72% more tests than the Wright method and 45% more tests 
than the Chen method. 
• The current method identified 69% more enrollees who underwent BRCA testing 
compared to the Wright method and 15% more than the Chen method. 
• Using the CPT codes that were being billed in specific time periods is key to correctly 
identifying BRCA claims. 
 
INTRODUCTION 
Identifying BRCA tests in claims analysis has been problematic as procedure codes (aka 
CPT codes) and approaches have changed over time.  Historically, a set of non-gene specific, 
methodology-based molecular analysis codes were used and billed in a stacked fashion with a 
very specific number of units to identify the number of molecular procedures performed on the 
two BRCA genes.  All codes were billed on the same date of service. Procedure codes that 
specified the gene on which the testing was performed did not exist until 2008 when temporary 
gene-specific codes were introduced, followed by bona fide gene-specific CPT codes in 2013.   
As such, from the mid-1990s until 2013, BRCA testing (complete sequencing of the 
BRCA1 and BRCA2 genes) was often represented in claims by using non-specific, methodology-
based codes, specifically: 83891, 83898, 83904, 83909 and 83912 (please see Ch. 2 Appendix, 
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Table 1 for descriptions of these codes).  Taken together (BRCA1 and BRCA2), there were 
approximately 81 pieces of DNA that needed to be amplified and analyzed when performing 
BRCA sequencing (the most common type of BRCA testing).  Therefore, for codes 83898, 83904 
and 83909, 81 units represented the total number of DNA segments amplified and analyzed 
across the two BRCA genes.  The DNA extraction and reporting codes were billed at one unit 
each.  
Other types of BRCA tests, such as single-site testing and testing of three common 
mutations seen in the Ashkenazi Jewish population, had other specific numbers of units for CPT 
codes 83898, 83904, 83909 that represented the number of DNA segments involved in the 
analysis (three units each for the Ashkenazi Jewish founder mutations and one unit each for 
single-site mutations). 
As the number of genes for which clinical testing was being ordered increased, it became 
increasingly difficult to track genetic testing billing practices and concerns pertaining to 
inappropriate code stacking grew among insurers and payers. 
The American Medical Association (AMA) and College of American Pathologists (CAP) 
consequently collaborated with Centers of Medicare and Medicaid Services (CMS) to create 
temporary codes (specifically, S3818, S3819, S3820, S3821, S3822 and S3823) that were 
evaluated through 2012 and then became approved CPT codes that were enforced starting on 
January 1, 2013.  These codes were designed to identify the gene(s) that were being tested and 
the methodology of the test itself.  In 2013, the gene-specific CPT codes that were enforced were 
81211, 81212, 81213, 81214, 81215, 81216 and 81217. They mirrored the previous temporary 
codes exactly (see Ch. 2 Appendix, Table 1). 
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Once these gene-specific CPT codes were enforced, the change was accompanied by a 
reduction in reimbursement for BRCA testing, most of which was already being performed as 
part of multi-gene hereditary cancer risk panels.  However, laboratories concluded that the new 
price for BRCA testing did not sufficiently represent the cost of the NGS procedures through 
which BRCA was now being analyzed. 
To compensate for the reimbursement shortfall, laboratories began utilizing non-specific 
CPT codes, such as 81479, that allowed for multiple units of the code to be billed on the same 
date of service and did not have a specific reimbursement amount set by CMS.  This practice 
caused some patients to receive Explanation of Benefits (EOB) letters in which laboratories 
billed as much as $60,000 for a multi-gene panel that included BRCA testing.  This practice has 
abated somewhat due mainly to insurers refusing to reimburse the CPT code 81479 and/or 
refusing to accept into their networks laboratories that bill exorbitant prices for hereditary cancer 
panels.  However, Medicare has still not set a reimbursement rate for code 81479. 
Recently, new codes for non-gene specific genetic testing were reintroduced (CPT codes 
81400-81408).  These codes were designed to be used when partial genes were analyzed or when 
there were no known gene-specific codes that described the lab methodology (please see Ch. 2 
Appendix, Table 1 for full description of these codes).  In some cases, labs used known BRCA 
CPT codes to account for panel testing that included non-BRCA genes, and then stacked these 
81400-08 codes on top of the BRCA codes when they billed.  
It is clear therefore that an accurate accounting of BRCA testing from claims necessitates 
utilization not only of the gene-specific temporary and final CPT codes, but also identification of 
BRCA testing that uses molecular procedure codes (83891, 83898, 83904, 83909 and 83912) that 
were billed together in the appropriate number of corresponding units.  Several papers have 
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attempted to identify BRCA tests using claims.  However, none have utilized the BRCA-specific 
units of service for BRCA sequencing, multi-site three testing and single-site testing. 
 
Previously reported estimates of BRCA tests 
 In June 2016, the first BRCA testing claims analysis was published by Wright et al 
looking at a period of five years before and immediately after Jolie’s editorial of May 2013 
which is believed to have led to a spike in BRCA testing (Anderson RM, 2014; H. J. Guo F, Lin 
Y, Richardson G, Levine L, Berenson A, Kuo Y, 2017; H. J. Guo F, Lin Y, Richardson G, 
Levine L, Berenson A, Kuo Y., 2017)  Wright et al used the Truven MarketScanTM claim 
database from July 2009 to June 2013, and specifically focused on newly diagnosed breast and 
ovarian cancer patients.  The study identified approximately 29,099 carriers (data not shown in 
paper, but calculations based on percentages of BRCA testing identified in patients with breast, 
male breast and ovarian cancer).  
 Although their methods were not clearly explained in the original paper, the methods 
were further detailed in their reply to researchers that commented on their methodology (H. D. L. 
Wright JD, 2016).  The detailed description revealed their methods of identifying BRCA included 
the non-specific molecular pathology methodology codes (83891, 83898, 83904, 83909 and 
83912) and the temporary and final gene-specific CPT codes.   
 However, they did not specify whether these codes were restricted to the number of units 
that represent BRCA sequencing and multi-site founder mutation testing.  Since these 
methodology codes were used for any and all DNA-based tests (from HPV to her2neu testing 
etc.), limiting the search to all five codes billed on the same date of service and in the specific 
number of units would have been the only way to ascertain that such claims truly represented 
BRCA testing and not different DNA test. 
  34 
 As such, it is likely that Wright and colleagues over-estimated the number of BRCA tests 
that were identified using the constellation of five methodology codes, and in fact the increase 
attributable to the Jolie effect is even larger. 
 Chen, Khoury and several other collaborators published a paper in September of 2017 
that utilized the Truven MarketScanTM database from 2003-2014 to assess trends in BRCA 
testing utilization over time.  Their methods identified BRCA tests by using BRCA-specific 
codes, including temporary BRCA codes S3818, S3819, S3820, S3821, S3822 and S3823 and 
CPT codes 81211, 81212, 81213, 81214, 81215, 81216 and 81217.  They specifically excluded 
the molecular pathology methodology-based CPT codes 83891, 83898, 83904, 83909 and 83912, 
which represented the only way to bill for BRCA testing until 2008, when the temporary S codes 
were developed. 
 Using their methodology they identified a total of 192,761 BRCA tests (number totaled 
from Chen et al Supplementary Table S4 in Appendix). (Chen et al., 2017). 
 
METHODS 
BRCA Test Identification  
 BRCA tests were identified using the HCCI outpatient and physician claims database 
from January 1, 2008 to December 31, 2017. Please refer to Ch. 2 Appendix, Table 2 for a 
detailed description of the codes that were used.  Claims with CPT codes 83891, 83898, 83904, 
83909 and 83912 that were all seen the same date of service were labeled as BRCA tests if 
83898, 83904 and 83909 were billed at 81 units, and 83891 and 83912 were billed one unit each. 
This method confirmed that the DNA test that was billed was BRCA1 and BRCA2 sequencing 
since the lab that provided all the tests during the period these codes were in use utilized 81 
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amplicons to sequence these two genes. (The likelihood that another genetic test also used 81 
amplicons is very low, especially during that period of gene paucity.)  For Ashkenazi Jewish, 
three units of 83898, 83904 and 83909 and one of the remaining two codes represented the 
“three founder mutations” BRCA test.  To account for cases of single-site BRCA testing (where 
one specific DNA location was interrogated) all five codes had to be billed on the same day at 
one unit each. 
 Claims coded with temporary BRCA-specific CPT S-codes, or BRCA-specific bona fide 
codes were considered BRCA tests.  Claims coded with hereditary breast and/or ovarian cancer 
gene panel codes were similarly included without restriction. 
 In addition, based on the author’s first hand knowledge of BRCA billing practices among 
laboratories, the CPT code for unlisted molecular pathology procedure (81479) was retained as a 
BRCA test, but only if the primary, secondary or tertiary diagnostic codes (ICD-9 or ICD-10 
codes) indicated a diagnosis, personal history and/or family history of breast and/or ovarian 
cancer, in situ breast cancer, unspecified cancer of female genital organs, benign ovarian tumor 
or unspecified family history of cancer. 
 In limiting the 81479 claims to those performed on individuals with breast and/or ovarian 
cancer, history of either disease or family history of either disease, we captured the BRCA tests 
that were part of large multi-gene panels, and which were billed using the 81479 non-specific 
code either to account for the complexity and cost of the test, or were used because BRCA-
specific CPT coding did not provide a sufficient level of reimbursement.   
 CPT codes used in next-generation sequencing (NGS) (81400-81408) that can be used to 
represent non-gene specific exon-based genetic testing were also labeled as a BRCA test, but 
only if they were associated with a known BRCA code on the same date of service, or with a 
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81479 that had been retained according to the algorithm described above. Unlike the 81479 code, 
which was considered a BRCA test if identified on its own according to the algorithm above, the 
81400-08 were not retained unless a known BRCA code was also used on the same date of 
service. 
 The codes for gene panels that include the two BRCA genes (CPT codes 81432 and 
81433) were also used to identify BRCA claims. 
 Finally, to account for the possibility that each enrollee may have had more than one 
BRCA claim and based on the knowledge that many laboratories after 2013 stacked several codes 
when billing for BRCA to maximize reimbursement, we identified and tabulated all the possible 
different CPT code combinations used for BRCA testing that were seen in the HCCI database. 
 
Comparison of Methodologies to Identify BRCA Testing from Claims Data 
 The algorithm for estimating BRCA tests described in the current paper was compared to 
other methods utilized in published claims data analysis. The methodologies outlined in the 
Wright (2016) and Guo (2017) publications were applied to the HCCI dataset and the number of 
claims and enrollees identified by both the method from current paper and those of the other two 
authors were compared. 
 
RESULTS  
 The methodology presented in this paper identified 794,113 BRCA claims (Table 1) using 
the CPT codes detailed in Ch. 2 Appendix, Table 1, which represented a total of 347,569 
enrollees (Table 1).  
 Table 1 illustrates the how the different CPT codes changed over the study period, with 
some codes being phased out and some codes coming into effect.  The molecular pathology CPT 
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codes (83891, 83898, 83904, 83909 and 83912) were used frequently until 2013 when the new 
gene-specific codes were enforced and the former were no longer reimbursed.  Until 2013, the 
temporary BRCA-specific CPT codes (S-codes) were also frequently used, but they were phased 
out thereafter consistent with the molecular pathology CPT codes.  2012 was a year of transition, 
when both S-codes and bona fide BRCA-specific codes were used.  Years 2013, 2014 and 2015 
saw a dramatic increase in the BRCA-specific codes, and 2016 and 2017 saw dramatic increases 
in non-specific new NGS codes (81400-08).  
Table 1. Claims identified as BRCA tests, or with BRCA as a component, and count of individuals by year of BRCA 
test using current paper method of BRCA test identification 
 Year  
CPT 
codes 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total 
81162 0 0 0 0 0 0 0 0 1,751 12,866 14,617 
81211 0 0 0 0 10,606 36,855 40,629 48,495 38,522 28,464 203,571 
81212 0 0 0 0 938 2,618 2,249 1,883 1,648 1,273 10,609 
81213 0 0 0 0 3,572 25,904 29,212 32,557 21,037 11,559 123,841 
81214 0 0 0 0 - - - 142 28 29 210 
81215 0 0 0 0 444 1,052 998 1,713 928 651 5,786 
81216 0 0 0 0 11 27 - 110 34 118 308 
81217 0 0 0 0 471 1,274 1,160 1,136 1,157 864 6,062 
81400 0 0 0 0 0 27 160 1,612 600 346 2,745 
81401 0 0 0 0 - 220 298 2,733 2,204 1,430 6,886 
81402 0 0 0 0 - 316 748 1,898 153 98 3,214 
81403 0 0 0 0 - 875 1,648 5,628 4,858 4,046 17,056 
81404 0 0 0 0 - 1,061 1,685 6,004 8,855 12,643 30,251 
81405 0 0 0 0 - 829 1,382 5,437 8,916 6,283 22,848 
81406 0 0 0 0 - 446 550 5,023 13,596 17,819 37,435 
81407 0 0 0 0 - 179 201 975 1398 1,168 3,922 
81408 0 0 0 0 - 629 783 2,976 5,219 5,252 14,860 
81432 0 0 0 0 0 0 0 0 6922 5,810 12,732 
81433 0 0 0 0 0 0 0 0 6492 4,934 11,426 
81479 0 0 0 0 0 1,683 8,700 35,108 34,963 10,871 91,325 
83891 617 1,105 1,394 1,728 12,456 - 0 0 0 0 17,301 
83898 911 1,290 1,469 2,023 11,139 - 0 0 0 0 16,833 
83904 763 1,398 1,561 2,139 11,139 - 0 0 0 0 17,001 
83909 601 1,133 1,435 1,856 11,496 - 0 0 0 0 16,522 
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83912 734 1,267 1,541 1,885 12,667 - 0 0 0 0 18,095 
S3818 - - 0 - - 0 0 0 0 0 - 
S3819 - - - - 0 0 0 0 0 0 - 
S3820 14,219 18,129 18,009 19,626 5,479 0 0 0 0 0 75,462 
S3822 1,041 1,254 1,407 1,544 404 0 0 0 0 0 5,650 
S3823 1,578 1,850 1,817 1,806 478 0 0 0 0 0 7,529 
Total 
Claims 
20,468 27,431 28,634 32,612 81,312 74,007 90,414 153,430 159,281 126,524 794,113 
Total 
En-
rollees 
16,251 20,933 21,317 23,332 27,680 38,993 43,649 51,882 52,217 51,315 347,569 
 
 When the 81400-08 claims were interrogated for other CPT codes billed on the same date 
of service, most also had a BRCA code (see Ch. 2 Appendix, Table 4).  In such cases, the claims 
were considered BRCA claims. The 81400-08 codes accompanied known BRCA CPT codes on 
the same date of service, but were not counted as BRCA tests if billed alone.  CMS did not 
establish the fee schedule for the 81400-08 codes until 2016. Many laboratories providing NGS 
hereditary testing used these codes to increase their charges, and thus their reimbursement 
(whether as part of a contracted rate or not).  
Using the methodology that Wright et al (2016) described in their paper, a total of 
218,744 BRCA claims were identified, representing a total number of 107,395 enrollees (Table 
2).  Wright and colleagues searched for BRCA tests only among newly diagnosed breast cancer 
patients (male and female) and ovarian cancer patients within 180 days before or after diagnosis. 
Their exact method was applied to the HCCI database by censoring enrollees who did not 
meet their diagnostic criteria. Their method overestimates the number of BRCA tests from 2008-
2012, using the molecular pathology codes without correct units of service and underestimates 
the number of BRCA tests from 2013-2017 by not using the cancer gene panel codes nor the non-
specific CPT code 81479.  For example, in 2008 the Wright method finds 2,970 claims with 
83891, whereas the current paper method limits this code to 81, 3 or 1 unit(s), all billed on the 
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same date of service and identifies 617 claims coded with 83891.  Similarly, in 2016, the Wright 
method finds zero claims billed with the gene panel code 81432, whereas the method in the 
current paper identifies 6,922 such claims.   
Table 2. Claims and enrollees identified as BRCA tests and BRCA tested individuals by year using methodology 
from Wright et al.  
CPT 
codes 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total 
81211 0 0 0 0 4,051 11,769 11,771 13,131 11,867 7,488 60,077 
81212 0 0 0 0 269 705 579 387 372 242 2,554 
81213 0 0 0 0 1,028 7,772 8,681 9,051 6,840 2,933 36,305 
81214 0 0 0 0 0 - 0 - - 0 - 
81215 0 0 0 0 60 119 120 139 75 38 551 
81216 0 0 0 0 0 - 0 - - - 11 
81217 0 0 0 0 62 155 126 99 73 60 575 
83891 2,970 3,349 3,193 3,299 7,431 0 0 0 0 0 20,242 
83898 2,343 2,586 2,556 2,775 6,956 0 0 0 0 0 17,216 
83904 856 997 980 1,049 4,878 0 0 0 0 0 8,760 
83909 1,250 1,593 1,939 2,071 6,212 0 0 0 0 0 13,065 
83912 4,059 4,559 3,968 3,951 8,127 0 0 0 0 0 24,664 
S3818 - 0 0 - 0 0 0 0 0 0 - 
S3820 7,197 7,018 7,117 7,911 2,205 0 0 0 0 0 31,448 
S3822 198 193 190 191 57 0 0 0 0 0 829 
S3823 608 568 558 542 165 0 0 0 0 0 2,441 
Total 
Claims 19,483 20,863 20,501 21,790 41,501 20,523 21,277 22,811 19,230 10,765 218,744 
Total 
En-
rollees 
10,531 10,340 9,988 10,807 11,943 11,041 11,275 12,367 11,610 7,493 107,395 
 
Similarly, the analysis performed by Chen et al (2017) was reconstructed using our HCCI 
database and their method.  Using the Chen method, a total number of 439,044 claims for BRCA 
testing were identified representing 295,612 unique enrollees who had BRCA testing (see Table 
3).  Because they did not use any of the five molecular pathology CPT codes, they did not 
identify any of the BRCA tests billed in this manner before 2013, of which there were over 
11,000 each, in 2012 (see Table 1).  In addition, they also did not account for the BRCA tests 
billed with gene panel codes, nor those billed using the non-specific, stackable 81479 code.  The 
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current paper method identified 6,922 claims billed with the former, and 34,963 billed with the 
latter CPT code in 2016. 
Table 3. Claims and enrollees identified as BRCA tests and BRCA tested individuals by year using methodology 
from Chen et al.  
CPT 
codes 2008 2009 2010 2011 2012 2013 2014 2015 2016 2016 Total 
81211 136 203 239 335 10,920 37,209 40,526 47,902 37,977 28,124 203,571 
81212 - - - - 938 2,620 2,252 1,882 1,653 1,257 10,609 
81213 183 225 281 395 3,839 25,586 28,917 32,151 20,784 11,480 123,841 
81214 0 0 0 0 - - - 142 28 27 210 
81215 - - - - 452 1,072 1,040 1,626 927 648 5,786 
81216 0 0 0 0 11 27 - 112 32 117 308 
81217 0 0 - 0 472 1,279 1,156 1,138 1,153 863 6,062 
S3818 - - 0 - - 0 0 0 0 0 - 
S3819 - - - - 0 0 0 0 0 0 - 
S3820 14,228 18,137 18,002 19,619 5,476 0 0 0 0 0 75,462 
S3822 1,043 1,255 1,407 1,541 404 0 0 0 0 0 5,650 
S3823 1,578 1,852 1,815 1,806 478 0 0 0 0 0 7,529 
Total 
Claims 17,180 21,686 21,750 23,708 22,992 67,801 73,904 84,953 62,554 42,516 439,044 
Total 
Enrollees 15,814 20,106 20,173 21,895 18,577 38,366 42,154 48,251 40,008 30,268 295,612 
 
The overall number of enrollees with BRCA testing identified by all three methods were 
tabulated and compared.   
The Wright et al overestimation of BRCA tests from 2008-2013 is 273. The 
overestimation from 2008-2012 is almost cancelled by the underestimation from 2013-2017, 
such that the actual difference in total BRCA claims is only 273 (see Table 4). 
 
Table 4. Comparison of the Wright vs. current method for identifying BRCA claims.  
Year of 
Diagnosis 
Wright et al. 
Overestimate 
Wright & 
Current 
Algorithm 
Current 
Algorithm 
Only 
Total 
Enrollees 
2008 3,121 8,218 - 11,346 
2009 2,903 7,306 64 10,273 
2010 2,425 7,595 146 10,166 
2011 2,407 8,342 242 10,991 
2012 2,483 9,311 409 12,203 
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2013 145 11,123 903 12,171 
2014 0 11,392 936 12,328 
2015 0 12,384 1,274 13,658 
2016 0 11,268 3,425 14,693 
2017 0 6,972 6,351 13,323 
Total 13,484 93,911 13,757 121,152 
Wright et 
al. Total 107,395    
Current 
Algorithm 
Total  
107,668   
 
A comparison of the Chen method to the algorithm from the current study demonstrates 
that the current method identifies almost 52,000 more BRCA tests than the Chen methodology.   
Table 5. Comparison of the Chen vs. our method for identifying BRCA claims 
Year 
Enrollees 
identified by 
Current 
Algorithm Only 
Enrollees 
identified by 
Current 
Algorithm and 
Chen et al. 
Total 
Enrollees 
2008 434 15,817 16,251 
2009 822 20,111 20,933 
2010 1,135 20,182 21,317 
2011 1,422 21,910 23,332 
2012 8,837 18,843 27,680 
2013 717 38,276 38,993 
2014 1,540 42,109 43,649 
2015 3,647 48,235 51,882 
2016 12,311 39,906 52,217 
2017 21,092 30,223 51,315 
Total 51,957 295,612 347,569 
 
 
DISCUSSION 
 The BRCA identification methodology outlined in this paper identified 13,757 more 
BRCA tests than the Wright methodology when applied to the same database (HCCI).  It also 
identified 51,957 more BRCA tests than the Chen methodology. 
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The CPT codes used by Wright and colleagues are almost identical to the method in this 
study with three exceptions: (1) for the methodology molecular pathology codes (83891, 83898, 
83904, 83909, 83912), the current study limited the middle three codes to 81 units and the same 
date of service; (2) the current study included the non-specific 81749 code for patients with 
diagnoses of cancer and family histories of cancer consistent with BRCA testing; and (3) the 
current study included the multi-gene panel CPT codes that include the BRCA genes (81432, 
81433). As such, it is likely the Wright method overestimated the number of BRCA tests when 
using the molecular pathology codes because due to the lack of restriction of units of service to 
the ones that represent BRCA1 and BRCA2 testing (n=81 for full sequencing, n=3 for Ashkenazi 
Jewish multi-site, and n=1 for single site, all billed on the same date of service) this is not a 
complete sentence.  Since these non-specific molecular pathology codes can be used for any 
genetic test, their method is likely to identify claims for other genetic tests related to cancer 
diagnoses, such as her2neu. 
The practice of not limiting the molecular pathology codes to the 81 units that represent 
the correct number of BRCA1 and BRCA2 amplicons used in sequencing led the Wright group to 
overestimate the number of BRCA tests from 2008-2013 when these non-specific molecular 
pathology codes were in frequent use.  In addition, from 2013-2017 they underestimated the 
number of BRCA tests, since they did not use the 81479 CPT code that laboratories started using 
in 2014 once the fee schedule for BRCA CPT codes decreased the reimbursable amount. Wright 
et al also did not use the BRCA-inclusive gene panel codes (81432, 81433).  Overall however, 
the actual difference between the Wright method and that from the current paper is only 273 
claims, most likely due to the fact that overestimation of BRCA tests from 2008-2013 is almost 
cancelled by the underestimation from 2013-2017 (see Table 4).  
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The Chen method used the same CPT codes as this paper, but they did not include the 
methodology molecular based CPT codes at all, nor did they include the 81479 non-specific code 
and the BRCA gene-panel codes (81432, 81433).  As such, it is likely they also underestimated 
the number of BRCA codes.  
 The current study method identified almost 52,000 more BRCA tests than the Chen study.  
This is most likely due to the fact that the Chen algorithm did not include the methodology-based 
molecular pathology CPT codes, nor the non-specific 81479 CPT code and the BRCA-panel CPT 
codes (81432, 81433).  The Chen BRCA claims are in fact a subset of the claims identified by the 
current study method. Therefore, the Chen method underestimated the number of BRCA claims 
throughout the study period; from 2008-2013 they did not identify the BRCA claims that use the 
molecular pathology codes; from 2013 to 2017 they did not identify the BRCA claims that use 
the non-specific, stackable 81479 code, and they also missed the BRCA-inclusive gene panel 
tests (CPT codes 81432, 81433). 
 Table 6 represents a summary of the three different claims and BRCA tests identified by 
each of the three algorithms.  For the current study, the ratio of claims to BRCA tests was 2.28, 
while the Wright method had a ratio of 2.03, and Chen had a ratio of 1.48.  The method for 
BRCA claim identification described in the current paper found 72% more tests than the Wright 
method and 45% more tests than the Chen method.  Similarly, the current method identified 69% 
more enrollees who underwent BRCA testing compared to the Wright method and 15% more 
than the Chen method. 
Table 6. Current method compared to the Wright et al, and Chen et al methods for identifying BRCA test using 
claims analysis. 
 Current Paper 
method 
Wright et al 
method 
Chen et al 
method 
Total number of BRCA claims 794,113 218,744 439,044 
Total number of enrollees who had BRCA testing 347,569 107,395 295,612 
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 The methodology in the current paper represents a more specific and accurate algorithm 
to identify claims for BRCA testing by taking into consideration changes in coding practices of 
billing laboratories over time.  As such, it more accurately identifies BRCA tests from claims 
data. 
 New methodology in hereditary cancer testing and BRCA testing in particular make it 
challenging to capture all the BRCA tests ordered on patients via claims analysis.  A thorough 
understanding of the BRCA testing methodology and billing practices of the laboratories 
combined with experience from the clinical and patient perspectives are important components 
of a strategy designed to maximize BRCA test identification from claims analysis. 
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 APPENDIX 
Chapter 2 Appendix, Table 1. Summary of various procedure codes used for BRCA testing 
Code Description Number 
of Units 
Name of Test, or what 
code represents 
clinically 
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 BRCA Sequencing  
(aka “Bracanalysis” TM) 
83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
81 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
81 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
81 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 “Multi-site 3 test”; 3 
BRCA mutations 
commonly seen in 
Ashkenazi individuals 
83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
3 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
3 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
3 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 BRCA single-site testing 
83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
1 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
1 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
1 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
S3818 
 
Complete gene sequence analysis: BRCA1 gene 1 BRCA1 sequencing 
S3819 
 
Complete gene sequence analysis: BRCA2 gene 1 BRCA2 sequencing 
S3820 Complete BRCA1 and BRCA2 gene sequence analysis 
for susceptibility to breast and ovarian cancer 
1 BRCA1 and BRCA2 
sequencing 
S3822 Single mutation analysis (in individual with a known 
BRCA1 or BRCA2 mutation in the family) for 
susceptibility to breast and ovarian cancer 
1 Single site testing in 
BRCA1 or BRCA2 
S3823 Three-mutation BRCA1 and BRCA2 analysis for 
susceptibility to breast and ovarian cancer 
1 3 BRCA mutations 
commonly seen in 
Ashkenazi individuals 
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81211 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary 
breast and ovarian cancer) gene analysis; full sequence 
analysis and common duplication/deletion variants in 
BRCA1 (i.e./ exon 13 del 3.835kb, exon 13 dup 6kb, 
exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 
7.1kb) 
1 BRCA1 and BRCA2 
sequencing and 5 known 
BRCA1 
deletions/duplications 
81212 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g./ hereditary 
breast and ovarian cancer) gene analysis; 185delAG, 
5385insC, 6174delT variants 
1 3 BRCA mutations 
commonly seen in 
Ashkenazi individuals 
81213 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g./ hereditary 
breast and ovarian cancer) gene analysis; uncommon 
duplication/deletion variants  
1 BRCA1 and BRCA2 
deletion and duplication 
analysis 
81214 BRCA1 (breast cancer 1) (e.g./ hereditary breast and 
ovarian cancer) gene analysis; full sequence analysis 
and common duplication/deletion variants (i.e./ exon 13 
del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, 
exon 22 del 510bp, exon 8-9 del 7.1kb) 
1 BRCA1 sequencing and 
5 known BRCA1 
deletions/duplications 
81215 BRCA1 (breast cancer 1) (eg, hereditary breast and 
ovarian cancer) gene analysis; known familial variant 
1 BRCA1 single site 
testing 
81216 BRCA2 (breast cancer 2) (eg, hereditary breast and 
ovarian cancer) gene analysis; full sequence analysis 
1 BRCA2 sequencing 
81217 BRCA2 (breast cancer 2) (eg, hereditary breast and 
ovarian cancer) gene analysis; known familial variant 
1 BRCA2 single site 
testing 
    
81162 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary 
breast and ovarian cancer) gene analysis; full sequence 
analysis and full duplication/deletion analysis 
1 BRCA1 and BRCA2 
sequencing and 
deletion/duplication 
analysis 
    
81479 Unlisted molecular pathology procedure 
 
Various 
number of 
units 
BRCA1, BRCA2 
sequencing and deletion 
and duplication testing, 
in conjunction with other 
genes, aka Next 
Generation Sequencing, 
or Multi-Gene Panel, 
usually billed when other 
codes perceived as not 
sufficiently 
representative of the 
procedures performed 
    
81432 Genomic Sequencing Procedures and Other Molecular 
Multianalyte Assays; Hereditary breast cancer-related 
disorders (eg, hereditary breast cancer, hereditary 
ovarian cancer, hereditary endometrial cancer); genomic 
sequence analysis panel, must include sequencing of at 
least 10 genes, always including BRCA1, BRCA2, 
CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11 
and TP53, effective 01/01/2018  
1 Breast Cancer Multi-
Gene large panel 
(includes BRCA1 and 
BRCA2 sequencing and 
deletion duplication 
testing via NGS) 
81433 Hereditary breast cancer-related disorders (e.g., 
hereditary breast cancer, hereditary ovarian cancer, 
hereditary endometrial cancer); duplication/deletion 
analysis panel, must include analyses for BRCA1, 
 Breast Cancer Multi-
Gene small panel 
(includes BRCA1 and 
BRCA2 sequencing and 
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BRCA2, MLH1, MSH2, and STK11 
 
deletion duplication 
testing via NGS) 
    
81400 Molecular pathology procedure, Level 1 (eg, 
identification of single germline variant [eg, SNP] by 
techniques such as restriction enzyme digestion or melt 
curve analysis) 
 
 N/A 
81401 Molecular pathology procedure Level 2 (eg, 2-10 SNPs, 
1 methylated variant, or 1 somatic variant [typically 
using non-sequencing target variant analysis], or 
detection of a dynamic mutation disorder/triplet repeat) 
 
 N/A 
81402 Molecular pathology procedure Level 3 (>10 SNPs, 2-
10 methylated variants, or 2-10 somatic variants 
[typically using non-sequencing target variant analysis], 
immunoglobulin and T-cell receptor gene 
rearrangements, duplication/deletion variants of 1 exon, 
loss of heterozygosity [LOH], uniparental disomy 
[UPD]) 
 N/A 
81403 Molecular pathology procedure, Level 4 (eg, analysis of 
single exon by DNA sequence analysis, analysis of >10 
amplicons using multiplex PCR in 2 or more 
independent reactions, mutation scanning or 
duplication/deletion variants of 2-5 exons) 
 
 N/A 
81404 Molecular pathology procedure, Level 5 (eg, analysis of 
2-5 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 6-10 exons, 
or characterization of a dynamic mutation 
disorder/triplet repeat by Southern blot analysis) 
 
 N/A 
81405 Molecular pathology procedure, Level 6 (eg, analysis of 
6-10 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 11-25 
exons, regionally targeted cytogenomic array analysis) 
 
 N/A 
81406 Molecular pathology procedure, Level 7 (eg, analysis of 
11-25 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 26-50 
exons, cytogenomic array analysis for neoplasia) 
Molecular pathology procedure, Level 8 (eg, analysis of 
26-50 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of >50 exons, 
sequence analysis of multiple genes on one platform) 
 
 N/A 
81407 Molecular pathology procedure, Level 8 (eg, analysis of  N/A 
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26-50 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of >50 exons, 
sequence analysis of multiple genes on one platform) 
 
81408 Molecular pathology procedure, Level 9 (eg, analysis of 
>50 exons in a single gene by DNA sequence analysis) 
 
 N/A 
 
Chapter 2 Appendix, Table 2. ICD-9 and ICD-10 codes used to select claims coded with CPT 81479 
ICD-9 code Code Description 
174.x Malignant neoplasm of the breast, female  
175.x Malignant neoplasm of the breast, male  
233.x In Situ neoplasm of the breast  
V10.3 Personal history of malignant neoplasm of the breast  
V16.3 Family history of malignant neoplasm of the breast  
183.0 Malignant neoplasm of the ovary/ovaries 
184.0 Malignant neoplasm of unspecified female organs 
220 Benign neoplasm of the ovary and other unspecified female organs 
V10.43 Personal history of malignant neoplasm of the ovary/ovaries 
V16.41 Family history of malignant neoplasm of the ovary/ovaries 
V16.8 Family history of malignant neoplasm of other organs or systems. 
V16.9 Family history of malignant neoplasm, unspecified. 
ICD-10 code Code Description 
C50.x Malignant neoplasm of the breast (male and female) 
D05.x In Situ neoplasm of the breast 
Z80.43 Personal history of malignant neoplasm of the breast 
Z80.3 Family history of malignant neoplasm of the breast 
C56.x Malignant neoplasm of the ovary/ovaries 
C57.x Malignant neoplasm of fallopian tube 
Z85.43 Personal history of malignant neoplasm of the ovary/ovaries 
Z80.43 Personal history of malignant neoplasm of the ovary/ovaries 
D27.x Benign neoplasm of the ovary 
Z80.8 Family history of malignant neoplasm of other organs or systems. 
Z80.9 Family history of malignant neoplasm, unspecified. 
 
Chapter 2 Appendix, Table 3: CPTs 81400-08 by year 
CPT 2012 2013 2014 2015 2016 2017 Total 
81400 0 27 160 1,612 600 346 2,745 
81401 - 220 298 2,733 2,204 1,430 6,886 
81402 - 316 748 1,898 153 98 3,214 
81403 - 875 1,648 5,628 4,858 4,046 17,056 
81404 - 1,061 1,685 6,004 8,855 12,643 30,251 
81405 - 829 1,382 5,437 8,916 6,283 22,848 
81406 - 446 550 5,023 13,596 17,819 37,435 
81407 - 179 201 975 1,398 1,168 3,922 
81408 - 629 783 2,976 5,219 5,252 14,860 
Total 10 4,582 7,455 32,286 45,799 49,085 139,217 
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Chapter 2 Appendix, Table 4: Thirty-five most frequent variations of CPT code combinations billed as BRCA testing 
when a 81400-81408 code is billed as well. 
Procedure Code Combinations Frequency Percent (%) Cumulative 
Percent (%) 
81211/81213/81404/81406 8,484 27.4 27.4 
81211/81213/81479/81406 1,948 6.3 33.7 
81211/81213/81406 1450 4.7 38.4 
81162/81404/81406 1146 3.7 42.1 
81211/81213/81408 892 2.9 45.0 
81211/81213/81403/81404/81405/81406/8.. 672 2.2 47.2 
81211/81401/81403/81404/81405/81406/8.. 585 1.9 49.1 
81211/81213/81479/81403/81404/81405/8.. 576 1.9 50.9 
81162/81406 540 1.8 52.7 
81162/81479/81403/81404/81405/81406/8.. 506 1.6 54.3 
81215/81400/81401/81402/81403/81404/8.. 473 1.5 55.8 
81162/81403/81404/81405/81406/81408 434 1.4 57.2 
81211/81213/81479/81405/81406/81408 417 1.4 58.6 
81211/81400/81402/81403/81404/81405 385 1.2 59.8 
81162/81479/81405/81406/81408 372 1.2 61.0 
81211/81213/81404 356 1.2 62.2 
81211/81213/81405/81406/81408 334 1.1 63.2 
81211/81401/81402/81403/81404/81405/8.. 333 1.1 64.3 
81211/81406 300 1.0 65.3 
81211/81404/81406 286 0.9 66.2 
81211/81213/81479/81408 265 0.9 67.1 
81211/81403 256 0.8 67.9 
81211/81408 247 0.8 68.7 
81162/81405/81406 242 0.8 69.5 
81211/81404/81405/81406 232 0.8 70.2 
81211/81213/81403 229 0.7 71.0 
81211/81479/81400/81402/81403/81404/8.. 229 0.7 71.7 
81211/81479/81401/81403/81404/81405/8.. 208 0.7 72.4 
81211/81402/81403/81404/81405 194 0.6 73.0 
81211/81400/81403/81404/81405 188 0.6 73.6 
81211/81404 184 0.6 74.2 
81211/81403/81404/81405/81406/81408 183 0.6 74.8 
81211/81213/81405/81406 180 0.6 75.4 
81211/81213/81404/81405/81406 176 0.6 76.0 
81215/81479/81400/81401/81402/81403/8.. 160 0.5 76.5 
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Chapter 2 Appendix, Table 5. Twenty most frequent variations of CPT code combinations billed as BRCA testing. 
BRCA_analysis=claims using the 5 CPT methodology-based codes billed with 81 units and on the same date of 
service.  SingleSite=claims using the 5 CPT methodology-based codes billed with 1 unit and on the same date of 
service 
Procedure Code Combinations Frequency Percent (%) Cumulative 
Percent (%) 
S3820 71,081 19.7 19.7 
81211/81213 69,780 19.3 39.0 
81211 69,529 19.2 58.2 
81211/81213/81479 27,134 7.5 65.7 
81479 19,961 5.5 71.2 
81432/81433 10,314 2.9 74.1 
81162 9,535 2.6 76.7 
BRCA_analysis 8,817 2.4 79.2 
81211/81213/81404/81406 8,484 2.4 81.5 
81217 5,677 1.6 83.1 
81212 5,555 1.5 84.6 
S3822 5,432 1.5 86.1 
81215 4,779 1.3 87.5 
S3823 4,382 1.2 88.7 
SingleSite 4,041 1.1 89.8 
81213 3,279 0.9 90.7 
S3820/S3823 3,063 0.9 91.5 
81211/81213/81479/81406 1,948 0.5 92.1 
81211/81212/81213 1,936 0.5 92.6 
81211/81212 1,451 0.4 93.0 
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CHAPTER 3.  UNADJUSTED BRCA RATES AMONG ELIGIBLE ENROLEES 
 
KEY FINDINGS 
• BRCA testing increased from 2008 to 2017, relatively slowly until 2012 and then more 
aggressively in 2013, 2014 and 2015.  
• The testing rate was 5.1%, among eligible enrollees 
• BRCA testing was driven by a family history of both breast and ovarian cancer, as well as young 
age. 
• The steepest increase in BRCA testing in unaffected enrollees occurred among those with a family 
history of both breast and ovarian cancer in 2013 when the rate increased by 13% over the 
previous year.  
• The steepest increase in BRCA testing in affected enrollees was observed among those with 
ovarian cancer and a family history of both breast and ovarian cancer; this 17% increase occurred 
in 2013. 
• There was a Jolie effect across most age, cancer, and family history categories, but it had varying 
degrees of magnitude.   
• Premenopausal women had the highest rates of testing in 2008 and maintained that ranking 
through 2017. 
• Patent dissolution led to an increase in average billed charges and paid amounts and, to a lesser 
degree, in patient cost-sharing amounts. 
 
INTRODUCTION 
 Numerous publications have documented the uptake of BRCA testing in clinical series, 
typically from large academic centers with dedicated genetics staff.  They have shown that 
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BRCA uptake has improved in both affected and unaffected patients with a family history of 
cancer.  However, caution should be taken when generalizing the findings of such studies to 
community settings, and questions about the actual uptake of BRCA testing outside of high-risk 
clinics remain.  In an effort to characterize BRCA uptake in a more representative sample of the 
U.S. population, several publications have attempted to estimate the uptake of BRCA testing 
from claims data with varying degrees of accuracy due to variations in BRCA billing codes over 
time and among various laboratory providers.  Please refer to Chapter 2 for discussion of the 
ideal algorithm to capture a complete and full accounting of BRCA testing. 
 Several publications have also demonstrated an increase in genetic testing since Angelina 
Jolie’s editorial documenting her journey to risk-reducing surgery as a known BRCA mutation 
carrier (Desai S, 2016; Evans DG, 2015; Evans DGR, 2014).  These findings were based on 
clinical series of patients and observations from academic high-risk clinics.  The studies analyzed 
the periods before and after Jolie’s editorial to evaluate its effect on the uptake of BRCA testing. 
 BRCA identification accuracy notwithstanding, Wright et al found that BRCA testing for 
breast (male and female) and ovarian cancer increased over time in individuals diagnosed with 
these three malignancies. They reported that from 2009 through 2013, BRCA testing increased 
from 42.3% to 57.3% in women with breast cancer under age 50, and from 15.8% to 23.3% for 
women with ovarian cancer over the same period.  BRCA testing increased from 20.9% to 41.6% 
for women (non-age specific) with breast cancer and from 12.1% to 21.0% for women (non-age 
specific) with ovarian cancer over the studied period (C. L. Wright JD, Tergas AI, Acordino M, 
Ananth CV, Neugut AI, Hershman DL, 2016)   
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Similarly, Chen et al. showed a dramatic increase in BRCA testing from 2012 to 2014 
with 68% more women undergoing BRCA testing.  Relative to 2012, BRCA testing rates in 2013 
increased by 57% compared to an average annual increase of 10% in the three preceding years 
(2009 to 2012) (Chen et al., 2017).  
Roberts and Dusetzina also looked at the MarketScanTM claims database from 2012 to 
2014 and found that BRCA testing increased between April and May 2013 (month of Jolie’s 
editorial) from 12.6 to 16.4 tests per 100,000 women, but no difference in testing over time by 
covariates (age, region, relationship to plan holder, and health insurance type) in bivariate 
analyses. In addition, they found that use of post-BRCA test health services (breast MRI, surgeon 
visits, mastectomy) declined, but there was a slight increase in mammography, and utilization of 
genetic counseling remained constant (Roberts MC, 2017).  
Finally, Guo and colleagues from University of Texas used the Optum claims database to 
identify use of the BRCA test from 2004 to 2014, originally agnostic to the natural experiment 
represented by the Jolie editorial.  They found that the proportion of BRCA testing increased 
from 24.3% in 2004 to 61.4% (a 150% increase) in 2014 at a p<0.001. Although their analysis 
identified significant interactions between year of BRCA testing and age, geographic region and 
family history of breast and/or ovarian cancer, they did not parse the data more finely to identify 
the degree to which the Jolie effect played a role in the increase in genetic testing.  Prompted by 
a later comment (Nabi H, 2017), they re-analyzed the data and identified that the month 
following the Jolie editorial showed an increase in BRCA testing of 42% in unaffected women 
and 14-20% in women with breast and ovarian cancer, respectively (compared to the month 
preceding the editorial (H. J. Guo F, Lin Y, Richardson G, Levine L, Berenson A, Kuo Y, 2017).  
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All these publications identified an increase in BRCA testing after the Jolie editorial.  
However, it is important to note that the methods used to identify BRCA testing were incorrect, 
and as a result, misestimated the effect of the Jolie editorial on BRCA uptake.  Additionally, the 
publications did not account for other drivers of genetic testing such as cancer diagnosis, family 
history of cancer, age and insurance type.  These gaps are addressed in the current chapter. 
 
METHODS 
Cohort Selection 
 Cohort 1 or “Eligible Enrollees Dataset” includes all enrollees with cancers caused by 
BRCA mutations and enrollees with a family history of cancers associated with BRCA mutations. 
These enrollees were included in Cohort 1 and are considered “eligible” for BRCA testing with 
the understanding that to cast as broad a net as possible for capturing enrollees that are 
candidates for BRCA testing, the indications for testing should be generous and much more 
relaxed than published guidelines.  
 To establish a pool of enrollees eligible for BRCA testing, we identified all patients with a 
diagnosis of invasive cancer of the breast (male and female), ovary, fallopian tube, pancreas, 
colon, eye (for uveal melanoma) and cutaneous melanoma, and a family history of breast, ovary, 
and gastrointestinal (for family history of pancreatic cancer) or other cancer.  Inclusion of colon 
cancer represents a more generous interpretation of most genetic testing guidelines, but the 
literature has demonstrated that in some BRCA families, colon cancer is part of the spectrum of 
disease (Phelan CM, 2014). 
Due to similarities in etiology, fallopian tube cancer and ovarian cancer were grouped 
together in further analyses.  The following cancers were grouped together under “other cancer” 
  56 
diagnosis: pancreatic, melanoma, uveal melanoma and colorectal cancer.  For family history of 
“other cancer”, family history of gastrointestinal cancer (to account for family history of 
pancreatic cancer), “family history of unspecified malignant neoplasm” and “family history of 
cancer of other specified malignant neoplasm” (to account for family history of cutaneous and 
uveal melanoma) were grouped together under family history of other cancer.  For a complete 
list of diagnostic codes (ICD-9 and ICD-10) please see Ch.3 Appendix, Table 2. 
Cancer status was determined using only primary ICD-9 and ICD-10 diagnostic codes, 
whereas family history of cancer was determined using primary, secondary and tertiary 
diagnostic codes.  All three diagnostic code fields were used to identify family history of cancer 
because based on the author’s clinical experience, family history is not always coded as a 
primary diagnosis, since non-V-codes (whether cancer-related or not) are typically reimbursed at 
higher rates.  Therefore, investigating secondary and tertiary diagnostic codes for family history 
is warranted.  For patients with cancer however, most of their cancer-related claims will be 
coded with an active cancer primary diagnostic code (i.e./not a V-code).   
An enrollee was considered affected if in the primary diagnostic field there was diagnosis 
of cancer.  An enrollee was considered unaffected if any of the three diagnostic fields had a 
family history of cancer. An affected enrollee may have also been categorized as having a family 
history in another diagnostic field, but was still excluded from the unaffected group (i.e. affected 
and unaffected are mutually exclusive; cancer status and family history are not).  
Cohort 2 is a subset of Cohort 1 and is comprised of enrollees who were identified as 
having had BRCA testing using the BRCA identification methodology outlined in Chapter 2 
Methods. 
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Enrollee characteristics 
 After all enrollees within the HCCI database with cancer, a family history of cancer, 
and/or BRCA testing were identified, they were matched to their member file for the month of 
enrollment in which they received BRCA testing among those with BRCA testing; the month of 
initial cancer diagnosis if they had cancer and no BRCA testing; or the month of initial family 
history of cancer if they had neither cancer nor BRCA testing. Member enrollment information 
included age band (0-17, 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85+, and unknown), 
insurance plan type (preferred provider organization, health maintenance organization, exclusive 
provider organization, indemnity, private fee-for-service, point of service, short-term plan, and 
unknown), sex (male, female, and unknown), state of residence, and five-digit zip-code.  
 
Statistical Analysis 
Descriptive analysis 
Univariate analyses were performed on Cohort 1 and Cohort 2 for the following: gender, 
insurance type, year of BRCA test, age band, cancer type (breast, ovarian, breast and ovarian 
cancer and other cancer) and family history (family history of breast, ovarian, breast and ovarian, 
and other family history). 
Bivariate analyses were also performed for insurance and year, gender and year, age band 
and year, cancer type and year, family history and year, and family history and cancer.   
Geographic Variation 
 To assess geographic variation for BRCA testing, we divided enrollees into three groups: 
(1) enrollees without cancer, but with a family history of cancer, (2) enrollees with cancer and a 
family history of cancer, and (3) enrollees with cancer, but no family history. For each, the 
following calculations were undertaken at the State level: percentage of eligible enrollees who 
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had BRCA testing; number of enrollees eligible for BRCA testing; and number of enrollees who 
had BRCA testing. The State of residence variable was used to match patients to States for 
geographic analysis or BRCA testing.   
 
RESULTS 
Demographics 
A total of 794,113 BRCA claims were identified (Ch. 3 Appendix, Table 3), which 
represent 347,569 enrollees (Ch. 3 Appendix, Table 4).  334,714 (96%) enrollees had one BRCA 
test; 12,026 (3.5%) enrollees had two BRCA tests; 707 (0.2%) enrollees had 3 BRCA tests, and 
122 (0.03%) enrollees had 4 or more BRCA tests (see Ch. 3 Appendix, Table 5). 
The majority (79%) of enrollees with indications for testing (Cohort 1) were female.  
21% identified as male, and 0.05% identified as unknown gender (see Ch. 3 Appendix, Table 
6).   
There were 6,495,815 enrollees who had an indication for BRCA testing.  An additional 
16,838 (0.3%) enrollees who had BRCA testing but for whom no clear indication for testing 
could be identified; that is, they had no family history of cancer, nor a diagnosis of cancer 
consistent with a BRCA mutation as defined in Ch. 3 Appendix Table 2.  Together, these two 
groups added up to a total of 6,512,653 (Cohort 1) (see Ch. 3 Appendix, Table 3).   
Enrollees who had BRCA testing but no clear indication for testing (n=16,838) were 
increasingly female (58% in 2008 vs. 75% in 2017, Ch. 3 Appendix, Table 18).  In 2008, 28% 
were children under 17, but that decreased to 1% by 2017.  The opposite occurred in the 45-64 
and 65-74 age groups, which started at 14% and 3%, respectively, in 2008 and increased to 20% 
and 13%, respectively, in 2017 (Ch. 3 Appendix, Table 17).  The insurance mix stayed relatively 
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constant, with a slight increase in HMOs (11% to 16%) and POS (55% to 60%) and a decrease in 
PPOs (27% to 18%) (see Ch. 3 Appendix, Table 19) 
From the 6,495,815 enrollees eligible for BRCA testing claims, 330,731 actually had the 
test (see Ch. 3 Appendix, Table 3) for an overall 5.1% testing rate. This rate does not include the 
16,838 who were tested without an indication for BRCA testing.  
Almost two thirds of enrollees with indications for BRCA testing did not have cancer, 
about a fifth had breast cancer, just over 2% had ovarian cancer, 0.3% had both breast and 
ovarian cancer, and 13% had an “other” cancer (i.e./pancreatic cancer, cutaneous melanoma, 
uveal melanoma, or colorectal cancer) diagnosis (Table 1). Approximately one third had no 
family history of cancer, another third had a family history of breast cancer, 2.8% had a family 
history of ovarian cancer, and another third had family history of other cancers (gastrointestinal 
or other cancer). Only 1.2% had a family history of both breast and ovarian cancer (Table 2).   
Table 1. Total number and percentage of enrollees with different types of cancer diagnoses 
Cancer Diagnosis Total Number Percent 
(%) 
Cumulative 
Percent (%) 
No Cancer 4,089,151 62.8 62.8 
Breast Cancer 1,394,424 21.4 84.2 
Ovarian Cancer 147,849 2.3 86.5 
Breast and Ovarian Cancer 18,708 0.3 86.8 
Other Cancer 862,521 13.2 100.0 
Total 6,512,653 100.0  
 
Table 2. Frequency and percentage of Cohort 1 enrollees with family history of cancer and without cancer. 
Family History of Cancer Total Number Percent 
(%) 
Cumulative 
Percent (%) 
No Family History of Cancer 1,985,810 30.5 30.5 
Family History of Breast Cancer 2,340,456 35.9 66.4 
Family History of Ovarian Cancer 180,912 2.8 69.2 
Family History Breast and Ovarian Cancer 79,324 1.2 70.4 
Family History of Other Cancer 1,926,151 29.6 100.0 
Total 6,512,653 100.0  
 Two thirds of enrollees in Cohort 1 did not have cancer.  Of those with a cancer 
diagnosis, the most common was breast cancer at with about 20% of enrollees, followed by other 
cancer at 13% and ovarian cancer at just over 2%.  Equal number of enrollees had no family 
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history and a family history of other cancer (approximately 30%) with 35% having a family 
history of breast cancer, and the remainder made up mostly of those with a family history of 
ovarian cancer (Table 3).  Almost two thirds (63%) of enrollees in Cohort 1 were affected with 
the cancers selected to be indicative of BRCA testing.  In the unaffected group, 50% had a family 
history of breast cancer, 44% had a family history of other cancers, 4% had a family history of 
ovarian cancer, and 1% had a family history of both breast and ovarian cancer. Among the 
enrollees affected with cancer, over half had breast cancer, about a third had other cancer, with 
most of the remainder having had ovarian cancer (Table 3).  
 Among breast cancer patients, 76% had no family history, 17% had a family history of 
breast cancer, approximately 1.1% had a family history of ovarian cancer, 1.1% had a family 
history of both breast and ovarian, and 4.4% had a family history of other cancer (Table 3). 
Please see Table 3 (raw numbers) for distribution of family history among enrollees affected 
with ovarian, ovarian and breast, and other cancer. 
Table 3. Distribution of enrollees in Eligible Enrollees Dataset (Cohort 1) by cancer diagnosis and family history of 
cancer. CA=Cancer; FHx= Family History 
 Type of Cancer Diagnosis  
Type of Family 
History of CA 
No Cancer Breast Ovarian Breast & 
Ovarian 
Other  Total 
No Fhx of CA 16,838 1,063,868 118,725 11,979 774,400 1,985,810 
FHx of Breast CA 2,053,939 238,894 14,028 4,003 29,592 2,340,456 
FHx of Ovarian CA 157,304 14,800 5,667 695 2,446 180,912 
FHx of Breast and 
Ovarian CA 
59,967 15,063 2,316 1,047 931 79,324 
FHx of Other Cancer 1,801,103 61,799 7,113 984 55,152 1,926,151 
Total 6,512,653 6,512,653 6,512,653 6,512,653 6,512,653 6,512,653 
  
 Analyses of enrollees who had BRCA testing (Cohort 2) revealed they were 
overwhelmingly female (96%) (Ch. 3 Appendix, Table 8). Pre- and peri-menopausal women 
(ages 35-44 and 45-54) represented more than half (25% and 29%, respectively) of all BRCA 
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tested enrollees.  Post-menopausal women (ages 55-64) and young women (ages 25-34) 
represented 20% and 13%, respectively (Ch. 3 Appendix, Table 9).    
 Additionally, there 1,343 (0.4%) minor enrollees (aged 0-17) who had BRCA testing (Ch. 
3 Appendix, Table 9).  Although several genetics societies do not support testing children under 
18 for adult onset diseases such as hereditary breast and/or ovarian cancer, if the parent provides 
consent and if the child assents to testing, then BRCA testing can be ordered at the clinician’s 
discretion.  Increasingly more female children were tested from 61% to 81% over the study 
period (Ch. 3 Appendix, Table 20) and the majority had a POS plan, the proportion of which also 
increased over time (Ch. 3 Appendix, Table 21).  Almost all (96%) did not have cancer, and 
among these, 60% had no family history of cancer either. Please see Ch. 3 Appendix, Table 22 
for further details.  
 Over 65% of BRCA tested enrollees had a POS plan type, 16% had a Preferred Provider 
Organization (PPO) plan type and 12% had a Health Management Organization (HMO) plan 
type (see Ch. 3 Appendix, Table 10).  These proportions are consistent with the proportion of 
enrollees with POS plans in the overall HCCI database (see Ch. 3 Appendix, Table 11). 
 
Annual BRCA tests 
Overall, BRCA testing increased from 2008 to 2017, relatively slowly until 2012, with a 
3.2% jump in testing in 2013, followed by a 1.3% jump in 2014, and another 2.4% jump in 
2015.  The first increase represents about 11,250 additional enrollees tested for BRCA while the 
second represents about 8,200 additional enrollees (see Table 4).   
Table 4.  Annual distribution of BRCA testing among enrollees 
Year of 
BRCA test 
Total number of 
Enrollees with BRCA 
Test per Year 
Percent 
(%) 
Cumulative 
Percent (%) 
2008 16,251 4.7 4.7 
2009 20,933 6.0 10.7 
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2010 21,317 6.1 16.8 
2011 23,332 6.7 23.5 
2012 27,680 7.9 31.5 
2013 38,993 11.2 42.7 
2014 43,649 12.6 55.3 
2015 51,882 14.9 70.2 
2016 52,217 15.0 85.2 
2017 51,315 14.8 100 
Total 347,569 100  
 
Unadjusted BRCA Testing Rates By Age and Cancer/Family History Status  
 Cells in Table 5 and in Figs. 1-5 with less than 10 enrollees were suppressed by HCCI, to 
preserve confidentiality.  Overall, BRCA testing appears to be driven by a family history of both 
breast and ovarian cancer and young age. Table 5 summarizes testing rates by cancer diagnosis 
and family history. 
Table 5. Unadjusted BRCA testing rates among enrollees with indications for BRCA testing by diagnosis, family 
history and age. (i.e./Cohort 1). FHX=Family history of cancer; Unk=Unkown age  
 
Age (categories in years) 
Type of Cancer 
Diagnosis and Type 
of Family History of 
Cancer 0-17 18-24 25-34 35-44 45-54  55-64 65-74 75-84 85+ Unk. 
No Cancer 
No FHX (% tested) 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Tested (n) 790 712 2,445 3,140 3,412 3,472 1,987 754 123 - 
Eligible (n) 790 712 2,445 3,140 3,412 3,472 1,987 754 123 - 
Breast FHX (% 
tested) 4% 14% 13% 6% 4% 3% 1% 0% 0% 1% 
Tested (n) 338 4,892 20,415 28,711 25,197 13,764 2,001 280 22 18 
Eligible (n) 7,625 36,225 154,946 
451,57
4 585,835 465,372 262,202 77,368 10,669 2,123 
Ovarian FHX (% 
tested) 9% 26% 30% 21% 15% 12% 4% 3% - - 
Tested (n) 83 1,467 6,137 8,155 6,810 3,795 513 71 - - 
Eligible (n) 961 5,658 20,728 38,234 45,294 30,995 12,406 2,620 268 140 
Breast & Ovarian 
FHX (% tested) 50% 65% 61% 47% 41% 36% 11% 7% 11% 10% 
Tested (n) 51 910 4,497 8,173 7,528 4,034 416 41 - - 
Eligible (n) 103 1,403 7,379 17,209 18,526 11,063 3,624 564 47 49 
Other FHX (% 
tested) 1% 2% 2% 1% 0% 0% 0% 0% 0% - 
Tested (n) 24 400 1,714 2,460 2,187 1,667 437 81 10 - 
Eligible (n) 4,356 17,441 77,146 
244,64
7 552,076 513,591 298,945 83,415 7,855 1,631 
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Breast Cancer  
No FHX (% tested) - 6% 18% 17% 6% 3% 2% 1% 0% 1% 
Tested (n) - 102 2,184 11,240 12,179 8,021 4,177 1,175 173 26 
Eligible (n) 855 1,773 12,337 67,595 200,203 288,303 280,546 159,179 49,636 3,441 
Breast FHX (% 
tested) 28% 49% 58% 58% 43% 31% 17% 10% 8% 18% 
Tested (n) 15 253 3,694 16,970 27,550 20,380 8,426 1,994 253 48 
Eligible (n) 53 520 6,407 29,492 64,134 65,710 49,413 19,529 3,374 262 
Ovarian FHX (% 
tested) - 77% 69% 68% 61% 53% 39% 34% 34% 28% 
Tested (n) - 34 307 1,557 2,831 2,230 937 213 35 - 
Eligible (n) - 44 445 2,302 4,675 4,185 2,387 630 103 25 
Breast & Ovarian 
FHX (% tested) - 75% 68% 70% 70% 68% 49% 46% 56% 57% 
Tested (n) - 77 755 2,325 3,417 2,517 758 167 18 - 
Eligible (n) - 102 1,118 3,314 4,888 3,696 1,532 363 32 14 
Other FHX (% 
tested) - 45% 71% 55% 22% 12% 6% 4% 5% 6% 
Tested (n) - 13 393 2,374 3,122 2,271 1,049 227 28 - 
Eligible (n) - 29 556 4,305 14,245 19,171 17,062 5,740 597 91 
Ovarian Cancer  
No FHX (% tested) - 2% 4% 5% 6% 6% 5% 4% 2% - 
Tested (n) - 44 230 556 1,261 1,831 1,288 541 96 - 
Eligible (n) 1,256 1,981 6,651 12,302 22,684 29,632 24,667 14,304 4,696 552 
Breast FHX (% 
tested) 13% 44% 42% 35% 35% 35% 27% 27% 28% 47% 
Tested (n) - 27 198 574 1,241 1,483 768 271 46 - 
Eligible (n) 15 62 472 1,643 3,584 4,222 2,839 1,008 164 19 
Ovarian FHX (% 
tested) 5% 22% 30% 27% 30% 29% 27% 31% 30% 60% 
Tested (n) - 16 99 251 496 446 215 81 11 - 
Eligible (n) 20 72 334 941 1,673 1,535 789 261 37 - 
Breast & Ovarian 
FHX (% tested) 0% 58% 55% 46% 51% 50% 37% 38% 40% 33% 
Tested (n) 0 - 68 209 417 297 97 17 - - 
Eligible (n) - 12 124 451 816 600 259 45 - - 
Other FHX (% 
tested) 33% 52% 31% 25% 23% 25% 23% 21% 20% 0% 
Tested (n) - 17 71 151 389 550 364 126 18 0 
Eligible (n) - 33 232 614 1,708 2,210 1,606 608 89 10 
Breast & Ovarian Cancer   
No FHX (% 
tested) 0% 0% 22% 21% 14% 15% 10% 5% 5% 12% 
Tested (n) 0 0 25 131 288 525 337 106 19 - 
Eligible (n) - 18 116 634 1,998 3,457 3,326 2,007 377 42 
Breast FHX (% 
tested) 0% - 63% 58% 54% 53% 37% 35% 19% 17% 
Tested (n) 0 - 69 259 559 662 304 97 - - 
Eligible (n) - - 110 445 1,036 1,250 829 279 43 - 
Ovarian FHX (% 
tested)  -  - 58% 58% 52% 55% 38% 42% 50% 0% 
Tested (n)  -  - 11 43 96 127 51 19 - 0 
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Eligible (n) -  - 19 74 183 233 134 45 - - 
Breast & Ovarian 
FHX (% tested)  - - 56% 65% 66% 65% 60% 50%  - 100% 
Tested (n) -  - 49 165 215 169 53 10  - - 
Eligible (n)  - - 88 254 327 259 89 20  - - 
Other FHX (% 
tested)  - - - 55% 32% 34% 23% 20% -  -  
Tested (n)  - - - 36 71 104 65 17 -   - 
Eligible (n)  - - 11 66 221 308 281 86 - -         
Other Cancer   
No FHX  
(% tested) 0% 0% 1% 1% 1% 1% 0% 0% 0% 0% 
Tested (n) 13 32 139 358 752 1,006 684 280 41 - 
Eligible (n) 5,938 6,604 24,477 50,627 115,554 176,590 192,768 144,234 54,400 3,208 
Breast FHX  
(% tested) 13% 23% 19% 13% 10% 8% 3% 2% 2% 5% 
Tested (n) - 26 185 450 739 589 175 49 11 - 
Eligible (n) 31 115 952 3,453 7,315 7,697 6,218 3,101 669 41 
Ovarian FHX 
(% tested) 0% 0% 24% 22% 23% 19% 10% 6% 25% 20% 
Tested (n) 0 0 35 93 161 127 35 - - - 
Eligible (n) - 27 143 415 687 673 348 125 20 - 
Breast & Ovarian 
FHX  (% tested) 0% 0% 48% 56% 51% 46% 20% 4% 0% 100% 
Tested (n) 0 0 22 106 145 126 21 - 0 - 
Eligible (n) - - 46 188 286 273 107 24 - - 
Other FHX  
(% tested) 0% 5% 4% 3% 2% 2% 1% 1% 0% 1% 
Tested (n) 0 - 44 123 234 228 135 43 - - 
Eligible (n) 50 177 1,155 4,257 11,566 14,815 14,191 7,525 1,321 95 
  
 Unaffected enrollees had the highest rate of BRCA testing if they were between 18-24 
years of age and had a family history of both breast and ovarian cancer (Fig. 1).  The testing rate 
declined precipitously amongst all older age groups. A similar pattern of lower magnitude was 
observed in unaffected enrollees with ovarian cancer.  Those with breast and other cancer had 
lower testing rates overall, which remained more constant and decreased at older ages. 
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Fig. 1. Unadjusted BRCA testing rates (in %) among unaffected enrollees with various types of family history, by 
age categories (unknown age category not graphed).  Unaffected enrollees without a family history were excluded 
from chart because they had no indication for testing, but can be seen in Table 5.  Cells with less than 10 enrollees 
have been suppressed. 
 
 Among enrollees with breast cancer (Fig. 2), 18-24 year olds with family histories of 
either ovarian, or breast and ovarian cancer once again had the highest testing rates 
(approximately 75%) and decreased thereafter, albeit at a more moderate pace than their 
unaffected counterparts.  In this category, those with a family history of other cancers had an 
almost equally high BRCA testing rate in age category 25-34.  All 64 year olds or younger had a 
high likelihood of BRCA testing (between 68-75%) if they had a family history of breast and 
ovarian cancer. 
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Fig. 2. Unadjusted BRCA testing rates among enrollees with breast cancer and with various types of family history, 
by age categories (unknown age category not graphed); cells with less than 10 enrollees have been suppressed. 
 
 For enrollees with ovarian cancer (Fig. 3), the highest BRCA testing rates were also 
driven by a family history of both cancers (between 33-58% across all ages in this group). 
However, in this category, those without a family history had low testing rates between 1% and 
6%, regardless of age. 
 
Fig. 3. Unadjusted BRCA testing rates among enrollees with ovarian cancer and with various types of family history, 
by age categories (unknown age category not graphed); cells with less than 10 enrollees have been suppressed. 
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Patients diagnosed with breast and ovarian cancer had small numbers, and as such many 
cells were undefined for privacy reasons (Fig. 4).  However, the results indicate that a family 
history of any cancer (breast, ovary or other) elevates the probability of BRCA testing with rates 
between 17-67%.   
 
Fig. 4. Unadjusted BRCA testing rates among enrollees with breast and ovarian cancer and with various types of 
family history, by age categories (unknown age category not graphed); cells with less than 10 enrollees have been 
suppressed. 
 
 A diagnosis of other cancers was less likely to lead to BRCA testing unless there was a 
family history of breast and ovarian cancer in which case the testing rate was approximately 50% 
among enrollees 25-64 years of age (Fig. 5). 
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Fig. 5. Unadjusted BRCA testing rates among enrollees with other cancer and with various types of family history, 
by age categories (unknown age category not graphed); cells with less than 10 enrollees have been suppressed. 
  
 In this study minor children did undergo BRCA testing.  Enrollees aged 0-17 had BRCA 
testing rates of 50% if they were unaffected with a family history of breast and ovarian cancer 
(Fig. 1), and 25% if they had breast cancer and a family history of breast cancer (Fig. 2).   In 
total, there were 919 enrollees under 17 coded as having had breast cancer.  The diagnosis of 
pediatric breast cancer is exceedingly rare; the CDC suppresses data for breast cancer under 14 
due to the very low number of cases.  As a reference, the annual incidence of breast cancer 
between the ages of 15-19 was 69 cases from 2011 to 2015 (U.S. Cancer Statistics, 2018).  If 
only 69 cases were seen in four years, then in nine years, the expected number is around 140, or 
around 6.5 times less than the 919 cases identified by our method in the HCCI database.  It is 
therefore likely that many if not all of those cases represent inaccurate coding in the claims or 
errors in analysis. Please see Table 5 for percentages in this age group.  
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Unadjusted Yearly BRCA Testing Rates by Year, Cancer/Family History Types and Age   
 Family history of breast and ovarian cancer was the strongest driver of BRCA testing, and 
rates increased across all categories over the study period (2008-2017), albeit at different rates, 
depending on the type of family history or the age category. 
Table 6. Enrollees who had BRCA testing, across various cancer diagnoses, types of family history and age ranges, 
as a proportion of eligible enrollees (number and percentage) (i.e./ Cohort 1). NB: “Age at Diagnosis or 
Testing”=Age at time of BRCA test, if had BRCA testing; for those who didn’t have BRCA testing, it represents the 
age at their first diagnostic code for cancer or family history of cancer. FHX=Family History of Cancer. 
 Year of 1st Diagnosis or Testing 
Cancer Status 
& FHX 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
No Cancer 
No FHX (% 
tested) 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Tested (n) 450 535 552 648 764 792 1,967 3,037 3,960 4,133 
Eligible (n) 450 535 552 648 764 792 1,967 3,037 3,960 4,133 
Breast FHX 
(% tested) 
2% 2% 3% 3% 4% 6% 7% 8% 6% 6% 
Tested (n) 3,624 4,968 4,820 5,262 7,023 10,906 12,786 15,239 15,272 15,738 
Eligible (n) 224,505 202,912 182,505 171,324 176,487 194,276 192,233 202,746 257,594 249,357 
Ovarian FHX 
(% tested) 
6% 8% 9% 11% 15% 21% 24% 25% 21% 23% 
Tested (n) 849 1,119 1,146 1,302 1,938 3,171 3,768 4,427 4,469 4,855 
Eligible (n) 14,785 13,540 12,536 12,395 12,803 15,283 15,763 17,819 21,081 21,299 
Breast & 
Ovarian FHX 
(% tested) 
16% 28% 32% 35% 39% 52% 52% 54% 52% 63% 
Tested (n) 1,028 1,527 1,662 1,783 2,153 3,492 3,601 3,787 3,508 3,119 
Eligible (n) 6,451 5,407 5,251 5,145 5,487 6,761 6,862 6,953 6,699 4,951 
Other FHX (% 
tested) 
0% 0% 0% 0% 0% 0% 1% 1% 1% 1% 
Tested (n) 197 245 267 308 466 632 1,040 1,815 2,009 2,002 
Eligible (n) 179,859 191,532 183,913 177,787 176,248 175,470 164,915 169,742 190,572 191,065 
Breast Cancer 
No FHX (% 
tested) 
1% 2% 2% 3% 4% 5% 5% 6% 6% 6% 
Tested (n) 1,869 2,214 2,344 2,682 3,165 4,499 4,743 5,402 6,354 6,012 
Eligible (n) 217,856 129,4
69 
98,124 84,49
6 
79,570 84,149 92,345 84,164 99,168 94,527 
Breast FHX 
(% tested) 
15% 27% 30% 34% 36% 40% 38% 42% 42% 44% 
Tested (n) 5,324 6,682 6,706 7,185 7,594 9,334 8,938 9,669 9,400 8,751 
Eligible (n) 36,603 25,19
9 
22,468 21,38
9 
21,304 23,274 23,253 22,936 22,500 19,968 
Ovarian FHX 
(% tested) 
30% 50% 52% 60% 58% 66% 59% 63% 59% 64% 
Tested (n) 599 699 675 757 771 983 863 1,015 901 890 
Eligible (n) 2,014 1,403 1,293 1,270 1,334 1,481 1,469 1,619 1,521 1,396 
Breast & 
Ovarian FHX 
44% 66% 66% 69% 70% 73% 71% 72% 71% 71% 
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(% tested) 
Tested (n) 796 990 948 1,052 1,075 1,264 1,144 1,124 908 744 
Eligible (n) 1,826 1,510 1,438 1,527 1,538 1,724 1,617 1,557 1,275 1,051 
Other FHX (% 
tested) 
4% 8% 10% 12% 15% 19% 20% 28% 26% 32% 
Tested (n) 526 566 605 664 789 1,028 1,156 1,480 1,329 1,339 
Eligible (n) 12,640 6,917 6,044 5,357 5,144 5,276 5,821 5,309 5,045 4,246 
Ovarian Cancer 
No FHX (% 
tested) 
1% 1% 2% 2% 3% 6% 7% 11% 12% 12% 
Tested (n) 101 172 212 265 299 606 788 1,122 1,154 1,142 
Eligible (n) 19,752 14,51
8 
12,266 11,10
2 
10,447 10,649 10,865 10,011 9,803 9,312 
Breast FHX 
(% tested) 
11% 20% 25% 28% 30% 36% 40% 49% 47% 47% 
Tested (n) 184 278 311 374 376 518 589 761 646 582 
Eligible (n) 1,640 1,391 1,269 1,360 1,274 1,448 1,469 1,567 1,361 1,249 
Ovarian FHX 
(% tested) 
10% 17% 17% 24% 28% 34% 40% 46% 47% 51% 
Tested (n) 90 114 105 145 150 190 206 265 178 176 
Eligible (n) 865 687 602 605 536 561 515 571 382 343 
Breast & 
Ovarian FHX 
(% tested) 
28% 41% 44% 39% 41% 58% 55% 64% 58% 66% 
Tested (n) 80 103 111 97 98 151 127 160 101 87 
Eligible (n) 281 250 250 250 237 262 231 251 173 131 
Other FHX (% 
tested) 
5% 8% 12% 13% 19% 22% 28% 45% 44% 48% 
Tested (n) 43 55 84 85 125 158 204 350 278 305 
Eligible (n) 918 660 724 654 658 718 738 780 630 633 
Breast & Ovarian Cancer 
No FHX (% 
tested) 
2% 6% 9% 11% 13% 20% 21% 31% 31% 33% 
Tested (n) 72 95 115 117 120 183 199 218 184 133 
Eligible (n) 3,308 1,693 1,347 1,098 945 919 957 709 594 409 
Breast FHX 
(% tested) 
20% 41% 49% 49% 58% 64% 60% 69% 70% 78% 
Tested (n) 166 215 219 191 222 251 194 224 160 119 
Eligible (n) 832 527 450 386 386 390 325 327 228 152 
Ovarian FHX 
(% tested) 
20% 55% 48% 55% 60% 62% 66% 72% 56% 80% 
Tested (n) 31 49 40 33 35 41 39 42 24 16 
Eligible (n) 158 89 84 60 58 66 59 58 43 20 
Breast & 
Ovarian FHX 
(% tested) 
39% 56% 66% 68% 74% 79% 74% 77% 78% 94% 
Tested (n) 86 78 85 82 83 78 73 59 28 16 
Eligible (n) 219 139 129 120 112 99 99 77 36 17 
Other FHX (% 
tested) 
6% 20% 16% 28% 33% 45% 48% 70% 68% 75% 
Tested (n) 14 24 20 27 28 35 49 50 28 24 
Eligible (n) 233 120 127 96 84 77 103 71 41 32 
Other Cancer 
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No FHX (% 
tested) 
0% 0% 0% 0% 0% 0% 1% 1% 1% 1% 
Tested (n) 16 57 118 81 120 235 616 813 644 608 
Eligible (n) 99,495 88,10
3 
78,236 73,19
8 
72,294 73,600 74,553 72,317 72,324 70,280 
Breast FHX 
(% tested) 
2% 4% 4% 5% 5% 7% 10% 13% 13% 12% 
Tested (n) 71 100 110 125 157 221 313 416 399 318 
Eligible (n) 3,187 2,850 2,774 2,788 2,923 3,018 3,178 3,161 3,020 2,693 
Ovarian FHX 
(% tested) 
6% 8% 8% 10% 11% 16% 26% 30% 35% 31% 
Tested (n) 13 18 17 21 23 44 72 83 97 77 
Eligible (n) 235 224 209 214 206 276 276 276 280 250 
Breast & 
Ovarian FHX 
(% tested) 
26% 32% 37% 33% 47% 44% 48% 61% 56% 50% 
Tested (n) 18 23 25 27 49 55 43 82 54 46 
Eligible (n) 70 71 67 82 104 124 90 134 97 92 
Other FHX (% 
tested) 
- - 0% 0% 1% 1% 2% 4% 4% 3% 
Tested (n) - - 20 19 57 62 117 207 190 138 
Eligible (n) 6,844 6,099 5,900 5,654 5,535 5,632 5,463 5,230 4,719 4,076 
0-17 years  
(% tested) 
6% 7% 6% 8% 8% 4% 5% 6% 5% 5% 
Tested (n) 154 148 135 146 170 85 118 139 127 121 
Eligible (n) 2,644 2,290 2,107 1,909 2,016 2,032 2,181 2,205 2,420 2,273 
18-24 years 
(% tested) 
5% 6% 7% 8% 11% 13% 15% 17% 16% 17% 
Tested (n) 307 359 406 508 689 966 1,169 1,466 1,571 1,606 
Eligible (n) 5,913 5,888 5,575 6,070 6,560 7,313 7,930 8,496 9,630 9,649 
25-34 years 
(% tested) 
6% 8% 9% 10% 12% 16% 17% 19% 18% 18% 
Tested (n) 1,880 2,487 2,326 2,666 3,394 4,894 5,676 6,701 6,862 6,903 
Eligible (n) 32,265 29,76
0 
26,532 26,66
5 
27,956 30,686 32,532 34,590 38,455 38,996 
35-44 years 
(% tested) 
4% 6% 7% 8% 9% 12% 13% 14% 12% 12% 
Tested (n) 4,976 6,301 6,318 6,526 7,657 10,117 11,097 12,417 11,765 11,436 
Eligible (n) 124,896 100,7
79 
88,013 85,25
1 
85,362 87,525 86,259 88,384 97,374 94,333 
45-54 years 
(% tested) 
2% 4% 4% 5% 6% 8% 9% 10% 8% 9% 
Tested (n) 5,635 6,946 7,054 7,411 8,666 11,850 12,482 14,105 13,998 13,150 
Eligible (n) 243,611 180,9
99 
163,19
0 
154,1
45 
150,999 151,399 146,668 147,736 169,42
4 
154,755 
55-64 years 
(% tested) 
1% 2% 3% 3% 4% 5% 6% 7% 6% 6% 
Tested (n) 3,062 3,983 4,011 4,595 5,367 7,952 8,887 10,882 11,210 10,472 
Eligible (n) 243,268 165,8
88 
152,88
5 
147,2
02 
144,244 145,999 148,096 151,940 184,25
5 
165,535 
65-74 years 
(% tested) 
0% 0% 1% 1% 1% 2% 3% 4% 4% 4% 
Tested (n) 210 586 849 1,152 1,354 2,441 3,232 4,607 5,139 5,723 
Eligible (n) 100,523 121,4
82 
109,17
5 
98,24
6 
102,278 118,630 121,038 120,341 138,02
6 
148,816 
75-84 years 
(% tested) 
0% 0% 0% 1% 1% 1% 2% 3% 3% 3% 
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Tested (n) 21 95 179 281 330 538 846 1,266 1,382 1,731 
Eligible (n) 65,993 67,11
1 
54,901 46,25
3 
44,448 48,831 47,328 43,994 51,059 53,916 
85+ years  
(% tested) 
0% 0% 0% 0% 0% 1% 1% 2% 2% 2% 
Tested (n) - 11 27 39 44 75 115 180 220 228 
Eligible (n) 15,748 17,34
5 
14,405 12,41
8 
11,854 13,179 12,435 11,292 12,459 13,409 
Unknown yrs  
(% tested) 
- 0% 1% - - 2% 2% 3% -   - 
Tested (n) - 17 12 - - 11 13 84 -   - 
Eligible (n) 165 4,303 1,775 846 761 731 699 2,444 44 - 
 
Unadjusted Yearly BRCA Rates among Unaffected Enrollees 
The rate of BRCA testing among unaffected enrollees in 2008 was highest in those with a 
family history of breast and ovarian cancer at 16% and continued to increase steadily through 
2017 when it reached 63%.  This group experienced the steepest rise in BRCA testing rate from 
2012 to 2013, increasing by thirteen percentage points, or 33%, representing a clear “Jolie 
effect”.  Testing rates for unaffected enrollees with a family history of ovarian cancer increased 
from 6% in 2008 to 23% in 2017 with an increase of 5% in 2013 and another 5% in 2014.  The 
rates remained constant between 0% and 6% for the other two types of family histories (breast 
cancer and other cancer) (Fig. 6).  
 
Fig. 6. Unadjusted Yearly BRCA rates among unaffected enrollees, by types of family history. Unaffected enrollees 
without a family history (dark blue line) were excluded from chart because they had no indication for testing, but 
can be seen in Table 6; cells with less than 10 enrollees have been suppressed. 
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Unadjusted Yearly BRCA rates among Enrollees with Breast Cancer 
For enrollees with breast cancer, BRCA testing increased rather steeply from 2008 to 
2009 and then leveled off with the highest rates in those with a family history of both breast and 
ovarian cancer.  That top ranking was maintained through 2017, with this category achieving the 
highest testing rate in 2017.  There was an eight-fold increase from 4% to 32% among breast 
cancer enrollees with family histories of other cancers.  The rest of the enrollees with breast 
cancer experienced approximately a doubling in BRCA testing rates over the same period (Fig. 
7).  A small, temporary “Jolie effect” is observable in enrollees with breast cancer and a family 
history of ovarian cancer (eight percentage points increase, or 14%) from 2012 to 2013.  
 
Fig. 7. Unadjusted Yearly BRCA rates among enrollees with breast cancer, by types of family history. Cells with less 
than 10 enrollees have been suppressed. 
 
Unadjusted Yearly BRCA Rates among Enrollees with Ovarian Cancer 
Enrollees with ovarian cancer had increases in BRCA testing across all types of family 
history.  In 2008, the highest testing rate was among those with a family history of both breast 
and ovarian cancer (28%) and that ranking was maintained through 2017 (66%).  Enrollees with 
no family history of cancer had a twelve-fold increase over the period studied (1% to 12%), 
doubling from 3% to 6% between 2012 and 2013 and doubling again between 2013 and 2016 
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(6% to 12%). Those with a family history of ovarian cancer recorded a quintupling in BRCA 
testing rate over the decade of the study period from 10% in 2008 to 51% in 2017.   Those with a 
family history of breast cancer more than quadrupled their testing rate (11% to 47%), while a 
family history of breast and ovarian cancer more than doubled the BRCA testing rate (from 28% 
to 66%). 
 
Fig. 8. Unadjusted Yearly BRCA rates among enrollees with ovarian cancer, by types of family history.  Cells with 
less than 10 enrollees have been suppressed. 
 
Unadjusted Yearly BRCA Rates among Enrollees with Breast and Ovarian Cancer 
Testing rates increased steadily for those diagnosed with both breast and ovarian cancer.  
In 2008, those with both diagnoses and a family history of both diagnoses had the highest test 
rates at 39%, which subsequently rose to 94% in 2017.  Although those diagnosed with both 
cancers and with a family history of other cancer had the lowest rate at 5% in 2008, they 
experienced a 15-fold increase by 2017 with rates reaching 75%, including a 36% increase 
between 2012 and 2013.  Those with family histories of breast and ovarian cancer follow almost 
identical trajectories with rates climbing from 20% in 2008 to approximately 80% in 2017.  For 
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those without a family history of cancer, the BRCA testing rate increased more than sixteen-fold 
(from 2% in 2008 to 33% in 2017), including a 50% increase from 2012 to 2013.  
 
Fig. 9. Unadjusted Yearly BRCA rates among enrollees with breast and ovarian cancer, by types of family history. 
Cells with less than 10 enrollees have been suppressed. 
 
Unadjusted Yearly BRCA Rates among Enrollees with Other Cancer 
As seen in previous categories, family history of breast and ovarian cancer is the 
strongest driver for BRCA testing among enrollees diagnosed with other cancers.  The rate 
among those with a family history of both breast and ovarian cancer more than doubled between 
2008 and 2015, from 26% to 61%, only to drop thereafter, but the actual difference in enrollee 
numbers was very small.  Those with no family history of cancer or family history of other 
cancers had 0% rates in 2008, which did not rise above 4% during the study period.  Enrollees 
diagnosed with other cancer and with a family history of breast cancer experienced a six-fold 
increase in testing from 2% to 12%.  A five-fold increase was seen among the group with a 
family history of ovarian cancer.  
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Fig. 10. Unadjusted Yearly BRCA rates among enrollees with other cancer, by types of family history.  Cells with 
less than 10 enrollees have been suppressed. 
 
Unadjusted Yearly BRCA Rates among Enrollees of Various Ages 
Young age at the time of testing appears to drive BRCA testing as well.  In Fig. 10, 
enrollees who are 0-17 years old and 25-34 years old had the highest testing rates in 2008 at 6%.  
25-34 year olds remained at the highest testing rate in 2017 at 18%.  The BRCA testing in 
pediatric enrollees (aged 0-17) declined from 6% in 2008 to 5% in 2017.  The 35-44 year olds 
increased from a 4% testing rate in 2008 to 12% in 2017. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Unadjusted Yearly BRCA rates among enrollees, by age category (unknown age category not graphed). 
Cells with less than 10 enrollees have been suppressed. 
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Unadjusted Yearly BRCA Rates among Male Enrollees 
Bivariate analysis of gender distribution across years revealed that male enrollees who 
had BRCA testing increased by a factor of seven until 2016 (477 in 2008 compared to 3,226 in 
2016), and then decreased slightly.  The annual share of BRCA tests increased from 2.9% of all 
BRCA tests in 2008 to 6.2% of all BRCA tests in 2016, only to drop slightly to 5.7% in 2017 (Ch. 
3 Appendix, Table 12).   
 
BRCA charges, paid amounts and cost-sharing  
 BRCA charges in 2008 averaged $2,580 and amount paid averaged $2,336.  Charges and 
amount paid increased slowly from 2008 to 2012 with the average charge in 2012 being $2,937 
and amount paid being $2,415. Starting in 2013 with the end of patent protection, both the billed 
amounts and the paid amounts increased substantially, with an increase in 2013 that doubled the 
entire increase from 2008 to 2012 (from $400 to $831) in 2013 alone, with billed charges being 
$3,768 and paid amount being $2,747 that year.  2014 saw an increase to $4,317 for BRCA 
charges and a widening standard deviation (SD). That same year, the average paid amount 
increased to $2,650. By 2016, average BRCA charges reached $6,878 with average amount paid 
at $3830, but by 2017 they had both dropped, to $6,422 and $3,262, respectively. 
 Enrollee cost sharing for BRCA testing increased over the study period, more than tripling 
from 2008 to 2017.  Although the increases were modest from 2012 through 2014, there was a 
jump of $120 in 2015.  By 2017, the mean cost-sharing was an $232 more than in 2012 (the year 
prior to patent dissolution).  Although the fiftieth percentile cost sharing amount was $0, the 
standard deviations after 2013 were wide, with some enrollees paying for the price of the entire 
test out of pocket (see Ch. 3 Appendix Table 16). 
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 Years 2015, 2016 and 2017 had large standard deviations with some charges as high as 
approximately $12,000 in 2016. However, the fiftieth percentile charge remained relatively 
constant over the years (see Ch. 3 Appendix, Table 14) and was very close to the price the sole 
test provider charged during that period, indicating that particular laboratory continued to 
perform a large portion of BRCA testing throughout that period.   
 The mean paid amount for BRCA testing also increased during the duration of the study, 
from 2008 to 2016, but did so gradually and then decreased in 2017 by almost $500 (see Ch. 3 
Appendix, Table 15). 
 
Geographic Variation   
 The data was examined to look for state level geographic variation in rates of adoption 
for BRCA testing. In 2008, there was low uptake of BRCA testing, but affected enrollees with 
family history of cancer had steeper increases compared to unaffected enrollees with family 
history, and affected enrollees without family history.  BRCA testing increased at a faster rate in 
the Southwestern part of the U.S. compared to other parts of the country regardless of cancer 
status or family history of cancer status.  Some leading states that appeared to be early adopters 
across all categories included Texas, Nevada, New Mexico and Colorado.  By 2017 there 
continued to be variations in the rates of testing in affected enrollees with no family of cancer, 
but the variance was much smaller for enrollees with cancer and family history of cancer, or 
those with family history of cancer, but no cancer. 
 
DISCUSSION 
 Young age was an important and consistent driver of BRCA testing during the time period 
studied.  Enrollees aged 18-24 with breast cancer had the highest testing rates when they also had 
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a family history of ovarian cancer, or breast and ovarian cancer. Unaffected enrollees aged 18-24 
with a family history of both breast and ovarian cancer had the second highest rates. Young age 
at diagnosis as a strong driver for BRCA testing is consistent with longstanding BRCA literature 
which states that early onset cancer is more likely to be associated with a BRCA mutation.  In 
addition, family history of both breast and ovarian cancer and family history of ovarian cancer 
are both classically considered strong indicators of a BRCA mutation, even in the absence of a 
cancer diagnosis in the individual undergoing testing. As such, most testing indications would 
recommend testing young individuals with a family history of ovarian cancer or both cancers.   
 Regardless of age group, ovarian cancer enrollees without a family history had very low 
testing rates, between 1% and 6%, throughout the study period.  Approximately 10% to 12% of 
all ovarian cancers are hereditary irrespective of age at diagnosis, and national guidelines have 
included a diagnosis of ovarian cancer (even in the absence of a family history of cancer) as a 
sufficient justification for BRCA testing since 2005.  The lack of uptake of BRCA testing in this 
subgroup is inconsistent with the published guidelines. 
 An unexpected finding was that minor children had BRCA testing.  Unaffected minors 
with a family history of breast and ovarian cancer had high BRCA testing rates, around 50%.  
BRCA testing in minors (17 years of age or less) is not consistent with guidelines.  In fact, many 
clinicians are unwilling to order BRCA testing in children or teenagers because mutation status in 
that age group has no clinical management implications but can be a heavy emotional and 
psychological burden.  One explanation for this finding may be that these individuals were part 
of known BRCA mutation families, and as such their a priori probability of a BRCA mutation 
may have been significant. Another explanation, not mutually exclusive, would be that having a 
family history of both breast and ovarian cancer is such a clear and strong indicator of the 
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presence of a BRCA mutation in the family that the threshold for ordering testing on minors was 
lowered in these cases. 
The annual number of BRCA tests increased slowly until 2012.  In 2013, however, there 
was a 3.2% jump, followed by smaller jumps in 2014 and 2015.  Therefore, when looking at raw 
numbers of BRCA tests, it would appear that the Jolie editorial had a positive effect on BRCA 
testing. 
The annual rates of BRCA testing also increased during the study period, albeit at 
different rates depending on cancer status and type and family history. Family history of breast 
and ovarian cancer was the strongest driver of BRCA testing from 2008 to 2017, and that ranking 
was maintained regardless of whether the enrollee was affected and regardless of the type of 
cancer.  
 Among unaffected enrollees the strongest Jolie effect occurred for those with a family 
history of breast and ovarian cancer with an increase of 13 percentage points, or 33%, in 2013.  
During the same time frame, unaffected enrollees with a family history of ovarian cancer 
experienced a 5% increase in BRCA testing rate, followed by another 5% in 2014.  Enrollees 
without cancer, but with family histories strongly indicative of a BRCA mutation pursued BRCA 
testing after Angelina Jolie wrote about her experience as a BRCA mutation carrier in May 2013.  
The current analysis does not provide the opportunity to clarify whether the increase was due to 
improved provider identification of eligible patients or elevated interest in BRCA testing among 
enrollees, but nonetheless demonstrates the presence of an observable “Jolie effect” in cancer-
free, at-risk individuals with claims in the HCCI database. 
 Among enrollees affected with cancer, there was a clear “Jolie effect” if diagnosed with 
ovarian cancer and a family history of both breast and ovarian cancer.  This group experienced a 
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50% increase in BRCA testing from 2012 to 2013. Among enrollees with both breast and ovarian 
cancer, the “Jolie effect” was noticeable for those with a family history of other cancer, whose 
testing rates increased by 12 percentage points (approximately 36% increase), and those with a 
family history of other cancer who experienced an approximately 50% increase, from 2013 to 
2014.  Conversely, enrollees with both breast and ovarian cancer and a family history of other 
cancers had the steepest acceleration in BRCA testing with an eight-fold increase from 2008 to 
2017.  One explanation for these observations may be that by the time of the Jolie OpEd in the 
New York Times, BRCA testing in the categories with clear indications for testing had existed 
for many years and was already at close to a saturation point (58-74%), and as such, only a 50% 
increase in testing was seen.  The 15-fold increase in testing for those with both cancers and a 
family history of other cancers could be due to increased awareness during this timeframe that a 
BRCA mutation may cause breast cancer as well as other cancers (such as pancreatic and/or 
melanoma), and the low rate seen in 2008 (5%).   
“Other” cancer is not a classic indication for BRCA testing, and therefore it is not 
surprising that testing rates in 2008 were so low for these enrollees regardless of their family 
history.  As research on BRCA continued and knowledge about BRCA phenotypes improved, it 
became apparent that other cancers such as melanoma (cutaneous and especially uveal) and 
pancreatic cancer were part of the spectrum of disease for BRCA.  Rates of testing in this group 
appear to mirror this improvement in knowledge with rates of testing reaching 50% in those with 
other cancers (such as pancreatic cancer) and a family history of breast and ovarian cancer.  
Although the BRCA testing rates showed large increases from 2008 compared to 2017, the 
increase during the Jolie period from 2012 to 2013 was modest, peaking at 5% among enrollees 
with other cancer and with a family history of ovarian cancer.  
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The increase in unadjusted BRCA testing rates over the 2012 to 2013 time-period is 
consistent with findings by previous authors (57% overall increase according to Chen et al, and 
42-57% according to Wright et al).  This unadjusted analysis therefore also supports the idea that 
the Angelina Jolie editorial led to increased BRCA testing immediately afterwards. 
Guo et al. (2017) presented a similar analysis with proportions of affected and unaffected 
erollees with and without family history of cancer who underwent BRCA testing from 2004 to 
2014 (H. J. Guo F, Lin Y, Richardson G, Levine L, Berenson A, Kuo Y, 2017).  However, 
affected status was assigned only for a diagnosis of breast or ovarian cancer, and family history 
of breast or ovarian cancer was included in addition to family history of breast cancer, family 
history of ovarian cancer and family history of both cancers.  The enrollee cancer diagnoses are 
represented in our analysis, but the family history of either breast or ovarian cancer is not.  Other 
BRCA-related cancers that we included such as pancreatic cancer, uveal melanoma, etc., were 
not included in the Guo et al. analysis, and neither was family history of other cancers or no 
family history.   
With these caveats, this analysis is most similar to Table 6, but given that the authors 
lumped breast and ovarian cancer enrollees together, only the unaffected enrollees can be 
compared.  Nonetheless, it is difficult to reconcile BRCA testing rates in the 90% in 2004 with 
published literature that showed significantly lower uptake in clinical series, and it is even harder 
to understand a downward trend in BRCA test uptake following the Jolie editorial.  Such findings 
may be attributable to incorrect assignation of BRCA testing in Guo’s methodology. The method 
of identifying BRCA tests that Guo used is similar to the one that Chen utilized and does not 
include the non-specific molecular pathology CPT codes (83891, 83898, 83904, 83909 and 
83912), nor the stackable non-specific CPT code 81479 that was frequently used after the BRCA 
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patent dissolution.  As a result, the shift to usage of 81479 for BRCA tests (or multi-gene panel 
tests that included BRCA) post patent dissolution would artificially appear as a decrease in BRCA 
testing if only the BRCA CPT codes were utilized.   
The 90% uptake of BRCA testing across the study period in unaffected enrollees with 
family history of breast cancer is also not consistent with published literature from that era that 
consistently showed uptake of less than 10% in series of clinically ascertained at-risk individuals.  
In a 2009 publication on a national sample of women using the National Health Interview Study 
(NHIS), only 1.4% of eligible women had undergone BRCA testing (Levy DE, 2009). Although 
that analysis was based on interviews, and may therefore be subject to recall bias, the sample 
nonetheless is more similar to a claims database than a clinical series of patients, and therefore 
the BRCA testing rate identified is more likely to be representative of the BRCA testing uptake in 
2000 and 2005 (the years the interviews took place).  The findings from the current analysis (2% 
in 2009) are more similar to the numbers found in the Levy et al. (2009) publication (1.4%) 
(Table 7, below), and the trajectory of BRCA testing over the time period studied herein (2008-
2009) is more consistent with expected diffusion of new technology. 
Table 7.  Adjusted predicted probabilities of BRCA testing rates among selected unaffected enrollees. Adapted from Guo et al, 
2017 publication and current analysis. Dx=diagnosis; FHx=family history; BR= breast cancer; OV=Ovarian cancer 
 Year 
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Guo 
2017 
No BR 
or OV 
Dx 
 
 FHx 
BR 
91% 93% 92% 92% 90% 92% 93% 91% 87% 87% 83% - - - 
FHx 
OV 
38% 37% 38% 40% 38% 38% 44% 43% 44% 42% 42% - - - 
FHx 
BR & 
OV 
31% 30% 32% 33% 29% 31% 36% 37% 30% 31% 29% - - - 
Current 
Analysis 
No BR 
of OV 
Dx 
 
 FHx 
BR 
- - - - 2% 2% 3% 3% 4% 6% 7% 8% 6% 6% 
FHx 
OV 
- - - - 6% 8% 9% 11% 15% 21% 24% 25% 21% 23% 
FH BR 
& OV 
- - - - 16% 28% 32% 35% 39% 52% 52% 54% 52% 63% 
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 Although men account for only 4% of enrollees who had BRCA testing, a “Jolie effect” 
was evident in men as well but was slightly more muted, increasing by about 300 tests in 2013 
and doubling in 2014 (Ch. 3 Appendix, Table 12).   
 BRCA charges increased slowly from 2008 to 2012, and then doubled in 2013 with an 
additional increase in 2014.  In 2015, the average BRCA charge was almost $2,000 more than the 
previous year and almost double the charge in the years prior to 2013.  By 2016, it was $4,300 
more than 2008.  Standard deviation also increased: years 2015, 2016 and 2017 had large 
standard deviations with some as high as approximately $12,000 in 2016.   
 Because BRCA charges do not represent the “true price” of BRCA testing, but rather an 
advertised price, the increase in mean charges after 2013 represents an inflation in the price of 
the BRCA test driven by the needs of newer laboratories without contracted rates to cover their 
Research and Development costs for the initiation of BRCA testing. The long right tail of the 
BRCA charge distribution with very large standard deviations that occur after 2013 provides 
support to this theory.  These pricing changes are a direct effect of the BRCA patent dissolution 
on a BRCA market that had only one provider for approximately twelve years, a time during 
which it controlled the price and rarely negotiated contracted rates with insurers. 
 The amount paid for BRCA testing also increased with significantly wider standard 
deviations after 2013. The twenty-fifth percentile decreased, however, which implies that there 
were fewer expensive BRCA tests in the market that were being reimbursed.  At the same time, 
the 75th percentile for paid BRCA tests increased, so there were some large BRCA payments in 
the dataset.  This is supported by the author’s personal experience with patients presenting 
Evidence of Benefits of upward of $60,000 for gene panels that included BRCA tests after 2013.  
Such large charges could only be achieved via code-stacking, a practice whereby the same CPT 
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code was billed multiple times.  After 2013, when gene-specific coding came into effect and 
Centers for Medicare and Medicaid set the BRCA sequencing price at approximately $900, many 
laboratory providers of BRCA tests billed additional stackable procedure codes such as 81479 
that did not have a set reimbursable amount.  Please see Ch. 2 Appendix, Table 1 for a summary 
of the different CPT codes billed during the study period, including the sudden appearance of 
81479 code in 2013 and its increasing use thereafter.  
 It would appear therefore that after patent protection ended, the hypothesized competition 
leading to “opening of the BRCA testing market,” actually resulted in an increase in charges and 
paid amounts and, to a lesser degree, in patient cost-sharing amounts.  This finding is in direct 
conflict with the claims made by proponents of patent dissolution who invoked the lack of 
market forces as a reason for the high cost of BRCA testing.   
 State analysis from 2008 to 2017 showed that the steepest acceleration in BRCA testing 
was among the affected enrollees with family history of cancer.  However, testing rates increased 
earlier and faster in the Southwestern part of the U.S. compared to other parts of the country 
regardless of cancer status or family history of cancer status.   The variance in testing rates 
decreased in the affected with family history of cancer group, but remained high in the other two 
groups.  The adoption of BRCA testing appeared to increase earlier and at a faster pace in the 
category for whom testing is clearly indicated (affected with family history of cancer).  The 
newer or softer indications for testing (affected with cancer without a family history and 
unaffected with a family history) had slower uptake with continued wide variation in rates 
through 2017. 
  One important limitation of the HCCI dataset when looking at geographic variation is 
that the market penetrance in each state for the insurers/payers comprised therein is not known.  
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It is possible that the HCCI claims have an over-representation of enrollees from the Southwest 
and therefore effects in other states would be muted.  This is an important reason that may 
explain the geographic diffusion rates seen in the analysis. 
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APPENDIX 
Chapter 3 Appendix, Table 1. Summary of various procedure codes used for BRCA testing 
Code Description Number 
of Units 
Name of Test, or what 
code represents clinically 
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 BRCA Sequencing  
(aka “Bracanalysis” TM) 
83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
81 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
81 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
81 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 “Multi-site 3 test”; 3 BRCA 
mutations commonly seen in 
Ashkenazi individuals 83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
3 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
3 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
3 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
83891 Molecular diagnostics; isolation or extraction of highly 
purified nucleic acid, each nucleic acid type  
1 BRCA single-site testing 
83898 Molecular diagnostics; amplification, target, each 
nucleic acid sequence 
1 
83904 Molecular diagnostics; mutation identification by 
sequencing, single segment, each segment 
1 
83909 Molecular diagnostics; separation and identification by 
high-resolution technique (e.g./ capillary 
electrophoresis), each nucleic acid preparation 
1 
83912 
 
Molecular diagnostics; interpretation and report 1 
    
S3818 
 
Complete gene sequence analysis: BRCA1 gene 1 BRCA1 sequencing 
S3819 
 
Complete gene sequence analysis: BRCA2 gene 1 BRCA2 sequencing 
S3820 Complete BRCA1 and BRCA2 gene sequence analysis 
for susceptibility to breast and ovarian cancer 
1 BRCA1 and BRCA2 
sequencing 
S3822 Single mutation analysis (in individual with a known 
BRCA1 or BRCA2 mutation in the family) for 
susceptibility to breast and ovarian cancer 
1 Single site testing in BRCA1 
or BRCA2 
S3823 Three-mutation BRCA1 and BRCA2 analysis for 
susceptibility to breast and ovarian cancer 
1 3 BRCA mutations 
commonly seen in 
Ashkenazi individuals 
    
81211 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary 
breast and ovarian cancer) gene analysis; full sequence 
analysis and common duplication/deletion variants in 
BRCA1 (i.e./ exon 13 del 3.835kb, exon 13 dup 6kb, 
exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 
7.1kb) 
1 BRCA1 and BRCA2 
sequencing and 5 known 
BRCA1 
deletions/duplications 
81212 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g./ 1 3 BRCA mutations 
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hereditary breast and ovarian cancer) gene analysis; 
185delAG, 5385insC, 6174delT variants 
commonly seen in 
Ashkenazi individuals 
81213 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g./ 
hereditary breast and ovarian cancer) gene analysis; 
uncommon duplication/deletion variants 
1 BRCA1 and BRCA2 deletion 
and duplication analysis 
81214 BRCA1 (breast cancer 1) (e.g./ hereditary breast and 
ovarian cancer) gene analysis; full sequence analysis 
and common duplication/deletion variants (i.e./ exon 13 
del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, 
exon 22 del 510bp, exon 8-9 del 7.1kb) 
1 BRCA1 sequencing and 5 
known BRCA1 
deletions/duplications 
81215 BRCA1 (breast cancer 1) (eg, hereditary breast and 
ovarian cancer) gene analysis; known familial variant 
1 BRCA1 single site testing 
81216 BRCA2 (breast cancer 2) (eg, hereditary breast and 
ovarian cancer) gene analysis; full sequence analysis 
1 BRCA2 sequencing 
81217 BRCA2 (breast cancer 2) (eg, hereditary breast and 
ovarian cancer) gene analysis; known familial variant 
1 BRCA2 single site testing 
    
81162 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary 
breast and ovarian cancer) gene analysis; full sequence 
analysis and full duplication/deletion analysis 
1 BRCA1 and BRCA2 
sequencing and 
deletion/duplication analysis 
    
81479 Unlisted molecular pathology procedure 
 
Various 
number 
of units 
BRCA1, BRCA2 sequencing 
and deletion and duplication 
testing, in conjunction with 
other genes, aka Next 
Generation Sequencing, or 
Multi-Gene Panel, usually 
billed when other codes 
perceived as not sufficiently 
representative of the 
procedures performed 
    
81432 Genomic Sequencing Procedures and Other Molecular 
Multianalyte Assays; Hereditary breast cancer-related 
disorders (eg, hereditary breast cancer, hereditary 
ovarian cancer, hereditary endometrial cancer); 
genomic sequence analysis panel, must include 
sequencing of at least 10 genes, always including 
BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, 
PALB2, PTEN, STK11 and TP53, effective 01/01/2018  
1 Breast Cancer Multi-Gene 
large panel (includes BRCA1 
and BRCA2 sequencing and 
deletion duplication testing 
via NGS) 
81433 Hereditary breast cancer-related disorders (e.g., 
hereditary breast cancer, hereditary ovarian cancer, 
hereditary endometrial cancer); duplication/deletion 
analysis panel, must include analyses for BRCA1, 
BRCA2, MLH1, MSH2, and STK11 
 
 
Breast Cancer Multi-Gene 
small panel (includes 
BRCA1 and BRCA2 
sequencing and deletion 
duplication testing via NGS) 
    
81400 Molecular pathology procedure, Level 1 (eg, 
identification of single germline variant [eg, SNP] by 
techniques such as restriction enzyme digestion or melt 
curve analysis) 
 
 
N/A 
81401 Molecular pathology procedure Level 2 (eg, 2-10 
SNPs, 1 methylated variant, or 1 somatic variant 
[typically using non-sequencing target variant 
analysis], or detection of a dynamic mutation 
disorder/triplet repeat) 
 
 
N/A 
81402 Molecular pathology procedure Level 3 (>10 SNPs, 2-
10 methylated variants, or 2-10 somatic variants 
[typically using non-sequencing target variant 
analysis], immunoglobulin and T-cell receptor gene 
rearrangements, duplication/deletion variants of 1 exon, 
loss of heterozygosity [LOH], uniparental disomy 
[UPD]) 
 
N/A 
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81403 Molecular pathology procedure, Level 4 (eg, analysis 
of single exon by DNA sequence analysis, analysis of 
>10 amplicons using multiplex PCR in 2 or more 
independent reactions, mutation scanning or 
duplication/deletion variants of 2-5 exons) 
 
 
N/A 
81404 Molecular pathology procedure, Level 5 (eg, analysis 
of 2-5 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 6-10 exons, 
or characterization of a dynamic mutation 
disorder/triplet repeat by Southern blot analysis) 
 
 
N/A 
81405 Molecular pathology procedure, Level 6 (eg, analysis 
of 6-10 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 11-25 
exons, regionally targeted cytogenomic array analysis) 
 
 
N/A 
81406 Molecular pathology procedure, Level 7 (eg, analysis 
of 11-25 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of 26-50 
exons, cytogenomic array analysis for neoplasia) 
Molecular pathology procedure, Level 8 (eg, analysis 
of 26-50 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of >50 exons, 
sequence analysis of multiple genes on one platform) 
 
 
N/A 
81407 Molecular pathology procedure, Level 8 (eg, analysis 
of 26-50 exons by DNA sequence analysis, mutation 
scanning or duplication/deletion variants of >50 exons, 
sequence analysis of multiple genes on one platform) 
 
 
N/A 
81408 Molecular pathology procedure, Level 9 (eg, analysis 
of >50 exons in a single gene by DNA sequence 
analysis) 
 
 
N/A 
 
 
Chapter 3 Appendix, Table 2. ICD-9 and ICD-10 codes used to label enrollees with cancer diagnoses  
ICD-9 code Code Description 
153.x Malignant neoplasm of colon 
157.x Malignant neoplasm of pancreas 
172.x Malignant neoplasm of skin and melanoma 
174.x Malignant neoplasm of the breast, female 
175.x Malignant neoplasm of the breast, male 
183.x Malignant neoplasm of the ovary/ovaries 
184.x Malignant neoplasm of unspecified female organs (Fallopian Tube) 
190.x Malignant neoplasm of eye (Uveal melanoma) 
V10.3 Personal history of malignant neoplasm of the breast 
V10.43 Personal history of malignant neoplasm of the ovary/ovaries 
V16.0 Family history of malignant neoplasm of gastrointestinal tract 
V16.3 Family history of malignant neoplasm of the breast 
V16.41 Family history of malignant neoplasm of the ovary/ovaries 
V16.8 Family history of other specified malignant neoplasm 
V16.9 Family history of unspecified malignant neoplasm 
ICD-10 code Code Description 
C18.x Malignant neoplasm of the colon 
C25.x Malignant neoplasm of the pancreas 
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C43.x Malignant neoplasm of the skin and melanoma 
C50.x Malignant neoplasm of the breast (male and female) 
C56.x Malignant neoplasm of the ovary/ovaries 
C57.x Malignant neoplasm of fallopian tube 
C69.x Malignant neoplasm of the eye (Uveal melanoma) 
Z80.0 Family history of malignant neoplasm of gastrointestinal tract 
Z80.3 Family history of malignant neoplasm of the breast 
Z80.41 Family history of malignant neoplasm of the ovary/ovaries 
Z80.8 Family history of other specified malignant neoplasm 
Z80.9 Family history of unspecified malignant neoplasm 
Z85.3 Personal history of malignant neoplasm of the breast 
Z85.43 Personal history of malignant neoplasm of the ovary/ovaries 
 
 
Chapter 3 Appendix, Table 3. Claims identified as BRCA tests, or with BRCA as a component, and count of 
individuals by year of BRCA test using current paper method of BRCA test identification 
 Year  
CPT 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total 
81162 0 0 0 0 0 0 0 0 1,751 12,866 14,617 
81211 0 0 0 0 10,606 36,855 40,629 48,495 38,522 28,464 203,571 
81212 0 0 0 0 938 2,618 2,249 1,883 1,648 1,273 10,609 
81213 0 0 0 0 3,572 25,904 29,212 32,557 21,037 11,559 123,841 
81214 0 0 0 0 - - - 142 28 29 210 
81215 0 0 0 0 444 1,052 998 1,713 928 651 5,786 
81216 0 0 0 0 11 27 - 110 34 118 308 
81217 0 0 0 0 471 1,274 1,160 1,136 1,157 864 6,062 
81400 0 0 0 0 0 27 160 1,612 600 346 2,745 
81401 0 0 0 0 - 220 298 2,733 2,204 1,430 6,886 
81402 0 0 0 0 - 316 748 1,898 153 98 3,214 
81403 0 0 0 0 - 875 1,648 5,628 4,858 4,046 17,056 
81404 0 0 0 0 - 1,061 1,685 6,004 8,855 12,643 30,251 
81405 0 0 0 0 - 829 1,382 5,437 8,916 6,283 22,848 
81406 0 0 0 0 - 446 550 5,023 13,596 17,819 37,435 
81407 0 0 0 0 - 179 201 975 1398 1,168 3,922 
81408 0 0 0 0 - 629 783 2,976 5,219 5,252 14,860 
81432 0 0 0 0 0 0 0 0 6922 5,810 12,732 
81433 0 0 0 0 0 0 0 0 6492 4,934 11,426 
81479 0 0 0 0 0 1,683 8,700 35,108 34,963 10,871 91,325 
83891 617 1,105 1,394 1,728 12,456 - 0 0 0 0 17,301 
83898 911 1,290 1,469 2,023 11,139 - 0 0 0 0 16,833 
83904 763 1,398 1,561 2,139 11,139 - 0 0 0 0 17,001 
83909 601 1,133 1,435 1,856 11,496 - 0 0 0 0 16,522 
83912 734 1,267 1,541 1,885 12,667 - 0 0 0 0 18,095 
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S3818 - - 0 - - 0 0 0 0 0 - 
S3819 - - - - 0 0 0 0 0 0 - 
S3820 14,219 18,129 18,009 19,626 5,479 0 0 0 0 0 75,462 
S3822 1,041 1,254 1,407 1,544 404 0 0 0 0 0 5,650 
S3823 1,578 1,850 1,817 1,806 478 0 0 0 0 0 7,529 
Total 
Claim
s 
20,468 27,431 28,634 32,612 81,312 74,007 90,414 153,430 159,281 126,524 794,113 
Total 
En-
rollee
s 
16,251 20,933 21,317 23,332 27,680 38,993 43,649 51,882 52,217 51,315 347,569 
 
 
Chapter 3 Appendix, Table 4. Total number and percentage of enrollees who had BRCA testing identified using CPT 
codes from Appendix Table 1 each year 
Year of 
BRCA test 
Total number of 
Enrollees with BRCA 
Test per Year 
Percent 
(%) 
Cumulative 
Percent (%) 
2008 16,251 4.7 4.7 
2009 20,933 6.0 10.7 
2010 21,317 6.1 16.8 
2011 23,332 6.7 23.5 
2012 27,680 7.9 31.5 
2013 38,993 11.2 42.7 
2014 43,649 12.6 55.3 
2015 51,882 14.9 70.2 
2016 52,217 15.0 85.2 
2017 51,315 14.8 100 
 
 
Chapter 3 Appendix, Table 5. Distribution of unique BRCA tests per enrollee 
Number of 
BRCA Tests 
Frequency Percent 
(%) 
Cumulative 
percent (%) 
1 334,714 96.3 96.3 
2 12,026 3.46 99.76 
3 707 0.2 99.96 
4 88 0.03 99.99 
5 17 0 100 
6 10 0 100 
7 - 0 100 
10 - 0 100 
12 - 0 100 
Total 347,569 100  
 
 
 
 
 
  92 
Chapter 3 Appendix, Table 6. Distribution of gender among eligible enrollees for BRCA testing (Cohort 1). 
Gender Frequency Percent 
(%) 
Cumulative 
Percent 
(%) 
Female 5,170,674 79.39 79.39 
Male 1,338,839 20.56 99.95 
Unknown 3,140 0.05 100 
Total 6,512,653 100  
 
 
Chapter 3 Appendix, Table 7. Age distribution across years 2008-2016 for eligible enrollees for BRCA testing 
(Cohort 1). Unknown=Unknown age 
 Age Band 
Year of 
BRCA 
test 
0-17 
(count) 
(%) 
18-24 
(count) 
(%) 
25-34 
(count) 
(%) 
35-44 
(count) 
(%) 
45-54 
(count) 
(%) 
55-64 
(count) 
(%) 
65-74 
(count) 
(%) 
75-84 
(count) 
(%) 
85+ 
(count) 
(%) 
Unk. 
(count) 
(%) 
Total 
(count) 
(%) 
2008 2,644 5,913 32,265 124,896 243,611 243,268 100,523 65,993 15,748 165 835,026 
 0.32 0.71 3.86 14.96 29.17 29.13 12.04 7.9 1.89 0.02 100 
2009 2,290 5,888 29,760 100,779 180,999 165,888 121,482 67,111 17,345 4,303 695,845 
 0.33 0.85 4.28 14.48 26.01 23.84 17.46 9.64 2.49 0.62 100 
2010 2,107 5,575 26,532 88,013 163,190 152,885 109,175 54,901 14,405 1,775 618,558 
 0.34 0.9 4.29 14.23 26.38 24.72 17.65 8.88 2.33 0.29 100 
2011 1,909 6,070 26,665 85,251 154,145 147,202 98,246 46,253 12,418 846 579,005 
 0.33 1.05 4.61 14.72 26.62 25.42 16.97 7.99 2.14 0.15 100 
2012 2,016 6,560 27,956 85,362 150,999 144,244 102,278 44,448 11,854 761 576,478 
 0.35 1.14 4.85 14.81 26.19 25.02 17.74 7.71 2.06 0.13 100 
2013 2,032 7,313 30,686 87,525 151,399 145,999 118,633 48,830 13,179 729 606,325 
 0.34 1.21 5.06 14.44 24.97 24.08 19.57 8.05 2.17 0.12 100 
2014 2,181 7,930 32,532 86,259 146,668 148,096 121,038 47,328 12,435 699 605,166 
 0.36 1.31 5.38 14.25 24.24 24.47 20 7.82 2.05 0.12 100 
2015 2,205 8,496 34,590 88,384 147,736 151,940 120,341 43,994 11,292 2,444 611,422 
 0.36 1.39 5.66 14.46 24.16 24.85 19.68 7.2 1.85 0.4 100 
2016 2,420 9,630 38,455 97,374 169,424 184,255 138,026 51,059 12,459 44 703,146 
 0.34 1.37 5.47 13.85 24.1 26.2 19.63 7.26 1.77 0.01 100 
2017 2,273 9,649 38,996 94,333 154,755 165,535 148,816 53,916 13,409 0 681,682 
 0.33 1.42 5.72 13.84 22.7 24.28 21.83 7.91 1.97 0 100 
TOTA
L 
22,077 73,024 318,437 938,176 1,662,926 1,649,312 1,178,558 523,833 134,544 11,766 6,512,653 
 0.34 1.12 4.89 14.41 25.53 25.32 18.1 8.04 2.07 0.18 100 
 
 
Chapter 3 Appendix, Table 8: Age distribution of BRCA tested enrollees (Cohort 2)   
Gender Frequency Percent (%) 
Cumulative 
Percent (%) 
Female 330,772 95.17 95.17 
Male 16,762 4.82 99.99 
Unknown 35 0.01 100 
Total 347,569 100  
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Chapter 3 Appendix, Table 9. Age category distribution of BRCA tested enrollees (frequency and percentage) 
Age Category Frequency Percent 
(%) 
Cumulative 
Percent (%) 
0-17 1,343 0.39 0.39 
18-24 9,047 2.6 2.99 
25-34 43,789 12.6 15.59 
35-44 88,610 25.49 41.08 
45-54 101,297 29.14 70.23 
55-64 70,421 20.26 90.49 
65-74 25,293 7.28 97.76 
75-84 6,669 1.92 99.68 
85+ 941 0.27 99.95 
Unknown 159 0.05 100 
Total 347,569 100   
 
Chapter 3 Appendix, Table 10. Distribution of health plan types among BRCA tested enrollees. EPO=Exclusive 
Provider Organization; HMO=Health Management Organizaton; IND=Independent plan; OTH=Other type of plan; 
PFF=Private Fee for Service; POS=Point of Service; PPO=Preferred Provider Organization; STP=Sustainability and 
Transformation Plan 
Type of 
Health 
Plan 
Frequency Percent 
(%) 
Cumulative 
Percent (%) 
EPO 21,918 6.31 6.31 
HMO 41,581 11.96 18.27 
IND 1,565 0.45 18.72 
OTH 193 0.06 18.78 
PFF 1,194 0.34 19.12 
POS 226,655 65.21 84.33 
PPO 54,343 15.64 99.97 
STP 120 0.03 100 
Total 347,569 100  
 
 
Chapter 3 Appendix, Table 11.  Proportion and counts of the various plans in the entire HCCI claims database, 
across all years. EPO=Exclusive Provider Organization; HMO=Health Management Organization; 
IND=Independent plan; OTH=Other type of plan; PFF=Private Fee for Service; POS=Point of Service; 
PPO=Preferred Provider Organization; STP=Sustainability and Transformation Plan; UNK=unknown plan 
Year EPO HMO IND OTH PFF POS PPO STP UNK Total 
2008 2,957,397 7,272,242 2,388,136 928,722 0 24,170,025 10,592,817 86,606 208 48,396,153 
  6% 15% 5% 2% 0% 50% 22% 0% 0%  100% 
2009 2,922,367 7,716,015 2,246,592 956,780 1,161,770 25,711,965 10,184,287 80,171 221 50,980,168 
  6% 15% 4% 2% 2% 50% 20% 0% 0%  100% 
2010 2,736,670 6,861,145 2,054,144 1,129,885 962,676 26,981,367 9,776,055 112,489 0 50,614,431 
  5% 14% 4% 2% 2% 53% 19% 0% 0%  100% 
2011 2,819,316 6,518,230 1,928,441 106,550 374,018 27,446,296 10,048,437 141,401 0 49,382,689 
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  6% 13% 4% 0% 1% 56% 20% 0% 0%  100% 
2012 2,730,815 6,418,619 1,817,854 120,660 332,547 28,442,842 10,507,693 114,793 208 50,486,031 
  5% 13% 4% 0% 1% 56% 21% 0% 0%  100% 
2013 2,626,873 6,808,949 1,588,703 153,707 306,952 29,392,980 11,148,847 100,291 0 52,127,302 
  5% 13% 3% 0% 1% 56% 21% 0% 0%  100% 
2014 2,389,442 7,436,632 1,494,929 182,957 244,673 30,348,585 10,986,773 226,414 0 53,310,405 
  4% 14% 3% 0% 0% 57% 21% 0% 0%  100% 
2015 2,578,297 7,822,853 1,223,309 174,074 216,131 30,906,387 10,195,173 356,399 0 53,472,623 
  5% 15% 2% 0% 0% 58% 19% 1% 0%  100% 
2016 2,896,814 8,859,745 965,628 163,338 189,480 32,688,330 11,459,162 509,323 0 57,731,820 
  5% 15% 2% 0% 0% 57% 20% 1% 0%  100% 
2017 2,545,126 7,489,197 799,525 118,379 150,512 32,073,761 11,244,267 561,148 0 54,981,915 
  5% 14% 1% 0% 0% 58% 20% 1% 0% 100%  
Total 27,203,11
7 
73,203,627 16,507,261 4,035,052 3,938,759 288,162,538 106,143,51
1 
2,289,035 637 521,483,537 
 5% 14% 3% 1% 1% 55% 20% 0% 0% 100% 
 
Chapter 3 Appendix, Table 12. Total number of males, females and unknown gender assignation among BRCA 
tested enrollees from 2008-20167  
 Gender   
Year of 
BRCA 
Test 
Female 
(count) 
(%) 
Male 
(count) 
(%) 
Unknown 
(count) 
(%) 
Total (count) 
(%) 
2008 15,774 477 0 16,251 
 97.06 2.94 0 100 
2009 20,262 664 - 20,933 
 96.79 3.17 - 100 
2010 20,541 771 - 21,317 
 96.36 3.62 - 100 
2011 22,426 906 0 23,332 
 96.12 3.88 0 100 
2012 26,582 1,096 - 27,680 
 96.03 3.96 - 100 
2013 37,573 1,352 - 38,929 
 96.52 3.47 - 100 
2014 41,406 2,228 - 43,635 
 94.89 5.11 - 100 
2015 48,701 3,137 - 51,847 
 93.93 6.05 - 100 
2016 49,047 3,226 - 52,275 
 93.82 6.17 - 100 
2017 48,460 2,905 - 51,370 
 94.34 5.66 0.01 100 
Total 330,772 16,762 35 347,569 
 95.17 4.82 0.01 100 
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Chapter 3 Appendix, Table 13. BRCA charges, paid amount and enrollee cost share. SD=standard deviation; 
p25=25th percentile; p50=50th percentile; p75=75th percentile 
 Mean SD p25 p50 p75 
BRCA 
Charges 4762 8164 3120 3340 4040 
BRCA net 
paid 2942 5004 1582 2654 3030 
BRCA cost 
share 295 1696 0 0 168 
 
 
Chapter 3 Appendix, Table 14. BRCA test mean charges, standard deviations, and percentiles (25th, 50th and 75th) from 
2008-2016. 
Year Mean S.D. 25th 
Percentile 
Median 75th 
Percentile 
2008 2,580 1,175 3,120 3,120 3,120 
2009 2,512 1,219 3,120 3,120 3,120 
2010 2,893 1,025 3,120 3,340 3,340 
2011 2,958 1,035 3,340 3,340 3,340 
2012 2,937 1,145 3,033 3,340 3,340 
2013 3,768 4,643 3,340 4,040 4,040 
2014 4,317 5,227 3,340 4,040 4,275 
2015 6,250 10,496 3,340 4,040 6,040 
2016 6,878 11,874 3,340 4,040 6,040 
2017 6,422 11,634 2,704 4,040 6,040 
Total 4,762 8,164 3,120 3,340 4,040 
 
 
Chapter 3 Appendix, Table 15. BRCA test paid amount, mean, standard deviations (S.D.), and percentiles (25th, 50th 
and 75th) from 2008-2016 
Year Mean S.D. 25th 
Percentile 
Median 75th 
Percentile 
2008 2,336 899 2,337 2,749 2,841 
2009 2,357 905 2,341 2,749 2,926 
2010 2,348 966 2,341 2,859 2,926 
2011 2,383 976 2,341 2,926 2,945 
2012 2,415 1,067 2,341 2,926 3,033 
2013 2,747 2,812 2,341 2,926 3,528 
2014 2,650 3,731 1,550 2,823 3,275 
2015 3,328 6,162 1,400 2,312 3,333 
2016 3,830 7,926 1,425 2,556 3,477 
2017 3,262 6,744 1,050 2,186 2,578 
Total 2,942 5,004 1,582 2,654 3,030 
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Chapter 3 Appendix, Table 16. BRCA enrollee cost-sharing amount, mean, standard deviations, and percentiles 
(25th, 50th and 75th) from 2008-2016. S.D.=standard deviation 
Year Mean S.D. 25th 
Percentile 
Median 75th 
Percentile 
2008 131 310 0 0 117 
2009 144 342 0 0 106 
2010 156 366 0 0 146 
2011 178 397 0 0 293 
2012 228 648 0 0 303 
2013 241 621 0 0 293 
2014 225 1,031 0 0 20 
2015 345 2,050 0 0 182 
2016 435 2,217 0 0 256 
2017 460 2,916 0 0 80 
Total 295 1,696 0 0 168 
 
 
Chapter 3 Appendix, Table 17. Age distribution by year of BRCA testing, for enrollees who had BRCA testing but 
did not have an indication for testing. Unknown age category not shown, represents0.18% of total count. 
	 Age (age range in years) 
Enrollee count 
(%)	
Year 0-17 
 
18-24  
 
25-34  
 
35-44  
 
45-54  
 
55-64  
 
65-74  
 
75-84  
 
85+  
 
Total  
 
2008 2,644 5,913 32,265 124,896 243,611 243,268 100,523 65,993 15,748 835,026 
 0.32 0.71 3.86 14.96 29.17 29.13 12.04 7.9 1.89 100 
2009 2,290 5,888 29,760 100,779 180,999 165,888 121,482 67,111 17,345 695,845 
 0.33 0.85 4.28 14.48 26.01 23.84 17.46 9.64 2.49 100 
2010 2,107 5,575 26,532 88,013 163,190 152,885 109,175 54,901 14,405 618,558 
 0.34 0.9 4.29 14.23 26.38 24.72 17.65 8.88 2.33 100 
2011 1,909 6,070 26,665 85,251 154,145 147,202 98,246 46,253 12,418 579,005 
 0.33 1.05 4.61 14.72 26.62 25.42 16.97 7.99 2.14 100 
2012 2,016 6,560 27,956 85,362 150,999 144,244 102,278 44,448 11,854 576,478 
 0.35 1.14 4.85 14.81 26.19 25.02 17.74 7.71 2.06 100 
2013 2,032 7,313 30,686 87,525 151,399 145,999 118,633 48,830 13,179 606,325 
 0.34 1.21 5.06 14.44 24.97 24.08 19.57 8.05 2.17 100 
2014 2,181 7,930 32,532 86,259 146,668 148,096 121,038 47,328 12,435 605,166 
 0.36 1.31 5.38 14.25 24.24 24.47 20 7.82 2.05 100 
2015 2,205 8,496 34,590 88,384 147,736 151,940 120,341 43,994 11,292 611,422 
 0.36 1.39 5.66 14.46 24.16 24.85 19.68 7.2 1.85 100 
2016 2,420 9,630 38,455 97,374 169,424 184,255 138,026 51,059 12,459 703,146 
 0.34 1.37 5.47 13.85 24.1 26.2 19.63 7.26 1.77 100 
2017 2,273 9,649 38,996 94,333 154,755 165,535 148,816 53,916 13,409 681,682 
 0.33 1.42 5.72 13.84 22.7 24.28 21.83 7.91 1.97 100 
Total 22,077 73,024 318,437 938,176 1,662,926 1,649,312 1,178,558 523,833 134,544 6,512,653 
 0.34 1.12 4.89 14.41 25.53 25.32 18.1 8.04 2.07 100 
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Chapter 3 Appendix, Table 18. Gender distribution by year of BRCA testing, for enrollees who had BRCA testing but 
did not have an indication for testing. Unk=unknown gender. 
Year Female Male Unk. Total 
2008 259 191 0 450 
  57.56 42.44 0 100 
2009 297 238 0 535 
  55.51 44.49 0 100 
2010 301 251 0 552 
  54.53 45.47 0 100 
2011 348 300 0 648 
  53.7 46.3 0 100 
2012 426 338 0 764 
  55.76 44.24 0 100 
2013 477 315 0 792 
  60.23 39.77 0 100 
2014 1,171 796 0 1,967 
  59.53 40.47 0 100 
2015 1,943 1,092 - 3,037 
  63.98 35.96 0.07 100 
2016 2,823 1,137 0 3,960 
  71.29 28.71 0 100 
2017 3,123 1,008 - 4,133 
  75.56 24.39 0.05 100 
Total 11,168 5,666 - 16,838 
  66.33 33.65 0.02 100 
 
Appendix Table 19. Distribution of insurance type by year of BRCA testing for enrollees who had BRCA testing but 
did not have an indication for testing. EPO=Exclusive Provider Organization; HMO=Health Management 
Organizaton; IND=Independent plan; OTH=Other type of plan; PFF=Private Fee for Service; POS=Point of Service; 
PPO=Preferred Provider Organization; STP=Sustainability and Transformation Plan; UNK=unknown plan 
Year of 
BRCA 
Test 
EPO HMO IND OTH PFF POS PPO STP Total 
2008 26 49 - - 0 247 121 0 450 
 5.78 10.89 - - 0 54.89 26.89 0 100 
2009 30 57 14 0 15 299 120 0 535 
 5.61 10.65 2.62 0 2.8 55.89 22.43 0 100 
2010 29 59 16 0 - 287 157 0 552 
 5.25 10.69 2.9 0 - 51.99 28.44 0 100 
2011 40 53 13 0 - 323 210 0 648 
 6.17 8.18 2.01 0 - 49.85 32.41 0 100 
2012 45 56 12 - 10 400 240 0 764 
 5.89 7.33 1.57 - 1.31 52.36 31.41 0 100 
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2013 21 66 - 0 - 383 312 - 792 
 2.65 8.33 - 0 - 48.36 39.39 - 100 
2014 67 230 - - 11 948 689 16 1967 
 3.41 11.69 - - 0.56 48.2 35.03 0.81 100 
2015 168 458 - - 19 1,632 747 - 3037 
 5.53 15.08 - - 0.63 53.74 24.6 - 100 
2016 248 605 14 0 26 2,338 726 - 3960 
 6.26 15.28 0.35 0 0.66 59.04 18.33 - 100 
2017 190 663 22 0 - 2,492 757 - 4133 
 4.6 16.04 0.53 0 0.15 60.3 18.32 - 100 
TOTAL 864 2,296 110 - 104 9,349 4,079 30 16,838 
 5.13 13.64 0.65 0.04 0.62 55.52 24.22 0.18 100 
 
 
Chapter 3 Appendix, Table 20. Gender or BRCA tested enrollees aged 0-17, by year of test. 
 Gender  
Year of 
BRCA 
Test 
Female 
(N) 
(%) 
Male 
(N) 
(%) 
Total 
(N) 
(%) 
2008 94 60 154 
 61.04 38.96 100 
2009 94 54 148 
 63.51 36.49 100 
2010 71 64 135 
 52.59 47.41 100 
2011 85 61 146 
 58.22 41.78 100 
2012 91 79 170 
 53.53 46.47 100 
2013 63 22 85 
 74.12 25.88 100 
2014 86 32 118 
 72.88 27.12 100 
2015 104 35 139 
 74.82 25.18 100 
2016 90 37 127 
 70.87 29.13 100 
2017 98 23 121 
 80.99 19.01 100 
Total 876 467 1,343 
 65.23 34.77 100 
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Chapter 3 Appendix, Table 21. Insurance types for BRCA enrollees aged 0-17, by year of test. EPO=Exclusive 
Provider Organization; HMO=Health Management Organizaton; IND=Independent plan; OTH=Other type of plan; 
PFF=Private Fee for Service; POS=Point of Service; PPO=Preferred Provider Organization; STP=Sustainability and 
Transformation Plan; UNK=unknown plan 
Year of 
BRCA 
Test 
EPO 
(N) 
(%) 
HMO 
(N) 
(%) 
IND 
(N) 
(%) 
OTH 
(N) 
(%) 
POS 
(N) 
(%) 
PPO 
(N) 
(%) 
STP 
(N) 
(%) 
Total 
2008 15 26 0 0 82 31 0 154 
 9.74 16.88 0 0 53.25 20.13 0 100 
2009 14 14 0 0 96 24 0 148 
 9.46 9.46 0 0 64.86 16.22 0 100 
2010 11 16 0 0 83 25 0 135 
 8.15 11.85 0 0 61.48 18.52 0 100 
2011 13 10 0 0 107 16 0 146 
 8.9 6.85 0 0 73.29 10.96 0 100 
2012 19 10 0 0 117 24 0 170 
 11.18 5.88 0 0 68.82 14.12 0 100 
2013 - - - 0 64 - 0 85 
 - - - 0 75.29 - 0 100 
2014 - - 0 0 93 12 0 118 
 - - 0 0 78.81 10.17 0 100 
2015 10 - 0 0 105 18 - 139 
 7.19 - 0 0 75.54 12.95 - 100 
2016 - 13 0 - 97 13 0 127 
 - 10.24 0 - 76.38 10.24 0 100 
2017 - - 0 0 96 14 0 121 
 - - 0 0 79.34 11.57 0 100 
Total 99 116 - - 940 185 - 1,343 
 7.37 8.64 - - 69.99 13.78 - 100 
 
 
Chapter 3 Appendix, Table 22. Cell percentages of BRCA tested enrollees aged 0-17, by cancer type and family 
history type. FHx=Family History; CA=Cancer 
Cancer 
Diagnosis 
No FHx FHx BR FHx OV FHx 
BR/OV 
FHx 
Other 
Total 
No Cancer 790 338 83 51 24 1,286 
 58.82 25.17 6.18 3.8 1.79 95.76 
Breast CA - 15 - - 0 27 
 - 1.12 - - 0 2.01 
Ovary CA - - - 0 - 13 
 - - - 0 - 0.97 
Other CA  13 - 0 0 0 17 
 0.97 - 0 0 0 1.27 
Total 819 359 86 54 25 1,343 
 60.98 26.73 6.4 4.02 1.86 100 
Chapter 3 Appendix, Table 23. Enrollees with Medicare plans among the eligible enrollees (Cohort 1) by age. 
  100 
 Age Categories (years)  
 0-17 
 
18-24 
 
25-34 
 
35-44 
 
45-54  
 
 55-64 
 
65-74 
 
75-84 
 
85+ 
 
Unk. 
 
Total 
No 
Medi-
care 
(N) 
22,077 72,976 317,361 930,169 1,624,059 1,536,620 403,310 196,699 55,702 2,395 5,161,368 
(%) 100 99.93 99.66 99.15 97.66 93.17 34.22 37.55 41.4 20.36 79.25 
Yes 
Medi-
care 
(N) 
0 48 1,076 8,007 38,867 112,692 775,248 327,134 78,842 9,371 1,351,285 
(%) 0 0.07 0.34 0.85 2.34 6.83 65.78 62.45 58.6 79.64 20.75 
Total 22,077 73,024 318,437 938,176 1,662,926 1,649,312 1,178,558 523,833 134,544 11,766 6,512,653 
 100 100 100 100 100 100 100 100 100 100  
 
 
Chapter 3 Appendix, Table 24. Proportion Medicare plans by type of plan among eligible enrollees (Cohort 1). 
EPO=Exclusive Provider Organization; HMO=Health Management Organizaton; IND=Independent plan; 
OTH=Other type of plan; PFF=Private Fee for Service; POS=Point of Service; PPO=Preferred Provider 
Organization; STP=Sustainability and Transformation Plan; UNK=unknown plan 
 EPO HMO IND OTH PFF POS PPO STP UNK Total 
No 
Medi-
care (N) 
290,282 582,615 349,614 14,664 0 3,162,447 760,384 1,357 - 5,161,368 
(%) 5.62 11.29 6.77 0.28 0 61.27 14.73 0.03 - 100 
Has 
Medi-
care (N) 
0 437,186 0 576 134,637 69,401 709,485 0 0 1,351,285 
(%) 0 32.35 0 0.04 9.96 5.14 52.5 0 - 100 
Total 
(N) 290,282 1,019,801 349,614 15,240 134,637 3,231,848 1,469,869 1,357 - 
6,512,65
3 
% 4.46 15.66 5.37 0.23 2.07 49.62 22.57 0.02 0 100 
 
 
Chapter 3 Appendix, Table 25. Proportion Medicare plans by year among eligible enrollees (Cohort1) 
Year of 
BRCA 
Test 
Does not 
have 
Medicare 
(count) 
(%) 
Has 
Medicare 
(count) 
(%) 
Total 
2008 16,251 0 16,251 
 100 0 100 
2009 20,486 447 20,933 
 97.86 2.14 100 
2010 20,500 817 21,317 
 96.17 3.83 100 
2011 22,065 1,267 23,332 
 94.57 5.43 100 
2012 26,126 1,554 27,680 
 94.39 5.61 100 
2013 36,194 2,735 38,929 
 92.97 7.03 100 
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2014 39,664 3,971 43,635 
 90.9 9.1 100 
2015 46,093 5,754 51,847 
 88.9 11.1 100 
2016 45,813 6,462 52,275 
 87.64 12.36 100 
2017 43,773 7,597 51,370 
 85.21 14.79 100 
Total 316,965 30,604 347,569 
 91.19 8.81 100 
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CHAPTER 4.  ADJUSTED BRCA RATES AMONG ELIGIBLE ENROLLEES  
 
KEY FINDINGS 
 After adjusting for cancer diagnosis and type, age at diagnosis, family history of cancer, 
and year of testing: 
• Family history of breast and ovarian cancer remained the strongest family history driver of BRCA 
testing across all cancer diagnoses and types of family histories of cancer. 
• Very young enrollees (ages 18-24) had the highest rates of BRCA testing starting at 50%. 
• Acceleration in BRCA testing predicted probabilities after 2013 was observed across most types 
of family histories and cancer diagnoses and types (i.e./ a “Jolie effect”) but its magnitude varied 
across the different subgroups. 
• Young, affected enrollees with a family history had testing rates that were approaching 100%.  
• Young, unaffected enrollees with a family history and young, affected enrollees without a family 
history had rates below 20%. 
 
INTRODUCTION 
 BRCA testing has for over two decades been performed based on the type of cancer, age 
at diagnosis and the presence of family history of cancer.  In order to fully assess the effects of 
these factors on the likelihood of BRCA testing, analysis focused on identifying the effects of a 
diagnosis of cancer consistent with BRCA phenotype, that of age at diagnosis and that of family 
history of cancer have, both alone and as a combined effect.  
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METHODS 
Cohort Selection 
 The analysis in this chapter was based on Cohort 1, which was described in Chapter 3.  
Enrollees with no indication for testing according to our coding described in “Cohort Selection” 
(n=16,838) were removed from the sample. 
 
Statistical Analysis 
Logistic regressions examining the likelihood of BRCA testing were fitted using Cohort 
1, stratified by year and cancer type (i.e. breast cancer, ovarian cancer, breast and ovarian cancer, 
other cancer, and no cancer). Because the effects of cancer diagnosis, type of cancer(s), family 
history of cancer, types of family history of cancer, age of testing and year of testing are 
expected to exert an effect on the likelihood of BRCA testing alone, and as interaction terms, 
several specific logistic regressions were fitted to assess their effects.  Four regression analyses 
are presented.   
Regression 1 was fitted using an interaction term composed of type of cancer diagnosis 
and type of family history.   
Regression 2 was fitted using a three-way interaction term: type of cancer diagnosis, type 
of family history of cancer, and age at BRCA testing.   
Regression 3 was also fitted using a three-way interaction term: type of cancer diagnosis, 
type of family history of cancer, and year of BRCA testing.  
To assess the combined effects of cancer diagnosis (regardless of type) and family history 
of cancer (regardless of type) when interacted with age, types of cancers and family histories of 
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cancer were collapsed into categories Cancer/No Cancer, and Family History of Cancer/No 
Family History of Cancer.  
Regression 4 was fitted using an interaction term between the two collapsed categories 
and age of BRCA testing, while stratifying the models by year.  
A fifth analysis was conducted to assess only the effects of breast and/or ovarian cancer 
diagnoses and family history of breast and/or ovarian cancer.  Regression 5 was fitted with only 
those subcategories interacted with age of BRCA testing and stratified by year of BRCA testing. 
The results from this analysis are presented in the Appendix. 
Regressions 4 and 5 also used gender and insurance plan type as independent variables.  
Reference groups were ages 45-54 across all regressions, and Breast Cancer, No Family 
History of Cancer for Regressions 1 through 3, and 5.  For Regression 4, a collapsed category of 
Cancer and Family History of Cancer was used as a reference group. 
The average marginal effects were calculated for all regression models within each 
combination of cancer type, family history status, and age group, as applicable in each set of 
regressions.  
Prior to fitting any of the regressions, the age groups of 0-17 years and “unknown age” 
were dropped. Additionally, any cells that had fewer than one enrollee tested and fewer than five 
enrollees eligible for testing were also dropped, as was the group of enrollees who had BRCA 
testing without any indication (i.e./No cancer diagnosis, no family history), n=16,838. 
 
RESULTS 
 Logistic regressions were conducted to assess adjusted rates of testing with cancer status, 
age group and family history of cancer serving as the primary regressors of interest. Regression 
model 2 was stratified by age (Figs. 2-4; Chapter 4 Appendix, Table 3 and Figs. 1, 2), while 
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regression model 3 (Figs. 5, 6; Chapter 4 Appendix, Table 5 and Figs. 3-5), model 4 (Figs. 7-9 
and Chapter 4 Appendix Table 7) and model 5 (Chapter 4 Appendix, Table 9 and Figs.6-18) 
were stratified by year. Regression models 4 and 5 controlled for gender and insurance type. 
Because the likelihood of testing changed over time across age groups, the odds ratios from these 
regressions are difficult to interpret. To address this, we estimated the adjusted probability of 
being tested across age groups by cancer and family history and over time.  For the full 
regression results, refer to Ch. 4 Appendix, Tables 1, 3, 5, 7, 9.  The adjusted probabilities are 
presented in Ch. 4 Appendix, Tables 2, 4, 6, 8, 10.  A selection of various types of enrollee 
subgroups from these five regressions will be discussed below.  Please refer to Chapter 4 
Appendix for complete results. Note that these analyses were performed using data that had at 
least 10 enrollees in each cell; as a result, there were some cells where the numbers were 
suppressed, leading to some artifacts in the regression results. At times, these are represented 
graphically by sudden drops to zero in the testing rates.  
 
Adjusted BRCA Rates by Cancer Diagnosis, and Family History of Cancer  
 Adjusted rates for BRCA testing from Regression 1 demonstrate that family history of 
breast and ovarian cancer remains the strongest driver of BRCA testing with rates between 45%-
67%.  The higher end of the range is seen in patients who have the family history of both cancers 
as well as a diagnosis of breast cancer, or a diagnosis of both breast and ovarian cancer (see Fig. 
1).  For regression results please see Chapter 4 Appendix, Table 1; for adjusted probabilities 
please see Chapter 4 Appendix, Table 2.   
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Fig 1. Adjusted probabilities of having BRCA testing based on cancer status, family history of cancer type and 
various combinations of family history and cancer status. *Enrollees without cancer and without a family history 
were not considered eligible for testing and were excluded from the model. 
 
Adjusted BRCA Rates by Cancer Diagnosis, Family History of Cancer, and Age  
 For additional granularity, age was added to the model and interacted with cancer 
status/type, and family history of cancer status/type and predicted probabilities were calculated 
(Regression 2).  Please see Ch. 4 Appendix, Figs. 1, 2 for cancer and family history categories 
not included below (enrollees with breast and ovarian cancer and enrollees with other cancer).   
Unaffected Enrollees (Fig. 2) 
Among unaffected enrollees, those who were very young (18-24 years of age) and had a 
family history of breast and ovarian cancer were more than twice as likely (65%) to undergo 
BRCA testing compared to the next highest category (those with a family history of ovarian 
cancer at 25%). Those with family history of other cancers had the lowest testing rate across all 
age categories.  The BRCA rates converged to about 10% for all categories after age 65. 
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Fig. 2 Adjusted BRCA testing rate among enrollees without cancer by various family histories and age. *Enrollees 
without cancer and without a family history were not considered eligible for testing and were excluded from the 
model. (For raw data refer to Chapter 4 Appendix Regression 2, margins, unaffected enrollees)  
 
Enrollees with Breast Cancer (Fig. 3) 
After adjusting for family history and cancer status/type, all enrollees 18-24 years old 
with a positive family history of any cancer showed at least a 45% rate of BRCA testing. There 
was a plateau in testing rates in the 25-34 age group for those with family histories of breast, 
ovarian or both cancers, but those with a family history of other cancer experienced a precipitous 
drop in rates. There was less pronounced drop for those with a family history of breast cancer 
and ovarian cancer after age 44. For enrollees with breast cancer and a family history of breast 
and ovarian cancer, BRCA testing remained constant until age 54, after which there was a spike 
to 100% in the 55-64 age group that may have been due to insufficient numbers, or artifact.  
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Fig.3 Adjusted BRCA testing rate among enrollees with breast cancer, by various family histories and 
age.  *Enrollees without cancer and without a family history were not considered eligible for testing and were 
excluded from the model. Dx=diagnosis; FHx=family history; CA=cancer. (For raw data refer to Chapter 4 Appendix, 
Regression 2, margins, breast cancer enrollees) 
 
Enrollees with Ovarian Cancer (Fig. 4) 
 Enrollees with ovarian cancer appeared to have a relatively constant BRCA testing rate 
from young to old with a slight overall decrease as age increases. BRCA rates at age 18-24 had 
wide variance, depending on the type of family history.  Those with a family history of both 
breast and ovarian cancer had the highest BRCA test rate, while those without a family history of 
cancer had the lowest rate of BRCA testing.  For enrollees with ovarian cancer and a family 
history of both breast and ovarian cancer, the rate dropped suddenly around age 65 (Fig. 4).   
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Fig. 4. Adjusted BRCA testing rate among enrollees with ovarian cancer, by various family histories and age. 
*Enrollees without cancer and without a family history were not considered eligible for testing and were excluded 
from the model. Dx=diagnosis; FHx=family history; CA=cancer. (For raw data refer to Chapter 4 Appendix Regression 
2, margins, ovarian cancer enrollees). 
 
Adjusted BRCA Rates by Cancer Diagnosis, Family History of Cancer and Year  
 To assess the effect of year in which BRCA testing took place and its interaction with 
cancer diagnosis and type and family history type, predicted probabilities were derived from 
fitting a regression model that included a three-way interaction between year of BRCA test, 
cancer diagnosis/type and type of family history (Regression 3).  Please see Ch. 4 Appendix 
Figs. 3-5 for subgroups in this analysis not presented below (enrollees with breast cancer, 
enrollees with ovarian cancer, and enrollees with both breast and ovarian cancer), and Chapter 4 
Appendix, Tables 5 and 6 for regression results and adjusted probabilities. 
Unaffected Enrollees (Fig. 5) 
 After adjusting for year of testing, family history and status/type of cancer, the highest 
increase in BRCA testing in unaffected enrollees was again seen in those with a family history of 
breast and ovarian cancer, starting at 15% in 2008 and ending at 63% in 2017, for an increase of 
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320% over the study period.  This group also had the steepest increase (13 percentage points, or 
a 33% increase) in BRCA testing from 2012 to 2013, for a robust “Jolie effect”.  Unaffected 
individuals with a family history of ovarian cancer experienced an increase from 2008 – 2015, 
with slight acceleration pre-Jolie in 2011, which continued at the same slope until 2015 when it 
tapered off. 
 
Fig 5. Adjusted BRCA testing rate among enrollees without cancer, by various family histories and year of testing. 
*Enrollees without cancer and without a family history were not considered eligible for testing and were excluded 
from the model. Dx=diagnosis; FHx=family history; CA=cancer. (For raw data refer to Chapter 4 Appendix, Regression 
3, margins, unaffected enrollees) 
 
Enrollees with Other Cancer (Fig. 6)  
 Enrollees with other cancers (pancreas, colon, cutaneous melanoma, eye, and other) had 
testing rates that were, similar to previous groups, driven by family history of breast and ovarian 
cancer.  This type of family history was once again instrumental in driving the overall uptake of 
BRCA testing among enrollees with other cancer.  In the family history of ovarian cancer group, 
there was evidence of a “Jolie effect”, with rates increasing from 11% in 2012 to 16% in 2013 
(representing a 45% increase), with even steeper acceleration beyond 2013. 
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Fig. 6. Adjusted BRCA testing rate among enrollees with other cancer, by various family histories and year of 
testing. Dx=diagnosis; FHx=family history; CA=cancer. (For raw data refer to Chapter 4 Appendix, Regression 3, 
margins, enrollees with other cancers) 
 
Adjusted BRCA Rates by Any Cancer Diagnosis, Any Family History of Cancer, and Year  
 To test whether the presence of a cancer diagnosis (regardless of type), a positive family 
history of cancer (regardless of type) as well as age and year of BRCA testing interact together to 
influence BRCA testing likelihood, the cancer and family history categories were collapsed into 
just yes/no variables.  These were then interacted with year of testing and age (Regression 4).   
 The adjusted testing rates are presented in Ch. 4 Appendix, Table 8, and presented 
graphically in Figs. 7-9.  Fig. 7 presents the rates of BRCA testing by age and year unaffected 
enrollees with a family history of cancer.  Fig. 8 presents the same information for those 
enrollees with cancer and with a family history of cancer, but note that the magnitude of the 
percentage scale is different.  Fig. 9 presents BRCA testing rates for enrollees with cancer, but 
without a family history of cancer.  Please note that Figs. 7-9 have varying scales among the y-
axis, so as to better illustrate some of the more modest changes in BRCA testing rates. 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
R
at
e 
of
 B
R
C
A
 T
es
tin
g 
Year of BRCA Test 
No CA 
FHx 
Breast  CA 
FHx 
Ovarian 
FHx 
Breast & 
Ovarian 
CA FHx 
Other CA 
FHx 
  114 
 
Fig. 7. Adjusted BRCA testing rate among enrollees without cancer but with a family history of cancer, by year and 
age of testing. 
 
For unaffected enrollees with a family history of cancer, the highest BRCA testing annual 
rate was 16%.  The rate accelerated in all age groups (except those 65+) starting in 2012, and 
peaking in 2015.  Of particular interest in this group were once again the young enrollees (aged 
18-24), whose rates of BRCA testing increased from 5.2% in 2008 to 14.8% in 2015 (with slight 
acceleration in 2012). This increase of ~10.5 percentage points over this seven year study period 
represented an increase of 185%.  The next youngest group (ages 25-34) increased from 4.3% in 
2008 to 16% in 2015, for a 272% over the same 7-year period. After 2015, BRCA testing rates 
that had been increasing began to decrease in 2016, with leveling off in 2017. 
The “Jolie effect” in this analysis with collapsed cancer and family history categories 
showed a distinct acceleration from 2012-2013, with almost parallel rates for all enrollees under 
age 65, with the average net difference in rates ~ 2.2% over the year in question.  The largest net 
difference occurred in the 25-34 year olds, with 3.6 percentage points, or a 39% increase. 
0.0% 
5.0% 
10.0% 
15.0% 
20.0% 
25.0% 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
R
at
e 
of
 B
R
C
A
 T
es
tin
g 
Age at BRCA Testing 
18-24 
25-34 
35-44 
45-54 
55-64 
65-74 
75-84 
85+ 
  115 
 
Fig. 8. Adjusted BRCA testing rate among enrollees with cancer and with a family history of cancer, by year and age 
of testing 
  
 For those with both cancer and a family history of cancer, the overall BRCA testing rates 
were much higher, especially in the young enrollees, peaking around 50%.  Rates in 2008 had a 
wider range, between 0-32% depending on the age category, and peaked at 10-50% in 2017.  In 
this group, the rates of increase were similar across all age groups with most of the lines parallel 
and only one crossover (45-54 age group and 18-24 age group) (Fig. 8).  
 The “Jolie effect” in this group is most evident in the youngest age category, with an 
increase of 5.1 percentage points, representing a 14% increase. 
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Fig. 9. Adjusted BRCA testing rate among enrollees with cancer, but no family history of cancer, by year and age of 
testing.  
 
Enrollees with cancer, but no family history also had lower BRCA testing rates overall, 
peaking at 13%.  The highest rate acceleration was seen in the 35-44 age group, with rates that 
increased from 2.6-13.2%, for a 400% increase over the study period (Fig 9).  The rest of the age 
groups had similar slopes for the BRCA rates, but of lower magnitude.  
The “Jolie effect” in this category of enrollees with cancer but no family history was seen 
best in the 35-44 age group, whose net BRCA rate increased by 2.2 percentage points from 2012-
2013, for an increase of 23%. 
Looking across Figs. 7-9, the BRCA testing rates increased in all ages and across years.  
The rates were lowest and remained the lowest in affected enrollees without a family history, 
followed by unaffected enrollees with a family history of cancer.   In no age group in either of 
these categories is the adjusted testing rate above 15%.  Adjusted BRCA testing rates are highest 
in affected enrollees with a family history of cancer, where the rates in 2017 varied between 
10%-50% depending on age, with older ages having lower testing rates.  
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DISCUSSION  
 BRCA testing rates adjusted for cancer status and type, as well as family history of cancer 
demonstrated that very young enrollees (ages 18-24) had the highest rates of BRCA testing, 
varying between 50-75% depending on affected status, type of cancer and presence of family 
history of cancer.  Family history of breast and ovarian cancer appeared to be strongest driver of 
BRCA testing across all cancer diagnoses and types of family histories of cancer. 
 These findings are consistent with those from unadjusted BRCA testing rates described in 
Chapter 3, and as such demonstrate the robustness of this finding, even after adjusting for the 
presence and type of cancer and presence and type of family history of cancer.   
 Young breast and ovarian cancer patients typically are referred have BRCA testing even 
though many of the very young cancers are not hereditary.  Because of their very young age at 
diagnosis and because of the attendant other risks of a BRCA mutation, clinicians like to rule out 
a BRCA mutation in this population.  The higher rates of BRCA testing seen in very young 
enrollees and in those with a family history of both breast and ovarian cancer are consistent with 
clinical practice. The drop-off in BRCA testing after the age of 54 in patients with breast cancer 
(see Fig. 3) reflects clinical testing guidelines, which emphasize breast cancer before age fifty as 
a hallmark of a BRCA mutation.   
 Across all types of cancer diagnoses and family histories, after adjusting for cancer 
status/type family history and year of testing, BRCA testing rates increased, but had large 
variance in percent increase, between 0% - 400% increase from 2008 to 2017, depending on 
how/if cancer diagnosis and family history, as well as interaction terms were included in the 
models.  Overall however, the highest adjusted BRCA rates were seen in those with a family 
history of breast and ovarian cancer, followed in decreasing order by family history of ovarian 
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cancer, family history of breast cancer, family history of other cancer and no family history.  
These findings  
 An acceleration in adjusted rates of BRCA testing from 2012 to 2013 (i.e./ a “Jolie 
effect”) was observed across most types of family histories, and cancer diagnoses/types (Figs. 5-
9, and Ch. 4 Appendix, Figs. 7-11), but its magnitude varied across the different subgroups, with 
anywhere between 14-45% increase (based on analysis described in Results section). One 
explanation for the observed variation may be that Jolie’s medical scenario may have been 
inspirational to younger individuals, who were like her, unaffected, but had a family history of 
cancer.  Another explanation may be that among those who had clear indications for testing and 
who fit traditional criteria for BRCA testing, such as those affected with cancer at young ages 
who also had a family history of breast and ovarian cancer (i.e./ those who fit Hereditary Breast 
and/or Ovarian Cancer Syndrome criteria) were already having BRCA testing at a high rate, and 
the effect was therefore muted among these enrollees.  Re-analysis of their data by Guo et al. (H. 
J. Guo F, Lin Y, Richardson G, Levine L, Berenson A, Kuo Y, 2017) of their data, showed a 
similar rate increase of abut 42% in unaffected women, and a lower rate of 14-20% in women 
with breast and ovarian cancer.  These findings are consistent with those from the current 
analysis. 
 The findings demonstrate the unequal application of BRCA testing guidelines.  NCCN 
guidelines historically have recommended BRCA testing for those with breast cancer under 50, 
ovarian cancer any age, and selected other cancers, or those with a family history of breast and 
ovarian cancer.  Among those under 55 in our sample, testing rates were approaching 100% for 
those with cancer and with family history of cancer, but remain below 20% for enrollees with 
cancer but no family history and those without cancer but with a family history.   
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During the study time period, ruling out a BRCA mutation became increasingly adopted 
by clinicians, especially with the rise of BRCA-specific treatments such as PARP inhibitors, 
which first arrived around 2011.  This change in clinical practice is reflected in the higher BRCA 
testing likelihood that affected enrollees but no family history less than 45 years old had.   
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APPENDIX 
 
REGRESSION 1: Dropped 0-17 age group, dropped unknown age, dropped 7,721 
Interacted CA type & Fhx; no age.  
 
Chapter 4 Appendix, Table 1. Odds ratios for likelihood of having BRCA testing based on cancer status, family 
history of cancer type and various combinations of family history and cancer status. (Regression 1 output). 
Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; #= interaction term  
 Odds Ratio Z-Score P-Value 
Type of Cancer Diagnosis 
No Cancer 0.0276328 -233.17 <0.0001 
Br  Reference Reference Reference 
Ov 1.368429 21.83 <0.0001 
Br+Ov 3.542042 44.15 <0.0001 
Other CA Only 0.1123085 -120.08 <0.0001 
Type of Family History of Cancer      
No FHx Reference Reference Reference 
Br FHx 12.99584 380.96 <0.0001 
Ov FHx 31.94529 199.95 <0.0001 
Br+Ov FHx 52.05225 219 <0.0001 
Other FHx 4.716866 126.18 <0.0001 
Type of Cancer Diagnosis & Type of Family History of Cancer 
Br#No FHx Reference Reference Reference 
No Cancer#No FHx (Empty) (Empty) (Empty) 
No Cancer#Br FHx 3.538962 77.38 <0.0001 
No Cancer#Ov FHx 6.141703 77.02 <0.0001 
No Cancer#Br+Ov FHx 13.52581 105.95 <0.0001 
No Cancer#Other FHx (Omitted) (Omitted) (Omitted) 
Ov#Br FHx 0.7176148 -14.16 <0.0001 
Ov#Ov FHx 0.2384776 -39.05 <0.0001 
Ov#Br+Ov FHx 0.3393537 -22.84 <0.0001 
Ov#Other FHx Only 1.25415 6.8 <0.0001 
Br+Ov#Br FHx 0.5436338 -14.21 <0.0001 
Br+Ov#Ov FHx 0.2337411 -17.55 <0.0001 
Br+Ov#Br+Ov FHx 0.2481301 -19.22 <0.0001 
Br+Ov#Other FHx 0.6791402 -5.1 <0.0001 
Other CA Only#Br FHx 1.451126 12.87 <0.0001 
Other CA Only#Ov FHx 1.70309 9.32 <0.0001 
Other CA Only#Br+Ov FHx 3.685127 18.49 <0.0001 
Other CA Only#Other FHx 0.7425723 -7.23 <0.0001 
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Regression 1, Margins (predicted probabilities): 
Chapter 4 Appendix, Table 2. Adjusted probabilities of having BRCA testing based on cancer status, family history 
of cancer type and various combinations of family history and cancer status. (Regression 1, Margins) 
	 Type of Cancer Diagnosis 
Type of Family 
History of Cancer 
No 
Cancer 
Breast 
Cancer 
Ovarian 
Cancer 
Breast & 
Ovarian 
Cancer 
Other 
Cancer 
No Family History - 0.04 0.05 0.12 0.00 
Breast Family History 0.05 0.33 0.33 0.49 0.08 
Ovarian Family 
History 
0.17 0.55 0.29 0.50 0.19 
Breast & Ovarian 
Family History 
0.43 0.67 0.48 0.64 0.45 
Other Family History 0.00 0.15 0.24 0.30 0.01 
 
 
 
REGRESSION 2: Dropped cells if N tested <1 or N eligible <5, with 3-way interaction: CA 
type/Fhx type/Age. 
 
Chapter 4 Appendix, Table 3. BRCA testing among different age groups and different types of cancer diagnoses and 
family histories of cancer. Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; 
Ref.=Reference Category 
Type of Cancer 
Diagnosis & Type of 
Family History of 
Cancer 
18-24 25-34 35-44 45-54 55-64 65-74 75-84 85+ 
No Cancer & Br FHx 2.56 0.71 0.34 0.69 1.06 0.51 0.49 0.6 
No Cancer & Ov FHx 5.73 1.96 1.36 2.73 5 2.85 3.74 8.8 
No Cancer & Br+Ov FHx 30.24 7.25 4.53 10.57 16.66 8.58 10.52 34.07 
No Cancer & Other FHx 0.38 0.11 0.05 0.06 0.28 0.1 0.14 0.38 
Br & No FHx Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Br & Br FHx 15.52 6.33 6.79 11.63 14.92 13.6 15.27 23.18 
Br & Ov FHx 55.7 10.34 10.48 23.7 38.14 42.76 69.14 147.17 
Br & Br+Ov FHx 50.46 9.67 11.79 35.86 1598.67 86.81 114.52 . 
Br & Other FHx 13.31 11.21 6.16 4.33 4.82 4.33 5.52 14.07 
Ov & No FHx 0.37 0.17 0.24 0.91 2.37 3.65 5.27 5.97 
Ov & Br FHx 12.64 3.36 2.69 8.18 16.38 24.54 49.52 111.47 
Ov & Ov FHx 4.68 1.96 1.82 6.51 13.92 24.78 60.33 121 
Ov & Br+Ov FHx 22.94 5.64 4.33 16.13 27.16 39.62 0 0 
Ov & Other FHx 17.41 2.05 1.64 4.55 11.48 19.39 35.17 72.49 
Br+Ov & Br FHx 32.76 5.84 9.3 29.64 11208.4 9.51E+93 .     -         
Br+Ov & Br+Ov FHx 0.08 0.03 0.04 0.1 0.33 0.24 0.26 0.26 
Br+Ov& No FHx -  6.39 6.95 17.04 41.82 40.66 0 . 
Br+Ov &  Ov FHx  - 1.74 6.02 7.31 16 19.91 33.15 81.69 
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Br+Ov & Other FHx  -  1.51 1.45 4.73 8.09 7.4 9.17 95.3 
Other CA & No FHx 4.79 1.12 0.75 1.73 3.01 1.92 2.16 4.78 
Other CA & Br FHx 0.88 0.18 0.15 0.32 0.59 0.64 0.77 0.87 
Other CA & Ov FHx -  1.28 1.31 2.6 6.31 7.46 7.48 15.17 
Other CA & Other FHx  - 7.82 6.98 18.09 37.14 38.31 76.15 65.35 
Other CA & Br+Ov FHx -  4.26 6.48 15.88 20.95 16.16 5.83 -             
 
Regression 2, Margins (predicted probabilities): 
Chapter 4 Appendix, Table 4. Adjusted probabilities for BRCA testing among enrollees by cancer type including 
unaffected, and with and without family history of different cancer type, by age of testing. Br=Breast Cancer; 
Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; Ref.=Reference Category. 
Type of Cancer 
Diagnosis  & Type of 
Family History 
18-24 
yrs 
25-34 
yrs 
35-44 
yrs 
45-54 
yrs 
55-64 
yrs 
65-74 
yrs 
75-84 
yrs 
85+ 
yrs 
No CA & Br FHx 0.14 0.13 0.06 0.04 0.03 0.01 0.00 0.00 
No CA & Ov FHx 0.26 0.30 0.21 0.15 0.12 0.04 0.03 0.03 
No CA & Br + Ov FHx 0.65 0.61 0.47 0.41 0.32 0.11 0.07 0.11 
No CA & Other FHx 0.02 0.02 0.01 0.00 0.01 0.00 0.00 0.00 
Br & No FHx 0.06 0.18 0.17 0.06 0.03 0.01 0.01 0.00 
Br & Br FHx 0.49 0.58 0.58 0.43 0.30 0.17 0.10 0.08 
Br & Ov FHx 0.77 0.69 0.68 0.61 0.52 0.39 0.34 0.34 
Br & Br + Ov FHx 0.75 0.68 0.70 0.70 0.98 0.57 0.46 -  
Br & Other FHx 0.45 0.70 0.55 0.22 0.12 0.06 0.04 0.05 
Ov & No FHx 0.02 0.03 0.05 0.06 0.06 0.05 0.04 0.02 
Ov & Br FHx 0.44 0.42 0.35 0.35 0.32 0.27 0.27 0.28 
Ov & Ov FHx 0.22 0.30 0.27 0.30 0.28 0.27 0.31 0.30 
Ov & Br + Ov FHx 0.58 0.55 0.46 0.51 0.44 0.37 0.00 0.00 
Ov & Other FHx 0.52 0.31 0.25 0.23 0.25 0.23 0.21 0.20 
Br+Ov & No FHx  - 0.22 0.21 0.14 0.15 0.10 0.05 0.05 
Br+Ov & Br FHx - 0.63 0.58 0.54 0.51 0.37 0.36 0.19 
Br+Ov & Ov FHx - 0.58 0.58 0.52 0.54 0.38 0.00  - 
Br+Ov & Br+Ov FHx - 0.56 0.65 0.66 1.00 1.00 1.00 0.22 
Br+Ov & Other Fx 0.67 0.27 0.55 0.32 0.31 0.23 0.20  - 
Other CA & No FHx 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 
Other CA & Br FHx 0.23 0.19 0.13 0.10 0.08 0.03 0.02 0.02 
Other CA & Ov FHx - 0.24 0.22 0.23 0.19 0.10 0.06 0.25 
Other CA & Br+Ov FHx - 0.48 0.56 0.51 0.37 0.20 0.04 -  
Other CA & Other FHx 0.05 0.04 0.03 0.02 0.02 0.01 0.01 0.00 
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Regression 2, Predicted Probabilities Figures: Below are figures from various margins that 
were not included in the text:  
 
 
Chapter 4 Appendix, Fig. 1. Adjusted BRCA testing rate among enrollees with both breast and ovarian cancer, by 
various family histories and age. *Enrollees without cancer and without a family history were not considered 
eligible for testing and were excluded from the model. (Regression 2, margins, enrollees with breast and ovarian 
cancer). 
  
  
Chapter 4 Appendix, Fig. 2. Adjusted BRCA testing rate among enrollees with other cancer, by various family 
histories and age. *Enrollees without cancer and without a family history were not considered eligible for testing 
and were excluded from the model. (Regression 2, margins, enrollees with other cancer). 
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REGRESSION 3: Same as Regression 2, but w/ 3-way interaction: Fhx type/Year/CA type 
  
Chapter 4 Appendix, Table 5. BRCA testing by year of testing and different types of cancer diagnoses and family 
histories of cancer.  Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; Ref.=Reference 
Category. 
	 Year of Testing 
Type of Cancer Diagnosis & Type 
of Family History of Cancer 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
No CA & Br FHx 1.9 1.44 1.11 0.97 1 1.05 1.32 1.18 0.92 0.99 
No CA & Ov FHx 7.04 5.18 4.11 3.58 4.31 4.64 5.8 4.82 3.93 4.35 
No CA & Br+Ov FHx 21.91 22.62 18.92 16.18 15.59 18.91 20.4 17.44 16.06 25.07 
No CA & Other FHx 0.13 0.07 0.06 0.05 0.06 0.06 0.12 0.16 0.16 0.16 
Br & No FHx Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Br & Br FHx 19.67 20.74 17.38 15.43 13.37 11.85 11.53 10.63 10.48 11.49 
Br & Ov FHx 48.92 57.07 44.63 45.01 33.06 34.95 26.3 24.5 21.23 25.9 
Br & Br+Ov FHx 89.31 109.43 79.06 67.56 56.05 48.65 44.67 37.85 36.14 35.68 
Br & Other FHx 5.02 5.12 4.55 4.32 4.37 4.28 4.58 5.64 5.22 6.78 
Ov  & No FHx 0.59 0.69 0.72 0.75 0.71 1.07 1.44 1.84 1.95 2.06 
Ov &  Br FHx 14.6 14.36 13.27 11.57 10.11 9.86 12.36 13.77 13.2 12.85 
Ov & Ov FHx 13.42 11.44 8.63 9.62 9.38 9.07 12.31 12.63 12.75 15.52 
Ov & Br+Ov FHx 46 40.27 32.63 19.34 17.02 24.08 22.55 25.64 20.49 29.11 
Ov & Other FHx 5.68 5.23 5.36 4.56 5.66 5 7.06 11.87 11.54 13.69 
Br+Ov & No FHx 2.57 3.42 3.81 3.64 3.51 4.4 4.85 6.47 6.56 7.09 
Br+Ov & Br FHx 28.8 39.61 38.74 29.88 32.68 31.97 27.35 31.71 34.37 53.09 
Br+Ov & Ov FHx 28.21 70.41 37.15 37.28 36.74 29.03 36.02 38.27 18.45 58.89 
Br+Ov & Br+Ov FHx 74.72 73.5 78.94 65.83 69.09 65.76 51.86 47.79 51.13 235.57 
Br+Ov & Other FHx 7.39 14.37 7.64 11.94 12.07 14.75 16.76 34.71 31.46 44.17 
Other CA & No FHx 0.02 0.04 0.06 0.03 0.04 0.06 0.15 0.17 0.13 0.13 
Other CA & Br FHx 2.63 2.09 1.69 1.43 1.37 1.4 2.02 2.21 2.22 1.97 
Other CA &  Ov FHx 6.77 5.02 3.62 3.32 3.03 3.36 6.52 6.27 7.74 6.55 
Other CA &  Br+Ov FHx 40 27.54 24.32 14.98 21.51 14.11 16.9 22.99 18.34 14.72 
Other CA & Other FHx 0.07 0.07 0.14 0.1 0.25 0.2 0.4 0.6 0.61 0.52 
 
 
Regression 3, Margins (predicted probabilities):  
Chapter 4 Appendix, Table 6. Adjusted probabilities for BRCA testing among enrollees by cancer type including 
unaffected, and with and without family history of different cancer type, by year of testing.   Br=Breast Cancer; 
Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; Ref.=Reference Category 
 Year of BRCA Testing 
Type of Cancer 
Diagnosis & Type of 
Family History of 
Cancer 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
No CA & Br FHx 0.02 0.02 0.03 0.03 0.04 0.06 0.07 0.08 0.06 0.06 
No CA & Ov FHx 0.06 0.08 0.09 0.11 0.15 0.21 0.24 0.26 0.21 0.23 
No CA & Br+Ov FHx 0.16 0.28 0.32 0.35 0.39 0.52 0.52 0.49 0.52 0.63 
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No CA & Other FHx 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 
Br & No FHx 0.01 0.02 0.02 0.03 0.04 0.05 0.05 0.06 0.06 0.06 
Br & Br FHx 0.15 0.27 0.30 0.34 0.36 0.40 0.38 0.23 0.42 0.44 
Br & Ov FHx 0.30 - 0.52 0.60 0.57 0.66 0.59 0.87 0.59 0.64 
Br & Br+Ov FHx 0.44 0.65 0.66 0.69 0.69 0.73 0.71 - 0.71 0.71 
Br & Other FHx 0.04 0.08 0.10 0.12 0.15 0.19 0.20 0.29 0.26 0.32 
Ov & No FHx 0.01 0.01 0.02 0.02 0.03 0.06 0.07 0.11 0.12 0.12 
Ov & Br FHx 0.11 0.20 0.25 0.28 0.30 0.36 0.40 0.26 0.47 0.47 
Ov & Ov FHx 0.10 0.17 0.17 0.24 0.28 0.34 0.40 0.23 0.47 0.51 
Ov & Br+Ov FHx 0.28 0.43 0.44 0.39 0.41 0.58 0.55 0.99 0.58 0.66 
Ov & Other FHx 0.05 0.08 0.12 0.13 0.19 0.22 0.28 0.22 0.44 0.48 
Br+Ov & No FHx 0.02 0.06 0.09 0.11 0.13 0.20 0.21 0.30 0.31 0.33 
Br+Ov & Br FHx 0.20 0.41 0.49 0.49 0.57 0.64 0.60 1.00 0.70 0.78 
Br+Ov & Ov FHx 0.20 - 0.48 0.55 0.48 0.62 0.66 - 0.56 0.80 
Br+Ov & Br+Ov FHx 0.39 0.00 0.11 0.68 - 0.79 0.74 - 0.78 0.94 
Br+Ov, Other FHx 0.06 0.20 0.16 0.28 0.33 0.45 0.48 0.17 0.68 0.75 
Other CA & No FHx 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 
Other CA & Br FHx 0.02 0.04 0.04 0.04 0.05 0.07 0.10 0.13 0.13 0.12 
Other CA & Ov FHx 0.06 0.08 0.08 0.10 0.11 0.16 0.26 0.30 0.35 0.31 
Other CA & Br+Ov Fhx 0.26 0.33 0.37 0.33 0.47 0.44 0.48 0.66 0.56 0.50 
Other CA & Other FHx 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.04 0.04 0.03 
 
 
Regression 3, Figures, Predicted Probabilities): Below are figures from various margins that 
were not included in the text:  
  
Chapter Appendix 4, Fig. 3. Adjusted BRCA testing rate among enrollees with breast cancer, by various family 
histories and year of testing 
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Chapter Appendix 4, Fig. 4. Adjusted BRCA testing rate among enrollees with ovarian cancer, by various family 
histories and year of testing 
 
 
 
Chapter Appendix 4, Fig. 5. Adjusted BRCA testing rate among enrollees with breast and ovarian cancer, by various 
family histories and year of testing 
 
 
REGRESSION 4: Same as Regression 3, but w/ collapsed categories (CA+No Fhx; CA +Fhx; 
No CA + Fhx) interacted with Year and Age.  
 
Chapter Appendix 4, Table 7.  Yearly BRCA testing, by cancer vs no cancer status and presence or absence of family 
history. Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; Ref.=Reference Category.  
 Year of Testing  
Characte
ristic 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Age Group (Main Effect) 
18-24 3.32 1.74 1.52 0.85 1.29 1.28 0.88 0.96 0.96 0.71 
25-34 2.56 2.15 1.90 1.95 1.79 1.67 1.34 1.37 1.27 1.23 
35-44 2.11 1.90 1.94 1.81 1.90 1.66 1.63 1.54 1.50 1.53 
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45-54 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
55-64 0.50 0.56 0.54 0.59 0.61 0.66 0.63 0.69 0.70 0.69 
65-74 0.12 0.12 0.15 0.23 0.25 0.31 0.36 0.45 0.55 0.55 
75-84 0.02 0.05 0.08 0.14 0.16 0.18 0.23 0.33 0.38 0.38 
85+ 0.02 0.02 0.09 0.10 0.15 0.14 0.17 0.26 0.33 0.20 
Cancer Status (Main Effect)  
NoCA+
FHX 
0.07 0.05 0.05 0.04 0.06 0.07 0.09 0.08 0.07 0.07 
CA+F
HX 
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
CA+No
FHX 
0.06 0.06 0.07 0.08 0.09 0.11 0.10 0.10 0.11 0.10 
Interaction Between Age And Cancer Status  
18-24 
& 
No 
CA+FHX 
1.59 1.98 2.42 4.96 2.95 2.52 3.40 3.12 3.27 4.15 
25-34 
& 
No 
CA+FHX 
1.66 1.76 1.88 2.01 2.10 2.11 2.45 2.40 2.62 2.53 
35-44 
& 
No 
CA+FHX 
0.86 0.95 0.93 1.01 0.93 1.06 1.06 1.12 1.13 1.07 
45-54 
& 
No 
CA+FHx 
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
55-64 
&  
No 
CA+FHx 
1.22 1.12 1.09 1.04 0.98 0.99 0.97 0.97 0.95 1.00 
65-74 
&  
No 
CA+FHx 
2.16 1.78 1.16 0.97 0.65 0.49 0.41 0.41 0.40 0.36 
75-84 
& 
No 
CA+FHx 
4.47 0.89 0.80 0.75 0.43 0.32 0.40 0.34 0.35 0.38 
85+ &  
No 
CA+FHx 
1.00 7.76 1.00 1.87 0.19 0.29 0.75 0.30 0.34 0.49 
18-24 
& CA+No 
FHx 
0.25 0.16 0.29 0.30 0.20 0.16 0.46 0.37 0.53 0.92 
25-34 
& CA+No 
FHx 
1.07 0.93 0.83 0.69 0.74 0.66 0.88 0.78 1.09 1.07 
35-44 
& CA+No 
FHx 
1.41 1.62 1.60 1.57 1.27 1.21 1.35 1.30 1.35 1.33 
45-54 
& 
No 
CA+FHx 
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
55-64 
& CA+No 
FHx 
0.69 0.74 0.76 0.71 0.73 0.79 0.96 0.94 0.92 0.88 
65-74 
& CA+No 
FHx 
0.61 0.58 0.72 0.59 0.55 0.67 0.97 1.05 1.09 0.94 
75-84 1.00 0.35 0.66 0.53 0.51 0.60 0.93 0.92 0.95 0.99 
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& CA+No 
FHx 
85+ & 
 CA+No 
FHx 
1.00 0.95 0.19 0.52 0.30 0.33 0.53 0.51 0.51 0.78 
   
 
Regression 4, Margins (predicted probabilities): 
Chapter 4 Appendix, Table 8. Adjusted BRCA testing (in %) as a function of cancer and family history status (ie/ 
Regression 4 = Regression 3 with collapsed categories). Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; 
FHx=Family History; Ref.=Reference Category.  
	 Year of BRCA Testing 
Age 
(years) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 9-yr 
Change 
No Cancer Diagnosis & Family History of Cancer  
18-
24 
5.2% 5.0% 6.3% 7.6% 9.3% 11.9% 13.2% 14.8% 13.1% 13.4% 8.2% 
25-
34 
4.3% 5.5% 6.1% 7.2% 9.2% 12.8% 14.4% 16.0% 13.8% 14.0% 9.8% 
35-
44 
1.9% 2.7% 3.2% 3.5% 4.6% 7.0% 8.2% 9.2% 7.6% 8.0% 6.1% 
45-
54 
1.0% 1.5% 1.8% 2.0% 2.7% 4.1% 5.0% 5.6% 4.7% 5.1% 4.0% 
55-
64 
0.6% 1.0% 1.1% 1.2% 1.6% 2.7% 3.1% 3.9% 3.1% 3.6% 2.9% 
65-
74 
0.3% 0.3% 0.3% 0.4% 0.4% 0.6% 0.8% 1.1% 1.1% 1.1% 0.8% 
75-
84 
0.1% 0.1% 0.1% 0.2% 0.2% 0.3% 0.5% 0.7% 0.6% 0.8% 0.7% 
85+ 0.0% 0.2% 0.0% 0.4% 0.1% 0.2% 0.7% 0.5% 0.5% 0.5% 0.3% 
Cancer Diagnosis & Family History of Cancer 
  
18-
24 
31.8% 34.0% 35.4% 26.2% 36.1% 41.2% 32.9% 38.6% 37.9% 33.9% 2.1% 
25-
34 
26.9% 38.3% 40.0% 43.0% 43.1% 46.8% 42.0% 46.6% 44.2% 46.1% 19.2% 
35-
44 
23.5% 35.7% 40.5% 41.4% 44.4% 46.8% 46.4% 49.4% 47.9% 51.0% 27.5% 
45-
54 
13.1% 23.8% 27.1% 29.2% 31.0% 35.9% 35.7% 39.6% 38.8% 41.4% 28.3% 
55-
64 
7.1% 15.4% 17.3% 20.1% 22.2% 27.6% 26.7% 31.7% 31.1% 33.2% 26.1% 
65-
74 
1.8% 4.0% 5.8% 9.1% 10.7% 15.6% 17.3% 23.6% 26.5% 28.7% 26.9% 
75-
84 
0.4% 1.7% 3.0% 5.9% 7.3% 10.1% 12.3% 18.8% 20.1% 22.0% 21.7% 
85+ 0.4% 0.6% 3.4% 4.1% 6.9% 7.8% 9.4% 15.6% 18.0% 13.3% 12.9% 
Cancer Diagnosis & No Family History of Cancer 
18-
24 
0.7% 0.5% 1.2% 0.9% 1.2% 1.4% 2.5% 2.6% 3.6% 4.8% 4.0% 
25-
34 
2.4% 3.8% 4.1% 4.4% 5.5% 6.9% 6.8% 7.4% 9.1% 9.0% 6.6% 
35-
44 
2.6% 5.7% 7.6% 8.7% 9.5% 11.7% 11.9% 12.9% 12.7% 13.2% 10.6% 
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45-
54 
0.9% 2.0% 2.6% 3.3% 4.2% 6.3% 5.9% 7.0% 6.8% 7.1% 6.2% 
55-
64 
0.3% 0.8% 1.1% 1.4% 2.0% 3.4% 3.7% 4.7% 4.5% 4.4% 4.1% 
65-
74 
0.1% 0.1% 0.3% 0.5% 0.6% 1.4% 2.1% 3.4% 4.2% 3.8% 3.7% 
75-
84 
0.0% 0.0% 0.1% 0.3% 0.4% 0.7% 1.3% 2.3% 2.6% 2.8% 2.8% 
85+ 0.0% 0.0% 0.0% 0.2% 0.2% 0.3% 0.6% 1.0% 1.2% 1.2% 1.2% 
 
 
REGRESSION 5: Dropped the following entire categories: No CA + Other Fhx; Other CA + 
No Fhx; Other CA + Other Fhx. This regression had only BR/OV/No CA + Fhx No/BR/OV/. 
Had 2-way interaction: CA type/Fhx type and 3-way interaction: CA type/Fhx type/Age. This 
regression does not include Other CA, only enrollees w/ BR and/or OV and/or NO cancer and 
only Fhx BR/OV/No CA. 
 
Chapter 4 Appendix, Table 9:  Yearly BRCA testing, for enrollees with and without: breast cancer and/or ovarian 
cancer, family history of breast with cancer and family history interaction, and cancer, family history and age 
interaction.  Br=Breast Cancer; Ov=Ovarian Cancer; CA=Cancer; FHx=Family History; Ref.=Reference Category. 
 Year of Testing 
Age (years) 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
18-24 2.39 0.87 1.11 0.56 0.49 0.38 0.86 0.51 0.92 1.35 
25-34 5.88 4.97 3.76 3.25 3.25 2.42 2.37 2.26 3.01 2.75 
35-44 3.48 4.03 4.12 3.82 3.27 2.75 3.24 2.70 2.70 2.73 
45-54 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
55-64 0.35 0.40 0.36 0.34 0.38 0.44 0.55 0.53 0.55 0.52 
65-74 0.24 0.25 0.18 0.08 0.09 0.16 0.36 0.33 0.51 0.43 
75-84 0.05 0.24 0.15 0.04 0.06 0.07 0.28 0.24 0.33 0.33 
85+ 8.72 0.24 0.14 0.05 0.04 0.04 0.22 0.12 0.22 0.20 
Cancer & Family History Interaction  
No Cancer +  
BR Fhx 
1.02 0.68 0.62 0.47 0.48 0.49 0.74 0.67 0.54 0.56 
No Cancer + 
OV Fhx 
3.21 2.15 1.72 1.55 1.86 1.96 3.14 2.70 2.21 2.41 
No Cancer + 
BR+OV Fhx 
11.62 9.23 8.96 7.85 7.64 8.96 11.75 10.54 8.31 15.91 
Br +  
No Fhx 
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Br +  
BR Fhx 
17.91 17.45 15.58 13.62 10.75 9.43 11.88 9.72 8.14 8.64 
Br +  
OV Fhx 
37.29 97.23 22.28 33.25 22.85 22.57 15.69 18.25 15.18 19.10 
Br +  
BR+OV Fhx 
23.50 1.46*10^
6 
27.37 57.34 38.83 29.18 0.35 25.57 96.30 17.30 
OV +  
No Fhx 
0.52 0.53 0.59 0.69 0.60 0.83 0.98 1.20 1.32 1.42 
OV +  
BR Fhx 
12.37 8.95 9.46 7.60 6.55 5.25 10.11 8.53 7.36 6.42 
OV +  
OV Fhx 
10.90 6.64 5.31 8.14 5.95 5.50 9.29 5.61 6.12 7.86 
OV +  
BR+OV Fhx 
27.40 24.47 19.95 10.16 8.27 14.40 11.83 25.97 11.68 16.54 
BR+OV + No 
FHx 
2.12 4.19 2.74 2.95 2.09 3.87 4.05 4.24 4.36 4.64 
BR+OV + 
Any Fhx 
25.67 36.75 27.72 27.06 25.30 24.00 0.00 21.57 55.91 462.30 
Cancer, Family History, & Age Interaction 
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18-24 &  
No Cancer + 
BR Fhx 
2.19 3.50 2.68 6.70 6.54 7.71 2.94 5.46 3.08 2.11 
18-24 &  
No Cancer +  
Ov Fhx 
1.29 1.88 2.37 4.96 4.52 5.04 2.08 2.43 1.87 1.05 
18-24 &  
No Cancer  + 
BR+OV Fhx 
1.56 3.30 1.67 7.06 6.37 5.37 7.24 3.51 0.04 4.36 
18-24 &  
Br +  
BR Fhx 
2.4*10^2
6 
3.03 1.18 1.30 1.72 2.62 0.77 1.69 0.94 0.49 
18-24 &  
Br +  
OV Fhx 
1.00 0.59 1.00 0.93 - 1.00 0.69 1.94 1.24 1.00 
18-24 &  
Br +  
BR/OV Fhx 
- 0.00 1.92 1.19 1.6*10^209 2.85 32.80 2.99 - 1.00 
18-24 &  
OV +  
No Fhx 
0.40 1.00 0.28 0.43 0.88 0.94 0.40 0.78 0.31 0.39 
18-24 &  
OV +  
BR Fhx 
 0.88 1.90 4.18 0.82 1.49 - 1.98 1.76 0.53 
18-24 &  
OV +  
OV Fhx 
1.00 1.00 0.64 0.66 0.59 3.20 1.29 1.84 0.39 0.61 
18-24 &  
OV +  
BR+OV Fhx 
1.00 1.00 1.00 1.00 6.65 1.00 1.00 1.24 1.00 1.00 
18-24 & 
BR+OV +  
Any Fhx 
1.27 1.00 1.00 1.00 1.00 0.93 1.00 1.00 1.00 1.00 
25-34 &  
No Cancer + 
BR Fhx 
0.66 0.64 0.72 1.06 1.00 1.28 1.24 1.32 1.05 1.08 
25-34 &  
No Cancer +  
Ov Fhx 
0.46 0.51 0.70 0.79 0.78 0.98 1.06 0.86 0.67 0.70 
25-34 &  
No Cancer + 
BR+Ov Fhx 
0.52 0.51 0.63 0.82 0.69 0.91 53.80 0.78 0.63 0.42 
25-34 &  
Br +  
BR Fhx 
0.45 0.51 0.40 0.62 0.53 0.70 0.39 0.58 0.57 0.50 
25-34 &  
Br +  
OV Fhx 
1.3*10^2
05 
- 0.00 0.53 0.42 0.48 0.30 0.55 - 0.25 
25-34 &  
Br +  
BR+OV Fhx 
- 2.5*10^7
3 
0.08 0.22 0.28 0.24 11.31 0.36 0.05 0.20 
25-34 &  
OV +  
No Fhx 
0.20 0.18 0.16 0.13 0.18 0.16 0.34 0.22 0.16 0.18 
25-34 &  
OV +  
BR Fhx 
0.28 0.21 0.28 0.51 0.31 0.65 0.47 0.79 0.30 0.94 
25-34 &  
OV +  
OV Fhx 
0.17 0.24 0.27 0.18 0.27 0.37 0.52 0.87 0.33 0.31 
25-34 &  
OV +  
BR+OV Fhx 
0.34 0.18 0.21 0.44 - - 29.07 0.22 0.36 0.38 
25-34 & 
BR+OV +  
No Fhx 
0.26 0.08 0.65 1.39 0.42 0.65 1.05 0.61 0.42 0.22 
25-34 & 
BR+OV +  
Any Fhx 
0.26 0.22 0.20 0.35 0.36 0.41 1.4*10^47 0.23 1.00 1.00 
35-44 &  
No Cancer + 
BR Fhx 
0.44 0.36 0.35 0.39 0.45 0.55 0.44 0.56 0.56 0.53 
35-44 &  
No Cancer +  
Ov Fhx 
0.51 0.36 0.43 0.45 0.48 0.56 0.54 0.53 0.54 0.51 
35-44 &  
No Cancer + 
BR+Ov Fhx 
0.39 0.42 0.35 0.38 0.41 0.47 0.28 0.43 0.46 0.39 
35-44 &  
Br +  
BR Fhx 
0.63 0.49 0.35 0.48 0.63 0.62 0.24 0.57 0.71 0.67 
35-44 &  
Br +  
OV Fhx 
0.47 10.05 0.57 0.41 0.52 0.61 0.00 0.49 0.41 0.31 
35-44 &  
Br +  
BR+OV Fhx 
1.09 0.01 0.09 0.21 1.2*10^16 0.34 71.22 0.37 0.08 0.85 
35-44 &  
OV +  
0.29 0.32 0.28 0.19 0.23 0.24 0.25 0.32 0.26 0.24 
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No Fhx 
35-44 &  
OV +  
BR Fhx 
0.20 0.30 0.33 0.30 0.36 0.38 0.30 0.34 0.44 0.37 
35-44 &  
OV +  
OV Fhx 
0.30 0.24 0.17 0.11 0.30 0.28 0.35 0.57 0.28 0.30 
35-44 &  
OV +  
BR+OV Fhx 
0.32 0.22 0.21 0.33 0.31 0.25 0.24 0.21 0.43 0.12 
35-44 &  
BR+OV + No 
Fhx 
0.67 0.38 0.62 0.50 0.71 0.22 0.48 0.42 0.55 0.40 
35-44 &  
BR+OV +  
Any Fhx 
0.54 1.14 0.26 0.48 0.31 0.37 1.2*10^48 0.20 0.07 2.3*10^171 
45-54 &  
Br +  
No Fhx 
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
55-64 &  
No Cancer + 
BR Fhx 
1.80 1.77 1.85 1.97 1.67 1.51 1.26 1.31 1.29 1.40 
55-64 &  
No Cancer +  
Ov Fhx 
2.41 1.99 2.31 2.34 2.02 1.96 1.22 1.35 1.37 1.49 
55-64 &  
No Cancer + 
BR+Ov Fhx 
2.29 1.93 2.07 2.38 1.99 1.99 1.75 1.58 1.41 1.55 
55-64 &  
Br +  
BR Fhx 
1.38 1.35 1.47 1.68 1.62 1.45 1.26 1.27 1.32 1.33 
55-64 &  
Br +  
OV Fhx 
2.00 0.60 2.33 1.96 1.12 1.69 1.11 1.64 1.84 1.60 
55-64 & 
Br +  
BR+OV Fhx 
5.35 0.00 3.21 1.56 1.95 2.18 1360.16 2.14 1.03 1.27 
55-64 & 
OV +  
No Fhx 
3.07 2.86 2.94 2.51 2.40 2.18 2.06 2.17 2.16 1.98 
55-64 &  
OV +  
BR Fhx 
2.34 2.59 2.13 2.78 2.35 2.95 1.88 1.92 1.71 2.08 
55-64 &  
OV +  
OV Fhx 
1.63 2.23 3.24 2.09 2.11 1.77 1.88 2.85 2.27 1.71 
55-64 &  
OV +  
BR+OV Fhx 
3.50 1.93 2.42 4.49 2.83 1.58 1.63 0.85 1.78 2.6*10^5 
55-64 & 
BR+OV +  
No Fhx 
3.67 1.84 3.90 2.98 4.08 2.24 1.95 2.25 1.97 1.79 
55-64 & 
BR/OV +  
Any Fhx 
2.62 1.76 2.20 2.73 3.08 2.09 2.0*10^48 2.37 8.13 0.00 
65-74 & 
No Cancer + 
BR Fhx 
1.52 1.79 1.87 2.89 2.08 1.03 0.95 0.55 0.74 0.76 
65-74 &  
No Cancer +  
Ov Fhx 
2.57 1.48 1.83 5.67 2.63 1.38 0.59 0.71 0.53 0.64 
65-74 &  
No Cancer + 
BR+Ov Fhx 
0.74 0.79 1.12 2.60 2.20 0.99 0.51 0.71 0.48 0.39 
65-74 &  
Br +  
BR Fhx 
0.35 0.34 0.73 2.61 2.83 1.81 0.84 1.27 1.28 1.50 
65-74 &  
Br +  
OV Fhx 
0.59 0.26 2.05 3.83 3.83 3.41 2.00 1.86 1.33 1.72 
65-74 &  
Br +  
BR+OV Fhx 
1.81 0.00 1.80 3.65 3.01 4.18 94.44 1.95 0.48 3.00 
65-74 &  
OV +  
No Fhx 
2.12 2.19 2.31 5.02 5.41 3.61 2.60 4.25 2.79 2.56 
65-74 &  
OV +  
BR Fhx 
1.05 1.24 1.77 6.10 7.95 4.23 2.35 3.40 2.17 2.61 
65-74 &  
OV +  
OV Fhx 
2.15 2.03 3.18 8.28 9.87 5.08 2.19 5.32 2.87 2.68 
65-74 &  
OV +  
BR+OV Fhx 
2.00 0.99 1.99 5.20 4.71 5.28 3.13 2.41 1.89 1.50 
65-74 &  
BR+OV +  
No Fhx 
0.92 0.38 2.13 5.32 8.30 2.45 2.13 3.62 3.20 2.90 
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65-74 &  
BR+OV +  
Any Fhx 
0.88 0.87 1.81 3.88 4.71 3.05 9.9*10^47 3.70 0.55 1.31 
75-84 &  
No Cancer +  
BR Fhx 
5.36 1.64 1.74 2.75 1.51 0.96 1.09 0.42 0.94 0.89 
75-84 &  
No Cancer +  
Ov Fhx 
20.55 1.00 1.80 3.39 2.18 2.18 0.59 0.76 0.50 0.66 
75-84 &  
No Cancer + 
BR+Ov Fhx 
1.00 0.55 0.38 5.78 1.57 0.59 0.29 0.72 0.83 0.43 
75-84 &  
Br +  
BR Fhx 
0.52 0.16 0.41 3.21 2.04 2.26 0.60 1.23 1.28 1.29 
75-84 &  
Br +  
OV Fhx 
1.00 0.19 1.67 7.05 4.73 3.95 2.64 2.15 1.88 2.55 
75-84 &  
Br +  
BR+OV Fhx 
1.00 0.00 2.40 5.67 5.69 10.21 141.44 2.20 0.61 2.91 
75-84 &  
OV +  
No Fhx 
1.00 1.97 3.03 6.60 4.69 6.41 2.79 4.46 3.84 3.32 
75-84 &  
OV +  
BR Fhx 
1.00 0.59 1.54 20.78 12.97 12.78 2.66 5.16 3.43 3.41 
75-84 &  
OV +  
OV Fhx 
1.00 1.38 1.00 13.98 11.73 15.91 4.19 11.56 14.58 10.85 
75-84 &  
OV +  
BR+OV Fhx 
1.00 1.00 2.48 15.33 5718.23 20.67 0.00 0.46 2.70 4.00 
75-84 &  
BR+OV +  
No Fhx 
1.00 1.00 0.73 6.27 4.46 4.40 1.24 2.90 2.49 3.40 
75-84 &  
BR+OV +  
Any Fhx 
1.00 1.00 1.57 8.11 8.56 5.22 1.4*10^48 10.07 - 0.06 
85+ &  
No Cancer + 
BR Fhx 
1.00 1.73 1.00 5.56 2.01 1.42 1.20 0.16 1.28 1.21 
85+ &  
No Cancer +  
Ov Fhx 
1.00 1.00 1.00 1.00 1.00 3.01 3.14 2.21 1.00 1.00 
85+ &  
No Cancer + 
BR+OV Fhx 
1.00 2.71 1.00 1.00 1.00 1.00 1.00 2.57 2.36 1.85 
85+ &  
Br +  
BR Fhx 
1.00 0.08 0.47 1.61 3.55 2.66 0.56 1.78 1.41 1.16 
85+ &  
Br +  
OV Fhx 
1.00 1.00 1.00 9.05 17.05 3.90 2.02 4.93 3.12 2.11 
85+ &  
Br +  
BR+OV Fhx 
1.00 1.00 1.00 1.00 17.87 18.99 571.03 13.97 - 2.38 
85+ &  
OV +  
No Fhx 
1.00 2.48 1.00 3.16 9.73 7.09 2.81 2.73 2.49 3.72 
85+ &  
OV +  
BR Fhx 
1.00 1.25 17.16 1.00 5.13 30.58 1.71 13.48 9.45 4.40 
85+ &  
OV +  
OV Fhx 
1.00 1.00 94.21 33.95 1.00 1.00 1.00 24.09 15.07 4.48 
85+ &  
OV +  
BR+OV Fhx 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
85+ &  
BR+OV + No 
FHx 
1.00 1.00 2.67 1.00 1.00 14.93 1.48 6.04 1.54 2.82 
85+ &  
BR+OV +  
Any Fhx 
1.00 1.00 1.00 4.36 1.00 1.00 1.00 9.46 1.00 1.00 
 
Regression 5, Margins (predicted probabilities):  
Chapter 4 Appendix, Table 10. Adjusted BRCA testing (in %) as a function of breast and oavarian cancer and family 
history of breast and ovarian cancer status (ie/ Regression 5 = Regression 4 with BR/OV and Fhx BR/OV only).   
Year of Testing 
Age 
(years) 
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 9-yr 
Change 
  133 
No Cancer and Family History of Breast Cancer 
18-24 0.07 0.07 0.07 0.09 0.10 0.14 0.15 0.17 0.14 0.15 8.4% 
25-34 0.05 0.07 0.07 0.08 0.11 0.14 0.17 0.18 0.15 0.16 10.6% 
35-44 0.02 0.03 0.04 0.04 0.05 0.08 0.09 0.10 0.08 0.08 6.2% 
45-54 0.01 0.02 0.03 0.03 0.04 0.05 0.06 0.07 0.05 0.06 4.5% 
55-64 0.01 0.02 0.02 0.02 0.02 0.03 0.04 0.05 0.04 0.04 3.5% 
65-74 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 1.5% 
75-84 0.00 0.01 0.01 0.00 0.00 0.00 0.02 0.01 0.02 0.02 1.4% 
85+  - 0.01 -  0.01 0.00 0.00 0.02 0.00 0.02 0.01  - 
No Cancer and Family History of Ovarian Cancer 
18-24 0.11 0.11 0.17 0.19 0.24 0.29 0.34 0.26 0.28 0.27 15.6% 
25-34 0.10 0.15 0.17 0.18 0.26 0.33 0.42 0.36 0.31 0.34 23.3% 
35-44 0.07 0.09 0.12 0.13 0.18 0.25 0.34 0.29 0.25 0.27 19.7% 
45-54 0.04 0.07 0.07 0.08 0.12 0.17 0.22 0.23 0.19 0.21 16.8% 
55-64 0.03 0.05 0.06 0.06 0.10 0.15 0.16 0.17 0.15 0.17 13.6% 
65-74 0.03 0.03 0.02 0.04 0.03 0.04 0.06 0.06 0.06 0.07 4.3% 
75-84 0.04 - 0.02 0.01 0.02 0.03 0.05 0.05 0.04 0.05 1.1% 
85+  - - - -  - 0.02 0.17 0.07 -  - - 
No Cancer and Family History of both Breast and Ovarian Cancer 
18-24 0.36 0.47 0.42 0.63 0.63 0.66 0.87 0.67 0.04 0.91 55.0% 
25-34 0.32 0.44 0.48 0.54 0.55 0.68 0.99 0.66 0.61 0.67 35.0% 
35-44 0.17 0.34 0.36 0.38 0.43 0.55 0.49 0.57 0.51 0.65 47.8% 
45-54 0.13 0.24 0.28 0.30 0.36 0.49 0.52 0.53 0.46 0.63 49.9% 
55-64 0.11 0.19 0.23 0.26 0.30 0.45 0.51 0.49 0.39 0.58 47.4% 
65-74 0.03 0.06 0.07 0.09 0.10 0.13 0.17 0.21 0.17 0.23 20.2% 
75-84 - 0.04 0.02 0.09 0.05 0.04 0.08 0.16 0.19 0.20 19.7% 
85+  - 0.17 -  - - - - 0.26 0.31 0.39 - 
Breast Cancer and No Family History of Cancer 
18-24 0.03 0.03 0.05 0.03 0.04 0.04 0.07 0.05 0.09 0.13 9.8% 
25-34 0.07 0.14 0.14 0.15 0.19 0.21 0.18 0.20 0.24 0.23 15.9% 
35-44 0.04 0.12 0.15 0.18 0.20 0.23 0.23 0.23 0.22 0.23 18.6% 
45-54 0.01 0.03 0.04 0.05 0.07 0.10 0.08 0.10 0.09 0.10 8.6% 
55-64 0.00 0.01 0.02 0.02 0.03 0.05 0.05 0.05 0.05 0.05 5.0% 
65-74 0.00 0.01 0.01 0.00 0.01 0.02 0.03 0.03 0.05 0.05 4.3% 
75-84 - 0.01 0.01 0.00 0.00 0.01 0.03 0.03 0.03 0.04 3.5% 
85+  - 0.01 0.01 0.00 0.00 0.00 0.02 0.01 0.02 0.02 -  
Breast Cancer and Family History of Breast Cancer 
  134 
18-24 - 0.60 0.47 0.35 0.40 0.50 0.42 0.47 0.42 0.38 38.3% 
25-34 0.38 0.59 0.50 0.60 0.57 0.63 0.50 0.58 0.58 0.56 18.5% 
35-44 0.34 0.53 0.50 0.58 0.61 0.63 0.46 0.61 0.61 0.63 29.3% 
45-54 0.19 0.37 0.40 0.43 0.44 0.50 0.52 0.51 0.45 0.48 29.4% 
55-64 0.10 0.24 0.26 0.30 0.33 0.39 0.43 0.41 0.38 0.39 29.3% 
65-74 0.02 0.05 0.08 0.14 0.17 0.22 0.25 0.30 0.35 0.38 36.0% 
75-84 0.01 0.02 0.04 0.09 0.09 0.14 0.16 0.23 0.26 0.29 28.0% 
85+  - 0.01 0.04 0.06 0.10 0.09 0.12 0.18 0.21 0.18 -  
Breast Cancer and Family History of Ovarian Cancer 
  
18-24 - 0.62 - 0.49 - - 0.46 0.66 0.63 - - 
25-34 - - - 0.75 0.69 0.74 0.51 0.70 - 0.59  - 
35-44 0.44 0.99 0.69 0.73 0.74 0.79 0.00 0.72 0.62 0.63 19.5% 
45-54 0.32 0.76 0.49 0.64 0.62 0.70 0.59 0.66 0.60 0.67 34.7% 
55-64 0.25 0.43 0.45 0.54 0.41 0.64 0.46 0.63 0.61 0.63 38.0% 
65-74 0.06 0.18 0.26 0.37 0.36 0.56 0.50 0.54 0.51 0.61 54.2% 
75-84 0.02 0.13 0.20 0.34 0.34 0.41 0.52 0.50 0.49 0.63 60.9% 
85+ -  - - 0.45 0.52 0.25 0.39 0.53 0.52 0.46  - 
Breast Cancer and Family History of Breast and Ovarian Cancer 
18-24 - 0.99 0.72 0.67 - 0.77 0.47 0.80 - - - 
25-34 - - 0.27 0.69 0.72 0.64 0.46 0.69 0.61 0.51 - 
35-44 0.53 1.00 0.31 0.71 - 0.74 0.88 0.73 0.66 0.81 28.0% 
45-54 0.23 1.00 0.54 0.75 0.73 0.75 0.03 0.73 0.90 0.65 41.6% 
55-64 0.36 0.03 0.58 0.62 0.67 0.74 0.96 0.75 0.85 0.55 19.2% 
65-74 0.12 0.26 0.27 0.49 0.43 0.67 0.52 0.64 0.70 0.71 59.0% 
75-84 - 0.17 0.30 0.41 0.50 0.69 0.56 0.59 0.66 0.64 64.1% 
85+  - - - - 0.66 0.68 0.80 0.82  - 0.47  - 
Ovarian Cancer and No Family History of Cancer 
  
18-24 0.01 - 0.01 0.01 0.02 0.03 0.03 0.05 0.04 0.08 6.9% 
25-34 0.01 0.02 0.02 0.02 0.03 0.03 0.07 0.06 0.06 0.07 6.2% 
35-44 0.01 0.02 0.03 0.03 0.03 0.06 0.07 0.10 0.09 0.09 8.6% 
45-54 0.01 0.02 0.03 0.04 0.04 0.08 0.08 0.12 0.12 0.13 12.8% 
55-64 0.01 0.02 0.03 0.03 0.04 0.08 0.09 0.13 0.14 0.14 13.1% 
65-74 0.00 0.01 0.01 0.02 0.02 0.05 0.08 0.15 0.16 0.15 14.4% 
75-84 - 0.01 0.01 0.01 0.01 0.04 0.07 0.12 0.15 0.15  - 
85+ -  0.01  - 0.01 0.02 0.02 0.05 0.04 0.07 0.10  - 
Ovarian Cancer and Family History of Breast Cancer 
18-24 - 0.19 0.46 0.49 0.17 0.24 - 0.48 0.55 0.33 - 
25-34 0.21 0.24 0.31 0.41 0.33 0.47 0.51 0.62 0.40 0.64 43.0% 
  135 
35-44 0.10 0.26 0.36 0.32 0.36 0.37 0.48 0.45 0.47 0.41 31.1% 
45-54 0.14 0.23 0.29 0.30 0.33 0.36 0.48 0.48 0.43 0.41 27.1% 
55-64 0.12 0.24 0.24 0.28 0.30 0.42 0.49 0.48 0.41 0.43 31.3% 
65-74 0.04 0.09 0.11 0.18 0.25 0.27 0.44 0.50 0.45 0.44 40.2% 
75-84 - 0.04 0.09 0.26 0.28 0.34 0.41 0.53 0.46 0.44 - 
85+  - 0.08 0.50 - 0.09 0.38 0.26 0.59 0.61 0.38 - 
Ovarian Cancer and Family History of Ovarian Cancer 
  
18-24 - - 0.14 0.14 0.12 0.42 0.48 0.36 0.19 0.41 - 
25-34 0.12 0.21 0.19 0.21 0.28 0.34 0.51 0.54 0.38 0.42 30.1% 
35-44 0.13 0.18 0.14 0.16 0.30 0.31 0.49 0.48 0.32 0.41 28.4% 
45-54 0.12 0.18 0.19 0.31 0.30 0.37 0.46 0.38 0.38 0.46 33.5% 
55-64 0.07 0.16 0.21 0.24 0.26 0.31 0.47 0.48 0.44 0.43 35.6% 
65-74 0.07 0.10 0.12 0.24 0.28 0.32 0.40 0.51 0.47 0.50 42.8% 
75-84 - 0.07 - 0.20 0.25 0.40 0.50 0.62 0.74 0.75  - 
85+ 0.55 -  0.76 0.43  - - - 0.63 0.67 0.43 42.9% 
Ovarian Cancer and Family History of Breast and Ovarian Cancer 
  
18-24 - - - - 0.66 - - 0.63 - - - 
25-34 0.41 0.42 0.41 0.45 - - 0.99 0.58 0.56 0.65 24.1% 
35-44 0.28 0.42 0.43 0.41 0.38 0.51 0.45 0.61 0.58 0.37 8.9% 
45-54 0.26 0.45 0.46 0.36 0.38 0.60 0.52 0.73 0.54 0.64 37.8% 
55-64 0.30 0.38 0.43 0.46 0.39 0.51 0.49 0.55 0.53 1.00 69.9% 
65-74 0.15 0.17 0.23 0.20 0.20 0.56 0.55 0.68 0.53 0.54 39.2% 
75-84 - - 0.24 0.25 1.00 0.69 - 0.23 0.51 0.70  - 
85+ -  - - - - - - - - - - 
Breast and Ovarian Cancer and No Family History of Cancer 
18-24 - - - - - - - - - - - 
25-34 0.04 0.05 0.23 0.42 0.17 0.39 0.48 0.39 0.36 0.23 19.3% 
35-44 0.06 0.18 0.23 0.24 0.26 0.20 0.37 0.34 0.40 0.35 29.3% 
45-54 0.03 0.12 0.11 0.14 0.13 0.29 0.27 0.31 0.31 0.34 30.8% 
55-64 0.03 0.09 0.14 0.14 0.19 0.29 0.28 0.35 0.33 0.32 28.5% 
65-74 0.01 0.01 0.04 0.07 0.10 0.14 0.22 0.35 0.42 0.39 38.2% 
75-84 - - 0.01 0.04 0.04 0.12 0.12 0.24 0.27 0.36 36.2% 
85+  -  - 0.04  - - 0.18 0.11 0.25 0.13 0.22 22.0% 
Breast and Ovarian Cancer and Family History of Breast and Ovarian Cancer 
18-24 0.50 - - - - 0.48 - - - - - 
25-34 0.34 0.57 0.48 0.63 0.68 0.71 0.51 0.55 - - - 
35-44 0.38 0.84 0.57 0.73 0.64 0.72 0.92 0.55 0.52 -  - 
  136 
45-54 0.25 0.55 0.55 0.60 0.64 0.72 0.00 0.69 0.85 0.98 73.0% 
55-64 0.23 0.46 0.49 0.57 0.68 0.70 0.77 0.74 0.96 0.04 -19.0% 
65-74 0.07 0.21 0.28 0.32 0.43 0.55 0.52 0.73 0.61 0.97 90.0% 
75-84 - 0.23 0.22 0.32 0.50 0.49 0.55 0.84 - 0.52 - 
85+ -  - - 0.24 -  - - 0.72 - - - 
 
Regression 5, Figures, Predicted Probabilities: Below are figures from various margins that 
were not included in the text:  
 
 
Chapter 4 Appendix, Fig. 6. Adjusted BRCA testing rates among enrollees without cancer and with family history of 
breast cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See legend on right 
for various age ranges. 
 
 
Chapter 4 Appendix, Fig. 7. Adjusted BRCA testing rates among enrollees without cancer and with family history of 
ovarian cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See legend on right 
for various age ranges. 
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Chapter 4 Appendix, Fig. 8. Adjusted BRCA testing rates among enrollees without cancer and with family history of 
both breast and ovarian cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See 
legend on right for various age ranges. 
 
 
Chapter 4 Appendix, Fig. 9. Adjusted BRCA testing rates among enrollees with breast cancer and no family history 
of cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See legend on right for 
various age ranges. 
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Chapter 4 Appendix, Fig. 10. Adjusted BRCA testing rates among enrollees with breast cancer and family history of 
breast cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See legend on right 
for various age ranges. 
 
 
 
Chapter 4 Appendix, Fig. 11. Adjusted BRCA testing rates among enrollees with breast cancer and family history of 
ovarian cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See legend on right 
for various age ranges. 
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Chapter 4 Appendix, Fig.12. Adjusted BRCA testing rates among enrollees with breast cancer and family history of 
breast and ovarian cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See 
legend on right for various age ranges. 
 
 
 
Chapter 4 Appendix, Fig. 13. Adjusted BRCA testing rates among enrollees with ovarian cancer and no family 
history of cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See legend on 
right for various age ranges. 
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Chapter 4 Appendix, Fig. 14. Adjusted BRCA testing rates among enrollees with ovarian cancer and family history 
of breast cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See legend on 
right for various age ranges. 
 
 
 
Chapter 4 Appendix, Fig. 15. Adjusted BRCA testing rates among enrollees with ovarian cancer and family history 
of ovarian cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See legend on 
right for various age ranges. 
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Chapter 4 Appendix, Fig. 16. Adjusted BRCA testing rates among enrollees with ovarian cancer and family history 
of breast and ovarian cancer, by year and age of testing.  Age categories (in years) depicted in various colors.  See 
legend on right for various age ranges. 
 
 
 
 
Chapter 4 Appendix, Fig. 17. Adjusted BRCA testing rates among enrollees with breast and ovarian cancer and no 
family history of cancer, by year and age of testing. Age categories (in years) depicted in various colors.  See legend 
on right for various age ranges. 
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Chapter 4 Appendix, Fig. 18. Adjusted BRCA testing rates among enrollees with breast and ovarian cancer and 
family history of breast and ovarian cancer, by year and age of testing. Age categories (in years) depicted in various 
colors.  See legend on right for various age ranges. 
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CHAPTER 5.  FOLLOW UP CARE IN BRCA POSITIVE ENROLLEES 
 
KEY FINDINGS 
• The BRCA mutation pick up rate was 7.3%. 
• A substantial number of enrollees underwent surgery in Year 1.  
• Almost all BRCA carriers received some type of recommended screening in Year 1. 
• Screening rates for specific procedures dropped into the single digits by Year 5. 
• Age was an important factor for RRM and RRSO with most of the former occurring pre-
menopausally and the latter occurring peri-menopausally. 
• A family history of both breast and ovarian cancer increased the likelihood of undergoing 
RRM and RRSO.  
• Year of testing showed the strongest effect on RRM in 2013, the year of the Jolie 
editorial.  
 
INTRODUCTION 
 Prior literature on the uptake of risk-reducing and screening procedures in BRCA carriers 
has reported on individuals from clinical samples (Beattie MS, 2009; Scheuer L, 2002) (Meijers-
Heijboer J, 2000).   
 A 2014 publication by Garcia et al., found that in a retrospective clinical sample, 45% 
had a trans-vaginal ultrasound in the first year after being identified as a BRCA carrier, which 
dwindled to 2.3% by Year 5.  Similarly, the breast MRI rate in year one was 43%, dropping to 
7% by year 5, and mammography decreased from 35% to 3% (W. J. Garcia C, Lyon L, Jones J, 
Littell RD, Armstrong MA, Raine-Bennett T, Powell CB, 2014).    
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 Another study from the UK, also in a clinic-based cohort, showed that there was a “Jolie 
effect” in risk-reducing surgery among BRCA carriers after 2013.  In addition, there was 
differential uptake of surveillance vs. risk-reducing surgery with age influencing choice or risk-
reducing procedures if there was a diagnosis of breast cancer, but age and family history did not 
affect choice or risk reducing procedures (L. L. Garcia C, Littell RD, Powell CB, 2014). 
 
METHODS 
Cohort Selection 
 Diagnostic codes (ICD-9 and ICD-10) were used to identify enrollees who had BRCA 
testing (Cohort 2 or BRCA Test Dataset) and to create Cohort 3, which was comprised 
exclusively of female enrollees (BRCA Positive Dataset).  Please See Ch. 4 Appendix, Table 1, 
for a list of diagnostic codes including codes that represent BRCA positive enrollees.  
To ensure a claim coded as a BRCA positive result was factually representing BRCA 
positive status post-BRCA testing, enrollees coded as BRCA carriers prior to their BRCA testing 
date were not included in the BRCA positive sample of enrollees.   
In addition, since many times BRCA positive status diagnostic codes are not used as soon 
as results are disclosed, in an effort to capture follow-up care for BRCA carriers, the date of the 
BRCA test was used as the date of assigning BRCA positive status.  The date of the first BRCA 
positive claim was not used given BRCA positive status would not necessarily be immediately 
coded into a claim as soon as it was known. 
All patients who had a code indicating they had breast, ovarian, or other cancer (i.e. 
pancreatic cancer, colon cancer, cutaneous melanoma, or uveal melanoma) prior to the date of 
BRCA test were dropped from the analysis (n=11,479).  Also dropped from analysis were people 
  146 
who did not have a full year of follow up (n=2,176), leaving an analysis sample for follow-up in 
the first year after BRCA testing of 10,744.   
 
Identification of BRCA-related procedures 
The following procedures were used to identify risk-reducing procedures recommended 
to BRCA carriers:  risk-reducing mastectomy (RRM), risk-reducing salpingo-oophorectomy 
(RRSO).   
Both unilateral mastectomy and bilateral mastectomy codes were used, because bilateral 
mastectomies can be coded as two unilateral mastectomies.  Mastectomy codes describing 
radical mastectomy(ies) including pectoral muscles, and/or lymph node dissection (axillary or 
internal mammary) were excluded, as such procedures are typically performed for treatment, not 
prevention, of breast cancer.   
Salpingo-oophorectomy codes included procedures for removing both the ovaries and/or 
tubes with and without the uterus.  Although the uterus itself is not at increased risk typically 
(except for very rare cases of papillary serous adenocarcinoma), oftentimes at time of RRSO the 
uterus and/or the cervix is/are also removed, typically for comorbidities or other non-BRCA 
related reasons.  Codes for RRSO performed via laparascopy with and without robotic 
assistance, vaginal or abdominal (open), were the procedure codes included.   
The following procedures were used for breast cancer screening: bilateral breast MRI, 
with and without contrast, and including computer-aided detection.  Screening as well as 
diagnostic mammography, bilateral, with and without tomosynthesis, and the computer-aided 
algorithm (CAD) code was included. Many providers choose a diagnostic mammogram for 
BRCA carriers, as it requires additional views.  Tomosynthesis and computer-aided algorithm 
detection may or may not be available, but they do represent improvements over traditional 
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mammography, and therefore are often used in BRCA carriers as well.  All mammography codes 
were bilateral, as unilateral codes typically represent repeat mammograms required as part of 
follow-up of an original finding.  National guidelines recommend that BRCA carriers undergo 
annual breast MRI and mammography spaced six months apart, although this time-frame is not 
always followed in clinical practice, for various reasons. 
The following procedures were included for ovarian cancer screening: trans-vaginal 
ultrasound (TVU) and CA125 serology, performed on the same day.  The typical 
recommendation for BRCA carriers when ovarian screening is ordered is that both procedures be 
performed on the same day to facilitate interpretation of both.  Because trans-vaginal ultrasounds 
may be performed for other reasons, such as vaginal bleeding, and CA125 blood tests may be 
ordered alone, but do not constitute a true ovarian cancer screen on their own, for this analysis, 
both the TVU and the CA125 blood test had to be billed on the same date of service in order for 
both to constitute an “ovarian cancer screen.” 
Please see Ch. 2 Appendix, Table 2 for a list of the procedure codes used as described 
above. 
Continuous enrollment was required for any of the procedures to be counted as having 
occurred.  If enrollment lapsed, then procedures thereafter were not counted for that enrollee. 
 
Algorithm for longitudinal follow-up of BRCA-related procedures 
The analysis focused on BRCA tested patients who were seeking surveillance and risk-
reducing surgery.  Given the complex and specific management procedures recommended to 
BRCA carriers, great care was taken to ascertain not only that the correct procedure took place 
within the expected timeframe (i.e./annual mammography).  In addition, enrollees who were not 
eligible for a procedure either because it was no longer warranted (i.e./breast MRI after RRM), 
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or because enrollment lapsed were censored, and not included in further analysis for that 
particular outcome. 
Women were omitted according to the algorithm below: 
Censoring algorithm for BRCA carrier follow-up of recommended procedures (not mutually 
exclusive): 
A BRCA positive enrollee had the following options for breast risk management care (not 
mutually exclusive) within one year: 
1. undergo breast MRI 
2. undergo mammography 
3. undergo risk-reducing mastectomy (RRM) 
4. receive a breast cancer diagnosis 
5. drop from enrollment  
 
Items 3, 4 and 5 led to the enrollee being censored and dropped from future analyses of screening 
for breast cancer but kept in the screening group for ovarian cancer. 
 A BRCA positive enrollee had the following options for ovarian risk management care 
(not mutually exclusive) within one year: 
1. undergo trans-vaginal ultrasound (TVU) and CA125 serology concomitantly; reasoning 
behind this may be found in Ch. 1, p.6 (Jacobs IJ, 2016; Menon U, 2009) 
2. undergo risk-reducing salpingo-oophorectomy (RRSO) 
3. receive an ovarian cancer diagnosis  
4. drop from enrollment 
Items 3, 4 and 5 led to the enrollee being censored, and dropped from future analyses of 
screening for ovarian cancer, but kept in the screening group for breast cancer. 
 Women were also omitted from analysis if their age was unknown (n=4) and if they were 
less than 18 years old (n=58).  The total number of enrollees in the follow-up group was 10,744.   
Other cancers (pancreas, colon, eye cancer (uveal melanoma) and cutaneous melanoma) 
were not used to censor enrollees in the follow-up group.   
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Identification of cancers during longitudinal follow up 
For those enrollees who developed cancer during the longitudinal follow up period, the 
date of cancer diagnosis was to better define cohorts as they are analyzed in one-year increments 
over a five-year period.  
After censoring patients who had breast, ovarian or one of the “other” cancers before the 
date of BRCA testing, six groups of cancer diagnosis timing were identified (cancer here only 
pertains to breast cancer or ovarian cancer):  
1. cancer within 1 year of BRCA testing; these were kept in the screening cohort, because 
incidental, screen-detected cancers are not uncommon in BRCA carriers, and they are a 
direct result of the BRCA-directed cancer screening; 
2. cancer between 1 and 2 years after BRCA testing;  
3. cancer between 2 and 3 years after BRCA testing; 
4. cancer between 3 and 4 years after BRCA testing; 
5. cancer between 4 and 5 years after BRCA testing; and  
6. no cancer within 5 years after BRCA testing.  
 
 
Identification of BRCA recommended procedures during longitudinal follow up 
 The risk-reducing procedures (RRM and RRSO) and the screening procedures (breast 
MRI, mammography, TVU and CA125) for the remaining BRCA positive enrollees were 
identified in claims after their date of BRCA testing took place using the CPT codes from Ch. 4 
Appendix, Table 2.  Both risk reducing and screening procedures were identified within five 
consecutive 365-day periods after BRCA testing.   
 Enrollees were censored from the screening cohort if: 
1. their enrollment did not extend into the year in question or was discontinuous between 
BRCA testing and the year in question;  
2. they had a risk-reducing procedure for the organ in question in the year in question or in a 
prior year (e.g. enrollees with RRM were omitted from mammography and breast MRI 
  150 
outcome measurement if their risk-reducing mastectomy occurred in a prior year, but 
they were not excluded from ovarian screening if they still had their ovaries);  
3. they were diagnosed with cancer of an organ (i.e./breast cancer) during the year in 
question, they were omitted from screening measures for that organ from that year 
onward (i.e./ omitted from breast MRI and mammography outcome measurements, but 
not omitted from ovarian screening). 
 
Data Analysis 
Screening 
 The descriptive analysis assessed the frequency of breast and ovarian cancer screening 
across five years after BRCA testing.  Five years was the maximum length of follow-up because 
the time frame (2008-2017) did not allow for five years of follow up for enrollees tested after 
2012. Enrollees who developed cancer in the first year post BRCA testing were kept in the 
screening cohort because that cancer was considered to have been identified as part of the 
follow-up care, once BRCA testing was done.  There were 10,744 enrollees in this group. 
 Enrollees in Year 1 enrollees had the following choices: screened once or not at all. In 
Year 2 enrollees were either screened in both the years, one of the years, or not at all.  This loop 
repeated through Year 5.  Screening procedures included: any breast or ovarian screening, 
mammography, breast MRI, and ovarian screening.  
 
Risk-reducing surgery 
 The occurrence of a risk-reducing mastectomy or risk-reducing salpingo-oophorectomy 
was assessed among the BRCA positive enrollees who did not have cancer at time of BRCA 
testing. This number was 10,744.  
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 The outcome for each surgery was binary; an enrollee only had two choices: surgery or 
no surgery, and they were not mutually exclusive.  If an enrollee had RRM, then they would be 
counted as having had the procedure in that year and dropped from future surgical analyses.  A 
similar method was used for RRSO. However, depending on what surgery they had, they were 
kept in the screening pool of the organ that was not removed.   If both breasts and ovaries were 
removed then they were dropped from the screening pool as well.  
Risk-reducing surgeries in Year 1, stratified by age, family history and year of testing 
 To assess the effects of age, year of testing and family history on the likelihood of 
undergoing surgery, a logistic regression was fitted with each of these three covariates for Year 1 
of follow-up post BRCA testing.  Interactions between age and year of testing, year of testing and 
family history, and age and family history were tested and shown not to have an effect, and will 
not be reported here. 
 
RESULTS 
Demographics 
 Using the ICD-9 and ICD-10 diagnostic codes typically used for BRCA mutation carriers, 
a total of 25,380 enrollees positive for a BRCA mutation were identified for an overall mutation 
pick up rate of 7.3% (see Table 1).  There were 25,380 total enrollees who were coded as BRCA 
carriers, 24,399 of whom were women (see Table 2), and almost 60% were between the ages of 
35-54 (Table 3).  The majority (70%) had a Point of Service (POS) insurance plan, followed by 
PPO and HMO a distant second and third at 13% and 10% (see Ch. 5 Appendix, Table 3) and the 
market share of the POS plans increased over the study period while the EPO plans lost market 
share (see Ch. 5 Appendix, Table 4). 
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Table 1.  Count and percent of BRCA positive carriers in Cohort 2 (BRCA Dataset) as a subset of Cohort 1 (Eligible 
Enrollees Dataset 
BRCA Mutation Status Total Number Percent (%) Cumulative  
Percent (%) 
Not coded as positive 322,189 92.70 92.70 
Positive 25,380 7.30 100 
Total 347,569 100  
 
Table 2. Count and percent of females only in Cohort 2 (BRCA Dataset) 
BRCA Mutation Status Total Number Percent (%) Cumulative  
Percent (%) 
Not coded as positive 306,373 92.62 92.62 
Positive 24,399 7.38 100 
Total 330,772 100  
 
Table 3. Age distribution (count and percentage) for BRCA carriers  
Age Category 
(years) 
Total 
Number 
Percent 
(%) 
Cumulative 
Percent (%) 
0-17 58 0.24 0.24 
18-24 929 3.81 4.05 
25-34 3,968 16.26 20.31 
35-44 7,215 29.57 49.88 
45-54 6,936 28.43 78.31 
55-64 4,084 16.74 95.04 
65-74 1,030 4.22 99.27 
75-84 159 0.65 99.92 
85+ - - - 
Unknown 12 0.05 100 
Total 24,399 100  
  
 Bivariate analysis of age and year of BRCA testing for BRCA mutation carriers showed 
that number of BRCA carriers increased across the study period, doubling in the middle age 
groups (Table 4).  Proportion-wise the annual mix of age groups fluctuated every year.  The 35- 
44 year olds lost most of their share, decreasing from 35% in 2008 to 26% in 2017.   
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Table 4. Annual proportion and raw counts of various age groups, among BRCA carriers. 
 Age Categories (years) 
Year 
of 
BRCA 
Test 
0-17 
(N) 
(%) 
18-24 
(N) 
(%) 
25-34 
(N) 
(%) 
35-44 
(N) 
(%) 
45-54 
(N) 
(%) 
55-64 
(N) 
(%) 
65-74 
(N) 
(%) 
75-84 
(N) 
(%) 
85+ 
(N) 
(%) 
Unk 
(N) 
(%) 
Total 
(N) 
(%) 
2008 - 36 193 470 429 218 - 0 0 - 1,358 
 - 2.65 14.21 34.61 31.59 16.05 0.59 0 0 - 10 
2009 - 42 255 604 496 225 27 - 0 - 1,658 
 - 2.53 15.38 36.43 29.92 13.57 1.63 0.24 0 - 100 
2010 - 50 248 557 527 235 39 - - - 1,668 
 - - 14.87 33.39 31.59 14.09 2.34 0.18 - - 100 
2011 - 73 312 590 552 301 47 - 0 0 1,887 
 - 3.87 16.53 31.27 29.25 15.95 2.49 0.37 0 0 100 
2012 - 86 358 644 594 319 55 10 - 0 2,077 
 - 4.14 17.24 31.01 28.6 15.36 2.65 0.48 - 0 100 
2013 - 115 428 778 772 436 102 18 - - 2,657 
 - 4.33 16.11 29.28 29.06 16.41 3.84 0.68 - - 100 
2014 - 117 466 893 817 486 137 24 0 - 2,948 
 - 3.97 15.81 30.29 27.71 16.49 4.65 0.81 0 - 100 
2015 - 148 575 972 982 673 211 42 - - 3,618 
 - 4.09 15.89 26.87 27.14 18.6 5.83 1.16 - - 100 
2016 - 153 635 977 1,009 693 223 28 - 0 3,724 
 - 4.11 17.05 26.24 27.09 18.61 5.99 0.75 - 0 100 
2017 - 109 498 730 758 498 181 23 - 0 2,804 
 - 3.89 17.76 26.03 27.03 17.76 6.46 0.82 - 0 100 
Total 58 929 3,968 7,215 6,936 4,084 1,030 159 - 12 24,399 
 0.24 3.81 16.26 29.57 28.43 16.74 4.22 0.65 - 0.05 100 
  
 There was an increase in each annual percentage of BRCA positive enrollees over the 
studied period (2008-2017).  Enrollees who had BRCA testing in 2008 represented 5.6% of all 
BRCA carriers; this increased to 11.5% by 2017.  However, the years when most of the BRCA 
carriers were identified were 2014 through 2016 with 2016 having the largest proportion at 
15.3% of all BRCA carriers.  The largest annual increase occurred in 2015, which featured an 
increase of 2.7 percentage points (Table 5).  To clarify how these finding relate to the total 
number of enrollees eligible for testing, annual BRCA mutation pick up rates were calculated 
(Table 7).  From 2008 to 2017, although the raw number of mutation carriers increased (see 
Table 6), overall annual mutation pick-up rates decreased from 8.3% to 5.5% in 2017.  
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Table 5. Annual distribution (counts and percentage) of enrollees coded as BRCA positive (Cohort 2) 
Year of 
BRCA 
Test 
Total 
Count 
Percent 
(%) 
Cumulative 
Percent (%) 
2008 1,358 5.57 5.57 
2009 1,658 6.8 12.36 
2010 1,668 6.84 19.2 
2011 1,887 7.73 26.93 
2012 2,077 8.51 35.44 
2013 2,651 10.87 46.31 
2014 2,947 12.08 58.39 
2015 3,609 14.79 73.18 
2016 3,739 15.32 88.5 
2017 2,805 11.5 100 
Total 24,399 100  
 
 
Table 6.  Annual distribution (counts and percentage) of BRCA testing among eligible enrollees (Cohort 1) 
Year Total 
Count 
Percent 
(%) 
Cumulative 
Percent (%) 
2008 16,251 4.68 4.68 
2009 20,933 6.02 10.7 
2010 21,317 6.13 16.83 
2011 23,332 6.71 23.54 
2012 27,680 7.96 31.51 
2013 38,993 11.22 42.73 
2014 43,649 12.56 55.29 
2015 51,882 14.93 70.21 
2016 52,217 15.02 85.24 
2017 51,315 14.76 100 
Total 347,569 100   
 
 
Table 7. BRCA mutation detection rate from 2008-2017 
Year of Test BRCA mutation rate (%) 
2008 8.3 
2009 7.9 
2010 7.8 
2011 8.1 
2012 7.5 
2013 6.8 
2014 6.8 
2015 6.9 
2016 7.2 
2017 5.5 
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 When interrogating family history associated with BRCA carriers, the mix of types of 
family history changed over the years with increasingly more enrollees who are positive but do 
not have a family history (89 in 2008 and 369 in 2017, which is also reflected in annual 
percentages for that group). The number of BRCA positive enrollees with family history of both 
breast and ovarian cancer fluctuated during the study period, peaking in 2013 and 2014, and 
therefore demonstrating a “Jolie effect” before dropping again through 2017.  The annual 
proportion of BRCA carriers in this group showed a constant decrease, however, probably 
because there were such large increases in proportion of BRCA carriers with no family history 
and family history of other cancers during the study period (Table 8).   
Table 8. Percent and frequency of different types of family histories among BRCA positive enrollees per year. 
FHX=Family History; BR=Breast Cancer; OV=Ovarian Cancer 
Year of 
BRCA 
Test 
No 
FHX 
(N) 
(%) 
Br 
FHX 
(N) 
(%) 
Ov 
FHX 
(N) 
(%) 
Br/Ov 
FHX 
(N) 
(%) 
Other 
FHX 
(N) 
(%) 
Total 
(N) 
(%) 
2008 89 702 83 451 33 1,358 
 6.55 51.69 6.11 33.21 2.43 100 
2009 96 870 103 552 37 1,658 
 5.79 52.47 6.21 33.29 2.23 100 
2010 97 901 96 535 39 1,668 
 5.82 54.02 5.76 32.07 2.34 100 
2011 130 1,039 114 552 52 1,887 
 6.89 55.06 6.14 29.25 2.76 100 
2012 170 1,099 153 579 76 2,077 
 8.18 52.91 737 27.88 3.66 100 
2013 238 1,404 182 731 102 2,657 
 8.96 52.84 6.85 27.51 3.84 100 
2014 292 1,602 201 734 119 2,948 
 9.91 54.34 6.82 24.9 4.04 100 
2015 350 2,037 312 729 190 3,618 
 9.67 56.30 8.62 20.15 5.25 100 
2016 494 2,083 291 658 198 3,724 
 13.27 55.93 7.81 17.67 5.32 100 
2017 369 1,571 269 431 164 2,804 
 13.16 56.03 9.59 15.37 5.85 100 
Total 2,325 13,308 1,804 5,952 1,010 24,399 
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Longitudinal Uptake of Risk-Reducing Surgeries 
 For all surgeries, the total enrollees at the beginning of year one was 10,744 and 
decreased every year thereafter due to loss of enrollment, cancer diagnosis, or insufficient years 
of follow-up (after 2012, we do not have a complete set of five years of follow up for enrollees, 
and in the later years, we have only one or two).    
 In the first year after undergoing BRCA testing, 22% of BRCA carriers chose to undergo a 
risk-reducing mastectomy (RRM) with that number increasing to a total of 38% by Year 5.  
Table 11 shows the annual rates for RRM in a cumulative fashion.  The increase between Years 
1 and 2 is 2.3% while the increase is 7% between Years 2 and 3, 3.7% between Years 3 and 4, 
and 3% between Years 4 and 5 (Table 9).  
 Uptake of risk reducing salpingo-oophorectomy (RRSO) was 24% in the first year, 
reaching 39% by Year 5.  The increase in RRSO between Years 1 and 2 was 3.4%, 4.3% 
between Years 2 and 3, 4.2% between Years 3 and 4, and 3% between Years 4 and 5 (Table 10). 
 In this analysis, enrollees were censored if they developed cancer or ended their 
enrollment.  Rates of risk-reducing surgeries are cumulative. 
Table 9. Cumulative rates of risk reducing surgeries Years 1 through 5 post BRCA testing, among BRCA carriers. 
RRM=Risk-Reducing Mastectomy 
 1 Year 2 Years 3 Years 4 Years 5 Years 
No RRM 77.9% 75.6% 68.6% 64.9% 61.6% 
Had RRM 22.1% 24.4% 31.4% 35.1% 38.4% 
 100% 
(n=10,744) 
100% 
(n=7,887) 
100% 
(n=6,118) 
100% 
(n=3,891) 
100% 
(n=2,459) 
 
Table 10. Cumulative rates of risk reducing surgeries Years 1 through 5 post BRCA testing, among BRCA carriers. 
RRSO=Risk-Reducing Salpingo-Oophorectomy 
 1 Year 2 Years 3 Years 4 Years 5 Years 
No RRSO 75.6% 72.2% 67.9% 63.7% 60.7% 
Had RRSO 24.4% 27.8% 32.1% 36.3% 39.3% 
 100% 
(n=10,744) 
100% 
(n=7,887) 
100% 
(n=6,118) 
100% 
(n=3,891) 
100% 
(n=2,459) 
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 Logistic regressions were fitted for Year 1 of follow up to assess risk-reducing surgeries 
alone or in combination, and the effects of age, family history and year of test have on surgical 
choice (Table 11).  Logistic models with each of these variables was interacted in pairs (age and 
family history; age and year of test; year of test and family history) were also fitted and showed 
that none of the interactions had an effect (results not shown).  
 In the first year post BRCA testing, BRCA carriers are almost twice as likely to choose 
RRM if they are 35-44 years of age (compared to 18-24 age group).  Age had a much stronger 
effect on RRSO, with odds ratios between 7-47 for choosing RRSO among different age 
categories.  BRCA carriers aged 45-54 (who presumably completed childbearing) were 47 times 
more likely to remove their ovaries than the young enrollees aged 18-24. 
 The effect of family history on surgical choice is strongest among enrollees with a family 
history of breast and ovarian cancer who choose an RRSO with an odds ratio (OR) of 1.84, 
followed by those choosing RRM (OR=1.54).  
 Year of BRCA testing shows an increase in surgical choices in 2013 that is most evident 
for RRM, with an OR of 1.27 that is statistically significant.   
Table 11: Odds Ratios for risk-reducing surgeries in year one (covariates = age, family history and year of test). 
RRM=Risk-Reducing Mastectomy; RRSO=Risk-Reducing Salpingo-Oophorectomy: Fhx=Family History; 
Br=Breast Cancer; Ov=Ovarian Cancer; Other=Other Cancer 
Variable  RRM RRSO RRM +RRSO 
Age Category (years)  
 18-24 Reference Reference Reference 
25-34 1.32 6.81*** 7.45** 
35-44 1.99*** 32.87*** 25.99*** 
45-54 1.83*** 46.71*** 29.21*** 
55-64 1.43* 42.29*** 20.42*** 
65-74 1.16 29.48*** 12.99** 
75-84 0.54 27.92*** - 
85+ - - - 
Family History  
 No FHx Reference Reference Reference 
Br FHx 1.46 1.00 1.20 
Ov FHx 0.45** 1.41 0.53 
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BR+Ov FHx 1.54* 1.84** 1.53 
Other FHx 0.36** 0.87 0.46 
Year of Test  
 2008 Reference Reference Reference 
2009 0.99 1.12 1.10 
2010 0.94 1.11 1.14 
2011 1.05 1.34* 1.35 
2012 1.01 1.15 1.21 
2013 1.27* 1.03 1.17 
2014 0.92 0.99 1.03 
2015 0.75* 0.79 0.85 
2016 0.78* 0.96 0.86 
2017 0.65*** 0.68** 0.58** 
Legend: * p<0.05; ** p<0.01; *** p<0.001; RRM= Risk Reducing Mastectomy; RRSO = Risk-Reducing Salpingo-
Oophorectomy; Fhx= Family history; Br=Breast Cancer; Ov= Ovarian cancer; Other= other cancer 
 
 
Longitudinal Uptake of Screening 
 The total number of enrollees for screening was the same as for surgery (10,744), and 
they experienced the same loss due to enrollment dropout, cancer diagnosis or insufficient year 
of follow up.  However, their annual numbers differed from surgery depending on the organ 
screened because screening for enrollees with breast cancer continued to be included in the 
ovarian screening cohort, and enrollees with ovarian cancer continued to be included in the 
breast screening cohort.  The number of enrollees eligible for screening via mammography and 
breast MRI was therefore be the same, whereas the numbers for any screening procedures and 
ovarian screening were different. 
 Uptake of any type of BRCA-recommended screening (breast MRI, mammography, 
ovarian screening) was high in the first year with 96% of BRCA positive, unaffected women 
undergoing one of these procedures.  However, uptake decreased significantly over the next five 
years, with only 33% receiving any annual screening in five years post-testing.  By end of Year 
5, only 33% had been screened five times, 27% had been screened four times, 15% had been 
screened three times, 13% had been screened twice, 11% had been screened once, and 1% had 
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never been screened (see Table 12).  By Year 5, only 1% those who were not otherwise censored 
had not had any screening.  
Table 12. Longitudinal uptake of annual screening rates of any screening procedure among BRCA carriers  
Cumulative number 
of ANY screenings 
1 year of 
follow-up 
2 years of 
follow-up 
3 years of 
follow-up 
4 years of 
follow-up 
5 years of 
follow-up 
0 4.3% 2.8% 1.9% 1.4% 1.0% 
1 95.7% 42.2% 22.6% 15.7% 11.5% 
2  55.0% 32.3% 17.7% 12.7% 
3   43.2% 27.3% 15.5% 
4    37.9% 26.6% 
5     32.7% 
 100% 100% 100% 100% 100% 
Number of enrollees 
eligible for ANY 
screening 
(n=10,744) (n=7,788) (n=5,259) (n=3,335) (n=2,115) 
  
 Annual mammography is a recommended procedure for all BRCA carriers over age thirty 
who have not undergone RRM.  Mammography rates in BRCA carriers started at 67% in the first 
year of follow-up, but decreased to 15% having had five mammograms in five years among 
BRCA carriers from who were not censored.  Table 12 demonstrates that by Year 5 almost 12% 
of BRCA carriers who were still eligible for mammograms did not have the procedure at all 
during that time frame.  The drop in annual mammography rate becomes noticeable in Year 4, 
with only 19% of enrollees who were still eligible to receive mammography having had four 
annual mammograms, 27% having had three mammograms, 21% having had two mammograms, 
29% having had one mammogram, and 13% having had none (see Table 13). 
Table 13. Longitudinal uptake of annual mammography rates among BRCA carriers  
Cumulative number 
of mammograms 
1 year of 
follow-up 
2 years of 
follow-up 
3 years of 
follow-up 
4 years of 
follow-up 
5 years of 
follow-up 
0 32.9% 18.8% 14.4% 12.8% 11.5% 
1 67.1% 46.7% 27.5% 20.3% 16.7% 
2  34.5% 35.0% 21.1% 14.6% 
3   23.1% 27.3% 19.2% 
4    18.5% 23.4% 
5     14.5% 
 100% 100% 100% 100% 100% 
Number of enrollees 
eligible for 
mammograms 
(n=10,744) (n=5,775) (n=3,732) (n=2,260) (n=1,368) 
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 Breast MRI, which is a recommended procedure for all female BRCA carriers without an 
RRM, even those under age 30, had a lower uptake than mammography with only 51% of BRCA 
carriers undergoing this procedure at Year 1, a drastic decline to 15% by Year 2, and another 
drop to 4% by Year 5 (see Table 14).  An important finding here is that 49% of BRCA carriers 
didn’t have an MRI during Year 1 post-BRCA testing, a level that was maintained through to 
Year 5 with 43% of BRCA carriers still not having had a breast MRI by Year 5.   
Table 14. Longitudinal uptake of annual breast MRI rates among BRCA carriers 
Cumulative number 
of breast MRIs 
1 year of 
follow-up 
2 years of 
follow-up 
3 years of 
follow-up 
4 years of 
follow-up 
5 years of 
follow-up 
0 49.3% 49.0% 46.2% 44.4% 42.5% 
1 50.7% 35.8% 28.7% 23.9% 22.8% 
2  15.1% 17.0% 14.9% 12.9% 
3   8.1% 11.7% 10.8% 
4    5.1% 6.8% 
5     4.2% 
 100% 100% 100% 100% 100% 
Number of enrollees 
eligible for breast 
MRIs 
(n=10,744) (n=5,775) (n=3,732) (n=2,260) (n=1,368) 
  
 Ovarian screening (which includes TVU+CA125) had the same uptake as breast MRI in 
Year 1 and through to Year 5 with 52% of BRCA positive enrollees having the procedures within 
one year of BRCA testing.  Thereafter, similar to breast MRI, the rate decreased to 18% in Year 2 
and fell to 7% by Year 5 (Table 15).  By Year 5, 34% had still not had any ovarian screening.  
Those who had an RRSO or who developed ovarian cancer were dropped from the analysis. 
Table 15. Longitudinal uptake of annual ovarian screening rates among BRCA carriers  
Cumulative number 
of ovarian 
screenings 
1 year of 
follow-up 
2 years of 
follow-up 
3 years of 
follow-up 
4 years of 
follow-up 
5 years of 
follow-up 
0 48.1% 47.3% 43.8% 38.1% 34.3% 
1 51.9% 34.3% 28.0% 26.9% 26.1% 
2  18.4% 16.7% 14.4% 13.9% 
3   11.6% 11.9% 10.0% 
4    8.7% 8.9% 
5     6.7% 
 100% 100% 100% 100% 100% 
Number of enrollees 
eligible for ovarian 
screening 
(n=10,744) (n=6,146) (n=4,095) (n=2,564) (n=1,602) 
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DISCUSSION 
 25,380 BRCA carriers were identified, almost all of whom (n=24,399) were women.  
Almost 60% were between the ages of 35-54.  These demographics are consistent with the 
guidelines for BRCA testing that recommend the test to be performed when clinical management 
changes can be implemented, typically over the age of 30, and which until very recently focused 
on women only.   
 The overall BRCA mutation-pick up rate across all years, and regardless of personal or 
family history, was 7.3%.  Although the raw number of BRCA positive enrollees increased 
overall, annual mutation pick up rates decreased from 8.3% to 6.9% in 2015. During the study 
timeframe, guidelines for selection of enrollees eligible for testing became less stringent, such 
that although more enrollees were being tested, there wasn’t an accompanying increase in BRCA 
mutation carriers.  This trend is reflected in the decreased annual mutation pickup rate.  
 Bivariate analysis demonstrated that the mix of family history types changed over the 
study period with increasingly more mutation carriers being identified without a family history 
of cancer. One explanation for the clear increase in BRCA carriers without a family history is the 
new BRCA testing guidelines, which have relaxed criteria so that more “unorthodox” indications 
for BRCA testing would be indicators for testing, such as family history of pancreatic cancer, 
which may not always be coded as “other” family history.  Finally, it is possible that some of 
these BRCA carriers were identified as a result of the newly clinician-ordered home tests (such as 
Color Genomics Labs), and these additional BRCA carriers were truly identified as part of an 
almost “population screening” effort, and as such may not have had a known family history as an 
indication. 
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 A “Jolie effect” was seen among mutation carriers with a family history of breast and 
ovarian cancer whose annual BRCA test numbers peaked in 2013 and 2014 and decreased 
thereafter.  
 BRCA carriers may choose to undergo risk reducing surgeries and/or increased screening 
and/or continue usual care.  Risk reducing surgeries include bilateral risk reducing mastectomies 
(RRM) and bilateral risk reducing oophorectomy RRSO.  Increased screening includes annual 
breast MRI and mammography and six monthly trans-vaginal ultrasounds with CA125 blood 
tests. National guidelines recommend, at a minimum, increased screening and consideration of 
risk-reducing surgery in an effort to reduce or prevent a cancer diagnosis since BRCA mutation 
carriers have significantly elevated risks of breast and ovarian cancer compared to the general 
population.   
 Analysis of healthcare utilization of BRCA carriers focused on 10,744 unaffected BRCA 
carriers, on whom there was sufficient annual follow up data.  Cumulative rates of RRM 
increased over the five years after first being identified as a BRCA carrier.  The uptake of RRM 
was 22% in the first year and 38% by the fifth year.  Similarly, cumulative rates of RRSO also 
increased with a similar pattern: 24% in the first year and 39% by the fifth year. 
 Multivariate analysis showed that in the first year after BRCA testing, women aged 35-44 
were almost twice as likely to choose RRM, but carriers aged 45-54 were 47 times more likely to 
choose RRSO. These findings are not surprising given fertility concerns among young BRCA 
carriers and the earlier onset of breast cancer (compared to ovarian cancer) that is typically seen 
in BRCA mutation carriers.  Family history of breast and ovarian cancer is once again a driver, 
but for surgical choices this time. Enrollees having this type of family history were 50% more 
likely to choose RRM (OR=1.54) and almost twice as likely to choose RRSO (OR=1.84).   
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 Year of testing shows the strongest effect in 2013, the year of the Jolie editorial, with an 
OR of 1.27 for RRM that year.  There does not appear to be a similar effect with RRSO 
(OR=1.03 that year), which is consistent with the nature of her OpEd, which espoused RRM; 
RRSO was discussed separately by Jolie in an editorial several years later.  The increase in RRM 
can be solely attributed to the “Jolie effect” because the ORs return to baseline in subsequent 
years and dissolution of the BRCA patent is not expected to affect surgical prevention rates, only 
the uptake of BRCA testing. 
 Consistent with findings from clinic-based series of BRCA positive patients, BRCA 
carriers in this database had dwindling screening rates after five years of follow up. Most 
enrollees had some type of screening in Year 1 with 96% having undergone one screening 
procedure (mammogram, breast MRI or ovarian screening). Although the percentage decreased 
over the years, 33% of BRCA carriers were having some type of screening by Year 5.   
 When looking at specific procedures, uptake of mammography was highest throughout 
Years 1-5.  Breast MRIs and ovarian screening had similar uptakes, starting with around 50% in 
Year 1 and ending between 4-5% by Year 5.  Considering that in this analysis enrollees with 
breast cancer and those who had an RRM are dropped from follow-up, all those that remain in 
each year have breast tissue that is at approximately 85% risk for breast cancer, and such a low 
level of uptake of a recommended procedure throughout five years is considered sub-optimal 
care for BRCA carriers.  Similarly those who had an RRSO or who developed ovarian cancer 
were dropped from the analysis, and therefore the enrollees in the analysis should have had 
ovarian screening at least annually according to national guidelines, given the elevated risk of 
this malignancy in BRCA carriers. 
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APPENDIX 
Chapter 5 Appendix, Table. 1 ICD-9 and ICD-10 codes used to identify BRCA carriers. 
Diagnostic Code 
Version 
Procedure  
Codes 
Description of Code 
ICD-9 V84.0 Root  (not supposed to be used, but it does appear in claims) 
 V84.01 Susceptibility to Breast 
 V84.02 Susceptibility to Ovary cancer 
 V84.09 Susceptibility to Other Cancer 
 V84.89 Genetic susceptibility to specified disease, not elsewhere classified (for 
Susceptibility to Pancreas, Melanoma, etc.) 
 V83.89 Other Genetic Carrier Status 
 
ICD-10 Z15.01 Susceptibility to Breast Cancer 
 Z15.02 Susceptibility to Ovary Cancer 
 Z15.09 Susceptibility to Other Cancer 
 Z15.89 Susceptibility to Other Disease 
 Z14.8 Genetic Carrier of Other Disease 
 
Chapter 5 Appendix, Table 2. CPT codes use to identify risk-reducing and screening procedures for BRCA positive 
enrollees. 
Organ at Risk Procedure 
Code 
Description of the Code 
BREAST  
Risk-reducing mastectomy 19180 Mastectomy, simple, complete, bilateral 
 19182 Mastectomy, subcutaneous, bilateral 
 19303 Mastectomy, simple, complete, unilateral 
 19304 Mastectomy, subcutaneous, unilateral 
 
Breast MRI 77047 
 
MRI, breast, with contrast, bilateral 
 77049 MRI, breast with and without contrast, including computer-
aided detection, bilateral 
 77059 
 
MRI, breast, with and without contrast, bilateral 
 
Mammography G0202 Screening mammography, bilateral (2-view study of each 
breast ), including (CAD) when performed. Code deleted in 
Jan 1 2018 
 G0204 Diagnostic mammography, including (CAD) when performed; 
bilateral.  Code deleted in Jan 1 2018 
 G0279 Diagnostic digital breast tomosynthesis, bilateral. (List 
separately in addition to code for primary procedure) 
 77051 CAD (computer algorithm analysis of digital image data for 
lesion detection) with further review for interpretation, with or 
without digitization of film radiographic images; diagnostic 
mammography (List separately in addition to code for primary 
procedure). To report see 77065, 77066. 
 77052 CAD (computer algorithm analysis of digital image data for 
lesion detection) with further review for interpretation, with or 
without digitization of film radiographic images; screening 
mammography (List separately in addition to code for primary 
procedure)  Becomes 77067 in 2017 
 77056 
 
Mammography; bilateral.  Becomes 77066 in 2017 
 77057 Screening mammography, bilateral (2-view 
study of each breast). Becomes 77067 in 2017 
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 77063 Screening digital breast tomosynthesis, bilateral (List 
separately in addition to code for primary procedure) 
 77066 Diagnostic mammography, including (CAD) when performed; 
bilateral. As of Jan 1, 2018 
 77067 Screening mammography, bilateral (2-view study of each 
breast), including 
CAD when performed. As of Jan 1, 2018 
 
OVARY  
Risk-reducing oophorectomy 58571 Robotic/Laparoscopy w/ total hysterectomy uterus < 250 gms 
w/ removal of tube(s) and/or ovary(s) 
 58573 Robotic/Laparoscopy w/ total hysterectomy uterus >250 gms 
w/ removal of tube(s) and/or ovary(s) 
 58661 
 
Laparascopy, surgical, removal of tubes and/or ovaries 
 58720 Salpingo-oophrectomy, partial or total, unilateral or bilateral 
spx 
 58940 
 
Ophorectomy, partial or total, unilateral or bilateral 
 58150 Open hysterectomy (TAH), w/w-o removal of tubes and/or 
ovaries 
 58152 Open hysterectomy (TAH) w/ or w/out tubes/ovaries, w/ 
colpo-urethrocystopexy 
 58262 Vaginal hysterectomy uterus <250 gms, w/ tubes and/or 
ovaries 
 58291 Vaginal hysterectomy uterus >250 gms, w/ tubes and/or 
ovaries 
 
CA125 86304 
 
Immunoassay for tumor antigen, quantitative (CA125) 
   
Trans-vaginal ultrasound 76830 Diagnostic ultrasound procedures of the pelvis, non-obstetrical, 
transvaginal 
 76856 Ultrasound, pelvic (nonobstetric), real time with image 
documentation, trans-abdominal 
 76857 Ultrasound, non obstetrical for follow-up or limited (e.g. 
follicles) 
 
 
Chapter 5 Appendix, Table 3. Insurance types among BRCA carriers.  EPO=Exclusive Provider Organization; 
HMO=Health Management Organizaton; IND=Independent plan; OTH=Other type of plan; PFF=Private Fee for 
Service; POS=Point of Service; PPO=Preferred Provider Organization; STP=Sustainability and Transformation Plan 
Type of 
Health 
Plan 
Total 
Count 
Percent 
(%) 
Cumulative 
Percent (%) 
EPO 1,571 6.44 6.44 
HMO 2,421 9.92 16.36 
IND 84 0.34 16.71 
OTH 25 0.1 16.81 
PFF 45 0.18 16.99 
POS 17,015 69.74 86.73 
PPO 3,237 13.27 100 
STP - 0 100 
Total 24,399 100  
  166 
Chapter 5 Appendix, Table 4. Annual distribution of insurance types among BRCA carriers. 
	 Type of Health Insurance Plan	
Year EPO HMO IND Other PFF POS PPO STP Total 
2008 7.36 10.68 0.29 0.00 0.00 64.43 17.23 0.00 100 
2009 8.87 11.16 0.60 0.00 0.30 63.03 16.04 0.00 100 
2010 8.21 10.79 0.66 0.00 0.30 67.39 12.65 0.00 100 
2011 8.37 9.27 0.37 0.00 0.11 67.51 14.36 0.00 100 
2012 7.90 8.62 0.39 0.24 0.24 70.49 12.13 0.00 100 
2013 6.06 10.09 0.49 0.00 0.26 70.53 12.57 0.00 100 
2014 5.66 9.12 0.17 0.27 0.25 72.18 12.35 0.00 100 
2015 5.36 9.65 0.36 0.11 0.14 71.70 12.69 0.00 100 
2016 5.42 10.50 0.24 0.11 0.16 70.81 12.73 0.03 100 
2017 5.03 9.99 0.14 0.14 0.11 71.33 13.27 0.00 100 
Total 6.44 9.92 0.34 0.10 0.18 69.74 13.27 0.00 100 
 
 
Chapter 5 Appendix, Table 5. Proportion of various cancers (diagnosed both before and after BRCA positive claim) 
and proportions of family history combinations among BRCA carriers. FHx=Family History; Br=Breast Cancer; 
Ov=Ovarian Cancer; Other=Other Cancer; CA=Cancer 
 Type of Family History of Cancer  
Cancer 
Diagnosis 
No FHx Br FHx Ov FHx Br+Ov 
FHx 
Other 
FHx 
Total 
No Cancer 226 4,790 838 2,499 254 8,607 
 0.93 19.63 3.43 10.24 1.04 35.28 
Br 1,671 7,259 704 2,722 557 12,913 
 6.85 29.75 2.89 11.16 2.28 52.92 
Ov 243 494 142 265 111 1,255 
 1 2.02 0.58 1.09 0.45 5.14 
Br+Ov 163 636 94 407 58 1,358 
 0.67 2.61 0.39 1.67 0.24 5.57 
Other CA  22 129 26 59 30 266 
 0.09 0.53 0.11 0.24 0.12 1.09 
Total 2,325 13,308 1,804 5,952 1,010 24,399 
 9.53 54.54 7.39 24.39 4.14 100 
 
 
Chapter 5 Appendix, Table 6. Proportion of various types of family history among the various cancer diagnoses 
(diagnosed both before and after BRCA positive claim) in BRCA carriers. FHx=Family History; Br=Breast Cancer; 
Ov=Ovarian Cancer; Other=Other Cancer; CA=Cancer 
 Type of Family History of Cancer  
Cancer Diagnosis No FHx Br FHx Ov FHx Br+Ov 
FHx 
Other 
FHx 
Total 
No Cancer 226 4,790 838 2,499 254 8,607 
 2.63 55.65 9.74 29.03 2.95 100 
Br CA 1,671 7,259 704 2,722 557 12,913 
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 12.94 56.21 5.45 21.08 4.31 100 
Ov CA 243 494 142 265 111 1,255 
 19.36 39.36 11.31 21.12 8.84 100 
Br+Ov CA 163 636 94 407 58 1,358 
 12 46.83 6.92 29.97 4.27 100 
Other CA 22 129 26 59 30 266 
 8.27 48.5 9.77 22.18 11.28 100 
Total 2,325 13,308 1,804 5,952 1,010 24,399 
 9.53 54.54 7.39 24.39 4.14 100 
 
 
Chapter 5 Appendix, Table 7. Distribution of BRCA positive enrollees eligible for screening and/or risk-reducing 
surgery across the study period. 
Year Total 
Count 
Percent 
(%) 
Cumulative 
Percent (%) 
2008 534 4.97 4.97 
2009 704 6.55 11.52 
2010 662 6.16 17.68 
2011 756 7.04 24.72 
2012 908 8.45 33.17 
2013 1169 10.88 44.05 
2014 1351 12.57 56.62 
2015 1669 15.53 72.15 
2016 1755 16.33 88.48 
2017 1236 11.5 100 
Total 10744     
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CHAPTER 6.  SUMMARY FINDINGS AND LIMITATIONS 
 
INTRODUCTION 
 A great deal of funding and research effort has been invested into personalized medicine.  
However, uptake and downstream healthcare utilization of genetic testing which is the 
underpinning of personalized medicine have not been well studied at broad, population levels.  
BRCA testing, by virtue of its 25 year history of facilitating personalized changes in management 
recommendations to improve patient outcomes, represents an ideal model for analyzing these 
two questions: which at-risk individuals in the general population choose genetic testing to 
inform medical care? And after genetic testing, how do they utilize the healthcare system and 
what informs their decisions?  
 The present study was undertaken with two broad goals. 
1. Understand expansion of BRCA, in particular the volume of testing and characteristics of 
those undergoing BRCA testing, and how they change over time. 
2. Understand decisions of unaffected BRCA carriers about mutation positive directed care 
(such as risk-reducing surgery(ies) and/or screening), in particular drivers for such 
decisions, including personal and environmental factors (such as public figure 
endorsements) 
 
 
 
 
 
 
 
 
 
 
 
175 
 In order to do correctly and completely identify BRCA tests from a claims database, I first 
delineated a method that takes into account the complexity and historical changes that have made 
this endeavor challenging and incomplete in previous research efforts. 
 Enrollees eligible for testing were identified, and the claims of those who underwent 
BRCA testing were interrogated regarding personal diagnosis or history of cancers, family 
history of cancers, age at testing, year of testing, type of insurance plan, state of residence, and 
various charges.  BRCA carriers were identified from among the enrollees who had BRCA 
testing, and the claims of females without a cancer diagnosis were analyzed for uptake of BRCA-
recommended risk-reducing and screening procedures. 
 Special attention was paid to the time period following the Jolie editorial discussing her 
BRCA positive status and choice for risk-reducing mastectomy and dissolution of the BRCA 
patent, specifically years 2013 and 2014. 
 In this chapter I briefly review findings and offer some concluding thoughts about what 
has been learned and future research directions. 
 
 
SUMMARY OF RESULTS 
 
BRCA Test Identification 
 An important part of this study was to delineate an appropriate methodology for 
identifying BRCA tests using claims data.   
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 The method outlined in Chapter 2, identifies more BRCA claims, as well as more 
enrollees who have had BRCA testing, than any of the other published methods.  
 The methodology in the current paper takes into consideration changes in coding 
practices of billing laboratories over time, and as such it more accurately identifies BRCA tests 
from claims data.  The current algorithm identified more than three times as many BRCA claims 
compared to the Wright et al method, and almost 1.5 times as many BRCA claims than the Chen 
et al method.  
 Using the method described in Chapter 2, a total of 794,113 BRCA claims were 
identified, which represent 347,569 enrollees.  334,714 (96%) enrollees had one BRCA test; 
12,026 (3.5%) enrollees had two BRCA tests; 707 (0.2%) enrollees had 3 BRCA tests, and 122 
(0.03%) enrollees had 4 or more BRCA tests.  The majority (79%) of enrollees with indications 
for testing (Cohort 1) were female, with 21% identified as male, and 0.05% identified as 
unknown gender.   
There were 6,495,815 enrollees who had an indication for BRCA testing (i.e./were 
eligible for testing due to an indication), plus an additional 16,838 (0.3%) enrollees who had 
BRCA testing but lacked a cancer diagnosis or a family history of cancer, for a total of 6,512,653 
(Cohort 1).  Out of 6,495,815 enrollees eligible for BRCA testing claims 330,731 actually had the 
test, for an overall 5.1% testing rate. This rate does not include the 16,838 who were tested 
without an indication for BRCA testing.  
Almost 63% of enrollees with indications for BRCA testing did not have cancer (i.e./ 
were “unaffected”), 21.4% had breast cancer, 2.3% had ovarian cancer, 0.3% had both breast and 
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ovarian cancer, and 13% had either other cancer (i.e./pancreatic cancer, cutaneous melanoma, 
uveal melanoma, or colorectal cancer) diagnosis. Approximately one third (30.5%) had no 
family history of cancer, another third (35.9%) had a family history of breast cancer, 2.8% had a 
family history of ovarian cancer, and 29.6% had family history of other cancers (gastrointestinal 
or other cancer). Only 1.2% had a family history of both breast and ovarian cancer. 
 
 
 
Unadjusted BRCA Testing Rates 
 Overall, BRCA testing appears to be driven by a family history of both breast and ovarian 
cancer and young age. 
 For unaffected enrollees, age 18-24 had the highest testing rates.  This trend continued for 
affected enrollees in the same age category, regardless of the type of cancer they had. The high 
testing rates in the 18-24 year olds may be due to reverse causality, where intent to test for BRCA 
mutations drives coding to justify the necessity of the test.   
 There was evidence that BRCA testing was performed on minors (enrollees aged 0-17), 
many of whom had a family history of both breast and ovarian cancer. This finding is 
unexpected, since there has long existed a well-established clinician unwillingness to order 
BRCA testing in minors.  Several explanations may justify this scenario including known family 
mutation testing and lowering age threshold due to overwhelming family-specific and age-
actionable reasons. 
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 Family history of both cancers (breast and ovarian) emerged as a strong driver of BRCA 
testing for enrollees with several different types of cancer and/or family histories of cancer, 
whether analyzed by age or by year of testing.  This finding is consistent with longstanding 
BRCA literature and testing guidelines which reinforce the concept that both breast and ovarian 
cancer in a pedigree is much more indicative of a BRCA mutation than finding either of those 
malignancies alone.  
BRCA testing consistently increased from 2008-2017 across all ages, cancer status, and 
types of family histories of cancer, albeit at different rates. The increase appears to take place 
among people who are good candidates for BRCA testing, and most likely would fit BRCA 
testing guidelines.  However, despite the growth in BRCA testing, the testing rates in enrollees 
with ovarian cancer but no family history of cancer remained low throughout the study despite 
societal and national guidelines recommending that all patients with ovarian cancer should 
undergo BRCA testing regardless of family history.  The current analysis indicates this 
recommendation is not followed by clinicians. 
A “Jolie effect” is observable in some subgroups of enrollees, in particular among those 
unaffected with a family history of both breast and ovarian cancer, where the BRCA rate 
increased by 13 percentage points from 2012-2013, and among enrollees with ovarian cancer and 
a family history of breast and ovarian cancer, who increased their BRCA testing rate by 17 
percentage points during the same time period.  Both of these effects were short lived with rates 
returning to baseline the next year (2014). In terms of a “Jolie effect” among different age 
groups, the increases were minimal, with the most clear effect seen among 35-44 age group.  
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Cost of BRCA Testing 
Analysis of charges for BRCA testing over the study period revealed an increase not only 
in charges, and paid amount, but also (and to a more modest degree) in patient cost-sharing 
amounts. This finding is in direct conflict with the assertions made by proponents of patent 
dissolution, who invoked the lack of market competition as a reason for the high cost of BRCA 
testing.  It would appear that, in the current insurance environment, after patent protection ended, 
charges and reimbursements increased, rather than decreased. 
 
 
Adjusted Rates of BRCA testing 
 Across all types of cancer diagnoses and family histories, the highest adjusted BRCA 
rates were seen in those with a family history of breast and ovarian cancer.  Regardless of cancer 
diagnosis and family history status, across the study period, the most likely group to undergo 
BRCA testing were young enrollees. Older people are consistently tested at lower rates.  This 
finding is consistent with clinical practice, which emphasizes testing unaffected younger people, 
so that hereditary risk is identified early, and preventive and risk reducing measures are put in 
place early to detect cancer early, or avoid it completely.  
  For unaffected enrollees with a family history, all age groups (except those 65+) saw 
acceleration in BRCA testing after 2013, which peaked in 2015. For those with both cancer and a 
family history of cancer, the BRCA testing rate had wide variance throughout the study period, 
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but the rates were higher overall compared to the unaffected with family history, and affected 
with no family history groups. Thus the highest rates of BRCA testing occurred in the affected, 
positive family history group, which once again is consistent with BRCA recommendations.  The 
steady increase in BRCA testing over the study period in this group reinforces the fact that 
clinicians continued to educate themselves and appropriately broaden their testing criteria as the 
national guidelines for BRCA testing were relaxed over this time period.  
 There does appear to be an acceleration in BRCA testing predicted probabilities after 
2013 across most types of family histories and cancer diagnoses and types (i.e./ a “Jolie effect”), 
but its magnitude varies across different subgroups. Many reasons may explain the variation; 
among them the fact that her health scenario may have been inspirational to only younger 
individuals, who were like her, unaffected, but had a family history of cancer., and as such the 
effect was either muted or non-existent among these enrollees.  
 
Geographic Variation of BRCA Uptake 
 
 BRCA testing uptake appeared to increase earlier in the Southewestern part of the US.  
Cancer status and family history status was instrumental in earlier and faster adoption of BRCA 
testing, with affected enrollees with family history of cancer having the widest geographic 
distribution and the fastest BRCA testing acceleration rates. Despite this, variations in test rates 
continued throughout the study period.      
 
Healthcare Utilization among BRCA carriers   
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 Unaffected enrollees who were BRCA carriers have a choice of increased screening, or 
risk-reducing surgery, specifically risk-reducing mastectomy (RRM), risk-reducing 
oophorectomy (RRSO), or both.   Uptake of risk-reducing procedures was 22% RRM and 24% 
for RRSO.  Five years after testing, those rates were 38% and 39% respectively. Enrollees 35-44 
years of age were almost twice as likely to undergo RRM compared to 18-24 year olds.  The 
effect of age was much more evident for RRSO, with peri-menopausal enrollees (those 45-54 
years of age) 47 times more likely to choose the procedure. The effect of family history was 
strongest among those with a family history of breast and ovarian cancer, who were almost twice 
as likely (OR 1.84) to choose RRSO.  The findings suggest that BRCA carriers of childbearing 
age with a family of history of breast and ovarian cancer wait to undergo RRSO until they are 
peri-menopausal, but at that point are more likely to opt for the procedure.   Family history of 
ovarian cancer, concern about menopausal effects post-RRSO and fertility issues all contribute to 
the delay in RRSO, despite concern about the inability to detect ovarian cancer early via 
screening. 
 A large percent of BRCA carriers undergo some type of screening procedure in Year 1.  
However this level of adherence is not maintained, with only 33% of BRCA carriers undergoing 
screening annually over 5 years of follow up (screening procedures include annual breast MRIs, 
annual mammography, and biannual ovarian screening).  The uptake of breast MRI and ovarian 
screening from year 1 through year 5 was only 50%, a level that is considered sub-optimal care 
for individuals whose lifetime risk of breast cancer approaches 85% and 50% for ovarian cancer.   
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LIMITATIONS 
Several limitations are inherent to this study. 
1. Coding issues (incorrect coding, miscoding, etc.).  There is undercoding for BRCA 
carriers, who are oftentimes are not coded as such.  This would affect Aim #2 in 
particular, since the inability to correctly BRCA carriers would lead to mis-estimation of 
effect BRCA mutation has on healthcare utilization. 
2. Reduced ability to clearly identify BRCA testing in cases where batch billing occurred. In 
such cases, the method described here would not identify those claims as BRCA, and 
would lead to an underestimation of the number of BRCA tests. 
3. Due to the timing of the Supreme Court decision to invalidate the BRCA patent (which 
occurred in June 2013) and Angelina Jolie’s editorial (which was published in May 2013) 
the effect of either of these events alone is difficult to ascertain.  The expectation is that 
the Jolie effect would be transitory, since it was caused through mimicking a famous 
figure, whereas the patent dissolution would lead to a longer lasting, more slow-growing 
effect. 
4. An inherent limitation of HCCI dataset when analyzing geographic variation is that the 
market penetrance in each state for the insurers/payers comprised therein is not known.  
As such, it is possible that the HCCI claims have an over-representation of enrollees from 
the Southwest, and therefore an effect in other states would be muted.  This is an 
important reason that may explain the geographic diffusion rates seen in the analysis. 
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5. From 2011 onwards, BRCA testing was available as part of multi-gene panels, which 
included genes that predisposed to both breast and pancreatic cancer (such as PALB2 in 
particular), and it is possible that BRCA testing may have been ordered as part of a multi-
gene panel.  The BRCA testing identification methodology for this analysis focused on 
BRCA1 and BRCA2 only, and as such it impossible to further clarify the degree to which 
in these cases BRCA was part of a multi-gene panel. 
 
CONCLUSION 
 The current study demonstrated that an algorithm that accounts for the changes in CPT 
coding for BRCA testing as well as the units of service identifies more tests than the other 
published methods.   
 Most BRCA tests are ordered on young enrollees, with a family history that justifies the 
medical necessity of the test.  There has been an increase in BRCA testing across all ages, cancer 
status and types of family history, and there is a clear “Jolie Effect” especially in the young, 
unaffected enrollees.  These effects persist after adjusting for covariates.   
 About one quarter of BRCA carriers choose risk-reducing procedures in the first year post 
BRCA testing.  The majority (97%) of BRCA carriers who choose screening undergo at least one 
recommended surveillance procedure in the first year, but adherence decreases throughout the 
five year follow-up period, reaching levels under 10% for annually recommended screenings. 
 Future analyses should investigate the role of providers in BRCA testing and follow up 
care, a goal that was originally proposed for this study, but was not achievable using this 
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database.  Because genetic testing is billed by laboratories but ordered by other clinicians, 
identifying the individual who ordered the test form claims data is a challenging endeavor. 
 New methodology in hereditary cancer testing and BRCA testing in particular make it 
challenging to capture all the BRCA tests ordered on patients via claims analysis.  A thorough 
understanding of the BRCA testing methodology and billing practices of the laboratories, as well 
as experience from the clinical and patient perspective are all important components of a strategy 
designed to maximize BRCA test identification from claims analysis.  
